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‘‘Imagination is more important than knowledge’’ 
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SYNTHESIS OF DESEPOXYISOTEDANOLIDE 
A Proposed Biosynthetic Precursor of the Marine Polyketide Tedanolide 
and Application of Kiyooka Aldol Reaction to generate  
Tertiary Alcohols Stereoselectively 
Abstract  
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Tedanolides are biologically active polyketides, isolated from various marine sponges at different 
locations. The isolation of these toxic metabolites first came into light in the year 1984 with the 
isolaton of tedanolide by Schmitz et al. from a marine sponge Tedania ignis. Until now several other 
molecules (13-deoxytedanolide, tedanolide C, candidaspongiolides) belonging to this family have 
been isolated. The radioactive labeled studies performed by Fusetani et al. on the derivative of 
tedanolide, confirmed that this polyketide binds to the 60S ribosomal unit. The tedanolides represent 
the first known macrolides binding to the eukaryotic proteins. The structural characteristics of the 
tedanolides are a 18-membered macrolactone and an epoxide on the side chain. The structural 
complexity of the tedanolides has attracted the attention of several groups, few groups have been 
successful in accomplishing the total synthesis of tedanolide. Tedanolides represent a rare class of 
compounds comprising a primary lactone linkage, which makes it very interesting point from the 
biosynthetic prospective of polyketides. Based on the biosynthetic principle of polyketides, this 
unique 18-membered primary lactone could arise from a skeletal rearrangement. In order to 
substantiate this hypothetical rearrangement, the synthesis of a 18-membered secondary lactone 
desepoxyisotedanolide was initiated. This work consists of the total synthesis of 
desepoxyisotedanolide followed by the biological studies concerning the activity and the efforts 
towards isomerization of the secondary lactone to the primary lactone. Additionally few truncated 
analogues of tedanolide C(10-23) fragment are synthesized to perform biological tests and obtain 
structure activity relationship of tedanolides. In another part of this work, the Kiyooka aldol reaction 
was used in our group in the synthesis of tedanolide C. To make this protocol a more general 
approach for the construction of complex molecules consisting tertiary alcohol, this method was 
tested with various types of aldehydes and proven to be successful.  
 
 
Kurzfassung 
Arun Naini 
Synthese von Isotedanolid 
Eine vorgeschlagene Vorstufe in der Biosynthese des marinen Polyketids Tedanolid 
und Anwendung der Kiyooka Aldolreaktion, stereoselektiv tertiäre Alkohole zu erzeugen 
 
Schlagworte: Tedanolid, Isotedanolid, Naturstoffe, Totalsynthese, Polyketid, Makrolacton, 
                           Isomerisierung, Kiyooka Aldol. 
 
Tedanolide sind biologisch aktive Polyketide, die aus verschiedenen marinen Schwämmen an 
unterschiedlichen Orten isoliert wurden. Die Isolierung dieser toxischen Metaboliten kam im Jahr 
1984 in den wissenschaftlichen Fokus mit der Isolierung von Tedanolid durch Schmitz et al. aus dem 
Meeresschwamm Tedania ignis. Bis jetzt sind mehrere weitere Mitglieder (13-Deoxytedanolid, 
Tedanolid C, Candidaspongiolide) dieser Familie isoliert worden. Durch Studien von Fusetani et al. an 
radioaktiv markierten Derivaten der Tedanolide ist bestätigt, dass dieses Polyketid an die ribosomale 
60S-Einheit bindet. Die Tedanolide stellen die ersten bekannten Makrolide dar, die an diese 
eukaryotischen Proteine binden. Strukturell betrachtet handelt es sich bei den Tedanoliden um 18-
gliedrige Makrolactone mit einem Epoxid in der Seitenkette. Die strukturelle Komplexität der 
Tedanolide hat die Aufmerksamkeit mehrerer Gruppen auf sich gezogen, von denen einige die 
Totalsynthese von Tedanolid erfolgreich abgeschlossen haben. Aus biosynthetischer Sicht stellen die 
Tedanolide mit ihrer seltenen primären Lactonbindung eine interessante Klasse von Verbindungen 
dar. Basierend auf dem Prinzip der Biosynthese könnte dieses einzigartige 18-gliedrige primäre Lacton 
durch eine Umlagerung generiert werden. Um diese hypothetische Umlagerung zu untermauern, 
wurde die Synthese des 18-gliedrigen sekundären Lactons Desepoxyisotedanolid geplant. Diese Arbeit 
beinhaltet die Totalsynthese von Desepoxyisotedanolid sowie die biologischen Studien über dessen 
Aktivität und die Bemühungen, das sekundäre zum primären Lacton zu isomerisieren. Zusätzlich ist 
das C(10-23)-Fragment von Tedanolid synthetisiert worden, um biologische Tests durchführen und 
Struktur-Aktivitäts-Beziehungen der Tedanolide bestimmen zu können. In einem weiteren Teil dieser 
Arbeit wird die Kiyooka Aldolreaktion, die in unserer Gruppe für die Synthese von Tedanolid C 
verwendet wird, etabliert und an verschiedenen Arten von Aldehyden getestet, um einen 
allgemeineren Ansatz für den Aufbau komplexer Moleküle, die aus tertiären Alkoholen bestehen, zu 
entwickeln.  
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General Comments 
The numbering of the atoms in the tedanolides is given beginning from the carboxylic group of 
macrolactone and followed it with the central framework. The eight methyl groups are separately 
given numbers. The numbering pattern is not in accordance with the IUPAC rules. 
 
In the diagrams and the schemes, the structures for absolute stereochemistry are represented with 
wedges whereas the relative stereochemistry is shown with bars. 
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0. Abbreviations: 
 
°C                       degrees Celcius 
13C NMR  carbon- 13 nuclear magnetic resonance spectroscopy 
1H NMR                hydrogen- 1 nuclear magnetic resonance spectroscopy 
Å   angstrom 
A   adenine 
A site                 aminoacyl site 
AA   amino acid  
abs.   absolute 
Ac   acetyl  
ACN   acetonitrile 
AcOH                 acetic acid 
AD   asymmetric dihydroxylation 
aq.                      aqueous 
Ar   aromatic 
Bn   benzyl 
BORSM                based on recovered starting material 
Bu   butyl 
n-BuLi                 n-butyl lithium 
c   concentration 
ca.   approximately 
cm-1   reciprocal centimeter 
Cp   cyclopentyl 
COSY                 correlation spectroscopy 
CSA   camphorsulfonic acid 
Cy   cyclohexane 
d   doublet 
DCM                dichloromethane 
DDQ   2,3-dichloro-4.5-dicyano-1.4-benzoquninone 
DH   dehydratase 
de   diastereomeric excess  
DIBAL-H  diisobutyl aluminium hydride 
DIPEA                diisopropyl ethyl amine 
DMAP                4-N,N-Dimethylaminopyridine 
DMF   dimethylformamide 
DMP                Dess-Martin Periodinane 
DMSO               dimethylsulfoxide 
DNA   desoxyribonucleic acid 
E   entgegen, opposite 
E site                exit site 
ED50   effective dosage 50% 
ee   enantiomeric excess 
eIF2   eukaryotic initiation factor 2  
eIF4A                eukaryotic initiation factor 4A 
eq   equivalent 
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ESI   electrospray ionisation 
ER   enoyl reductase 
Et   ethyl 
Et2O   diethyl ether 
EtOAc                ethylacetate 
Fig   Figure 
FT-IR   Fourier transform infrared spectroscopy 
g   gram 
G   guanine 
h   hour 
HMDS   hexamethyldisilazide 
HMPT   hexamethylphosphorustriamide 
HRMS   high resolution mass spectrometry 
HWE   Horner-Wadsworth-Emmons-Olefination 
Hz   hertz 
IBX   o-iodoxybenzoic acid 
IC50   inhibitory concentration 50% 
i-Pr   isopropyl 
Ipc   isopinocampheyl 
J   coupling constant 
KR   ketoreductase 
L   litre 
LDA   lithium diisoproyl amide 
LiAlH4   Lithium aluminium hydride 
Lut   lutidine 
LiHMDS  Lithium bis(trimethylsilyl)amide 
m   multiplet 
M   molar 
M+   molecular ion 
m/z   mass-to-charge ratio 
m-CPBA  meta-chloroperbenzoic acid 
Me   methyl 
mg   milligram 
MHz   megahertz 
min   minute 
MgSO4   magnesium sulfate 
mL   millilitre 
MT   methyl transferase 
mmol   millimole 
MMTr   monomethoxytritylchloride 
MS   Mass spectrometry 
MTBE   tert-Butylmethyl ether 
mRNA   messenger ribonucleic acid 
NaCl   sodium chloride 
NaHCO3  sodium bicarbonate 
NaSO4   sodium sulfate 
ng   nanogram 
NH4Cl   Ammonium chloride 
nM   nanomole 
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NMR   nuclear magnetic resonance  
NMO   N-methylmorpholine-N-oxide 
NOE   nuclear Overhauser effect 
pet ether  petroleum ether 
P site   peptide site 
pg   picogram 
Ph   phenyl 
Piv   pivolyl 
PMB   para-methoxy benzyl 
PMP   para-methoxy phenyl 
ppm   parts per million 
PPTS   pyridinium para-toluenesulfate 
Pr   propyl 
Py   pyridine 
RNA   ribonucleic acid 
rRNA   ribosomal ribonucleic acid 
rt   room temperature 
s   singlet 
SAR   structure-activity relationship 
sat   saturated 
SEM   2-(trimethylsilyl)ethoxymethyl 
SNi’   intramolecular nucleophilic substitution 
t   triplet 
Tf   triflate 
TBAF   tetra-n-butylammoniumfluoride 
TBS   tert-Butyldimethylsilyl 
TBSCl   tert-Butyldimethylsilylchloride 
TBSOTf   tert-Butyldimethylsilyltriflate 
TE   thioesterase 
TES   triethylsilyl 
TESCl   triethlsilylchloride 
TESOTf   triethlsilyltriflate 
TEMPO   2,2,6,6-tetramethylpiperidin-1-oxyl 
THF   tetrahydrofuran 
TLC   thin layer chromatography 
TMNO   trimethylamine-N-oxide 
TMS   trimethylsilyl 
TMSCl   trimethylsilylchloride 
TMSOTf  trimethylsilyltriflate 
TPAP   tetrapropylammoniumperruthenate 
tRNA   transfer ribonucleic acid 
Ts   p-toluylsulfonyl 
U   uridine 
UV   ultraviolet 
Xc   chiral auxiliary 
Z   Zusammen  
   chemical shift in parts per million 
µL   microlitre 
µM   micromolar 
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1. Introduction: 
1.1. Natural Products in Treatment of Cancer: 
In 2008, approximately 12.7 million cancers were diagnosed (excluding non-melanoma skin cancers 
and other non-invasive cancers) and in 2010 nearly 7.98 million people died. Cancer accounts for 
approximately 13% of all deaths. This makes invasive cancer the leading cause of death in developed 
world and the second most in developing countries.1 Cancer figures among the leading cause of death 
worldwide, accounting for 8.2 million deaths in 2012. Lung, liver, stomach, colorectal and breast 
cancer are the most common cancer deaths every year. It is expected that annual cancer cases will 
rise from 14 million in 2012 to 22 million within the next two decades.2 
Natural products are the most important anti-cancer agents and accommodate three quarters of the 
anti-tumor compounds used as medicine. Out of 140 anti-cancer agents approved since 1940, over 
60% can be accommodated as natural products. Of the 126 small molecules among them, 67% are 
natural in origin. In order to fight against cancer effectively new lead chemotherapeutic agents are 
necessary, thus increasing the survival rate and minimizing side effect of chemotherapies.3 
Compounds with anti-tumor activity belong to several structural classes such as anthracyclines, 
enediynes, indalocarbazoles, isoprenoids, polyketide macrolides, non-ribosomal peptides including 
glycopeptides and others. Most of the polyketides are produced from the bacteria or fungi. They 
include a number of anti-tumor drugs (e.g. Taxol), which is made by both plants and fungi. 
Halogenated anti-tumor candidates include salinosporamide A and rebeccamycin. 
The anti-tumor compounds act by several mechanisms such as including apoptosis (programmed cell 
death) through DNA cleavage mediated by topoisomerase I or II inhibition, mitochondrial 
permeabilisation, inhibition of key enzymes involved in signal transduction (e.g. proteases), or cellular 
metabolism, and by inhibiting tumor-induced angiogenesis (recruitment of new blood vessels). 
Most of the important compounds used for the chemotherapy of tumors are microbially produced 
antibiotics or derivatives. Some of the microbial anti-tumor drugs are depicted below (Table 1.1). 
Table 1.1: Some of the microbial anti-tumor compounds. 
Group Examples 
Aromatic polyketides 
(anthracyclines) 
Daunorubicin, doxorubicin (adriamycin), epirubicin, pirirubicin, 
idarubicin, valrubicin, amrubicin. 
Glycopeptides Bleomycin, phleomycin 
Non-ribosomal peptides Actinomycin D (dactinomycin) 
Anthracenones Mithramycin, streptozotecin, pentostatin 
Quinones Mitosanes mitomycin C 
Polyketides Enediynes calicheamycin 
Indolcarbazoles  Glycosides rebbecamycin 
Polyketides Macrolide lactones epothilones, ixebepilones 
Nucleosides 2’’-deoxycoformycin (pentastatin) 
Halogenated compounds Salinosporamide A 
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Plants have been another useful source for the anti-tumor agents. Since 1961 nine plant derived 
compounds have been approved as anti-cancer drugs in the USA. Vinblastine (velban), vincristine 
(oncovin), etoposide, teniposide, taxol (paclitaxel), navelbine (vinorelbine), taxotere (docetaxel), 
camptothecin (camptosar, campto), topotecan (hycamtin) and irinotecan are some of the plant 
derived approved anti-tumor compounds. Although the ocean represents the center of biological 
diversity, prospecting the marine sources for the biotechnological use in drug discovery is a relatively 
recent activity. Marine sponges produce numerous bioactive compounds with pharmaceutical 
properties. Cyatrbine (Cyto star), pederin, theopederins, annamides, trabectedin (yondelis), aplidine, 
ectienascidin 743 (ET743) are few among the marine products with anti-tumor activity. Sixty eight 
percent of the pharmaceutically useful marine natural products employed are for cancer and the rest 
of them for anti-inflammatory, pain, asthma and Alzheimer’s disease.  
Most often the isolation process of the pharmacologically active substances from the natural 
resources results in very little quantities. Here comes the necessity of the total synthesis of the 
natural product through an effective synthetic strategy to produce them in substantial quantities in 
order to produce a scarce, but biologically intriguing, natural product for further extensive biological 
investigations and/or medicinal applications. A natural substance of some potential application can 
be synthesized in the laboratory, or the chemical plant. Natural product synthesis will be a more cost-
effective process than the one entailing its extraction from nature, its use becomes economically 
more feasible and desirable. It provides the scope to tweak the structure of a natural product for the 
purposes of enhancing its potency or improving its selectivity and physical and chemical properties. 
Such endeavours often lead to superior pharmacological properties than those possessed by the 
natural products themselves in terms of efficacy and safety giving an insight into the structure activity 
relationship. And, as surprising as this may sound these days, the chemical synthesis of a natural 
product still provides the absolute proof of the assigned structure, for the recent literature abounds 
with revisions of structures of natural products whose originally isolated minute quantities 
complicated their characterization.4,5 
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1.2. Sponges (Porifera): 
Sponges are sessile aquatic animals of the phylum Porifera. Sponges are similar to the other animals 
having multicellular, heterotopic, lack cell walls and produce sperm cells. Approximately 5000-10000 
known species of sponges are known, which are available in the marine environment ranging from 
tidal zones to depths exceeding 8,800 meters.6,7 
Sponges as primitive filter-feeders, produce a high frequency of bioactive components for their 
chemical defences against environmental stress factors. Highest concentrations of toxic or 
antioxidant sponge metabolites are found in inhabitants such as coral reefs. Sponges produce high 
level of cytotoxic chemicals by the emission of mucus in order to create a clear zone around it and 
push back other marine species. Secondary metabolites can protect the sponge from the predation, 
which is especially important for physically unprotected sessile organisms like sponges. Sponges and 
their microscopic endosymbionts are now being researched as possible sources of medicines for 
treating a wide range of diseases. 
Demosponges constitute about 90% of all known sponges, including all fresh water ones, and have 
the widest range of habitats. Fossils of all types have been found in rocks dated from 580 million 
years ago. In addition, Archaeocyathids, whose fossils are common in rocks from 530 to 490 million 
years ago, are also regarded as sponges. 
A sponge’s body is hollow and is held in shape by the mesohyl, a jelly like substance made mainly of 
collagen and reinforced by a dense network of fibers also made of collagen. The inner surface is 
covered with choancocytes, cells with cylindrical or conical collars surrounding one flagellum per 
choanocyte. The wave-like motion of the whip-like flagella drives water through the sponge’s body. 
All sponges have Ostia, channels leading to the interior through the mesohyl, and in most sponges 
these are controlled by tube-like procytes that form closable inlet valves. Pinacocytes, plate-like cells, 
form a single layered external skin over all other parts of the mesohyl that are not covered by 
chanocytes, and the pinacocytes also digest food particles that are too large to enter the Ostia, while 
those at the base of the animal are responsible for anchoring it. 
Most sponges work rather like chimneys; they take in water at the bottom and eject it from the 
osculum at the top. The simplest body structure in sponges is a tube or vase shape known as 
‘’asconoid’’. Sponges can have structures can be varying from simple asconoid (pinacocytes) to 
syconoid (chancocytes) and leuconoid (water flow) types. A simple asconoid sponge seldom exceeds 
1mm (0.039 inch) in diameter, whereas a leuconid sponge grows to over 1 m (3.3 feet). All fresh 
water and most shallow-water marine sponges have leuconid bodies. The fact the growth in any 
direction increases the number of chancocyte chambers enabling them to take a wider range of 
forms. The body structure is characterized by a stalk-like spongocel surrounded by a single layer of 
chanocytes (Figure 1.1).  
Sponges are traditionally classified into three different types, calcareous sponges (Calcarea), glass 
sponges (Hexactinellida) and demosponges (Demospongia). Much later a new class 
homoscleromorpha was identified as a different class from demospongiae. 
1. Introduction  Tedanolides 
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Fig. 1.1: Schematic representation of a sponge. Arrows indicate the direction of water flow through the sponge. 
Marine sponges have been ranked at the top with respect to the discovery of bioactive compounds 
with potential pharmaceutical applications. More than 15,000 marine products have been isolated 
and tested in the last 20 years until 2012. In 2011 the total number of natural products was 1152. The 
new natural chemical components from the phylum Porifera (sponges) has increased slightly from 
previous years to 269 compounds. The chemical diversity of sponge natural products is remarkable, 
including unusual nucleosides, bioactive terpenes, sterol, cyclic peptides, alkaloids, fatty acids, 
peroxides and amino acid derivatives.  
In the last few years several candidates from marine sponges were undergoing preclinical and clinical 
trials (I, II, III) for anti-cancer activity. Among them are Hemiasterlins A & B, modified halochondrin B, 
KRN-70000, alipikinidine, fascaphysins, isohomohalichondrin B, halochondrin B, and 
laulimide/fijianolide, 5-methoxyamphimedine and variolin.6 The first successful sponge-derived 
pharmaceutical drugs were the nucleosides spongothymidine and spongouridine which were isolated 
from Tectitethya crypta (Figure 1.2). A derivative of these nucleosides, Ara-C is documented as the 
first marine derived anticancer agent that is recently used for the treatment of leukemia. 
Renieramycin M is another natural compound derived from marine sponge with promising anti-
cancer activity. Renieramycins belong to the family of the tetrahydroiso-quinoline isolated from the 
marine sponges belonging to genera Reniera. Monanchocidin (Monanchora pulchra), smenospongine 
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(Smenospongina), spongistatin 1 (Spongia) and Heteronemin (Hytrios sp.) are few other compounds, 
which exhibited anti-tumor activity. 
 
Fig. 1.2: Natural products obtained from marine sponges. 
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1.3. Bermuda Fire Sponge Tedania Ignis and its Metabolites: 
The fire sponge tedania ignis is found abundantly in its endemic locations in the West Indies, Puerto 
Rico, Bermuda, and southern Florida and other areas (Figure 1.3). The exterior of the fire sponge 
varies from vermilion to orange. It is brighter red when exposed to sun, the red color is supposedly 
due to carotenoid pigment. With age, the color of sponge fades to orange-brown and in alcohol 
preservatives after months become off-white.8 
The marine sponge is popularly known as fire sponge, as the handling of sponges caused an itching 
sensation which lasted for several days, it reputedly causes varying degrees of dermatitis upon 
contact. The reason for the dermatitis is not clear whether by sponge metabolites or due to 
mechanical irritation by sponge spicules. 
 
Fig. 1.3: Fire sponge Tedania ignis growing in a turtle grass bed in Beliz; a cross section of Tedania ignis from Florida.9 
But the more interesting part is that these sponge extracts showed cytotoxicity in vivo tumor 
inhibition.10 In the course of a bioassay-guided search by Schmitz et al. for the tumor-inhibitory 
principles, a number of inactive or mildly cytotoxic components were found. After using different 
isolation and extraction techniques, initially two pure solids were isolated as epiloliolide (1) and the 
other was asitane-3, 16-diol (2) (Figure 1.4). Compound 1 and 2 were found to be slightly cytotoxic 
to a cell culture of human carcinoma of the nasopharynx with an effective dosis 50 (ED50) value of 21 
µl/mL. In the course of fractionation, a different class of compounds, diketopiperazines 3-5 were also 
isolated. 11 
 
Fig. 1.4: Secondary metabolites from Tedania Ignis. 
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Later in 1984, Schmitz et al. group reported an isolation of a potent cytotoxic macrolide named 
tedanolide 6 from the sponge Tedania Ignis (Figure 1.5). Around 20 kg of the dry sponge yielded 2 mg 
(app.) of white crystals of tedanolide. The structure of tedanolide (6) was determined by X-ray 
diffraction and NMR studies. Tedanolide is a 18-membered lactone differing from other macrolides at 
the site of lactonisation, which was found to be highly cytotoxic exhibiting an ED50 value of 2.5 × 10
-4 
µg in human carcinoma of the nasopharynx and 1.6 × 10-5 µg in vitro lymphocytic leukemia.12 Cell-flow 
cytofluorometry analysis revealed that tedanolide causes accumulation of the cells in the S-phase at 
concentrations as low as 0.01 µg/mL. 
 
Fig. 1.5: Structure of tedanolide (6). 
 
1.4. Family of Tedanolides: 
The highly cyclotoxic substance tedanolide (6) was first isolated from the marine sponge Tedania Ignis 
(a.k.a firesponge) and characterized by Schmitz et al. in 1984.12 Tedanolide represent the most 
structurally complex, biological potent polyketide within this group of marine derived inhibitors of 
protein synthesis. In addition to their potent biological activity, the tedanolide represent interesting 
structures consisting a rare primary lactone linkage with 18-membered lactone, C(18-19) epoxide and 
constituting several labile aldol subunits (Figure 1.6). According to the biosynthesis of polyketides,13-15 
tedanolide is made of mixed acetate-propionate biogenesis (acetate units at C-1,2 and -11,12). It 
differs from other macrolides in that site of lactonization is not the near the end of carbon skeleton.16 
Continuous search for cytotoxic metabolites from marine invertebrates, In the year 1991, Fusetani et 
al. discovered a new member of natural product 13-deoxytedanolide (7) from the the Japanese 
sponge Mycaleadhaerens (purple scallop sponge) belonging to the family of tedanolides (Figure 1.6).17 
Along with this four other active compounds were isolated, out of which compound 7 and a 
brominated isocoumarin named hiburipyranone are new. 13-Deoxytedanolide (7) showed remarkable 
cytotoxicity against P388 murine leukemia cells with inhibition concentration (IC50) values of 94 pg/mL 
and 0.19 µg/mL respectively. Structurally, natural product 7 is very much similar to the parent 
compound tedanolide (6) just lacking at the C(13)-hydroxyl group.  
As a part of natural products screening program for new anticancer lead compounds, in the year 2005 
Ireland et al. isolated a new entity in the family of tedanolides, named tedanolide C (8) from the 
extract of the marine sponge Ircina sp. (a.k.a stinky sponge) collected in Milne Bay, Papua New 
Guinea (Figure 1.6).18 Tedanolide C (8) exhibited potent cytotoxicity against haematocrit (HCT-116) 
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cells in vitro with an IC50 values of 57 ng/mL and arrested cell lines in S-phase. Tedanolide C (8) has 
the same eighteen membered primary lactone ring, C(18-19) epoxide as tedanolide (6) and 13-
deoxytedanolide (7), but consisted a rather complex oxygenation and methylation patterns. The 
structure was solved by interpreting NMR and MS data, and the relative stereochemistry was 
determined from a combination of homo- and heteronuclear coupling constants in conjunction with 
molecular modelling. 
 
 
Fig. 1.6: Structures of tedanolide (6), 13-deoxytedanolide (7) and tedanolide C (8). 
 
The latest additions in the family of tedanolides are candidaspongioldes 9-13 (Figure 1.7). Isolation of 
candidaspongiolides (9) and (10) was first reported in 2007 by Mc. Kee et al. from the sponge of the 
genus Candidaspongia (Great Barrier Reef, Australia).19 The candidaspongiolides mixture was 
potentially toxic, exhibiting a mean panel 50 % growth inhibition (GI50) value of 14 ng/mL in the 
National Cancer Institute’s 60-cell line in vitro antitumor screen, protein synthesis inhibition, and 
apoptosis induction. Continued investigation of the sponge species extracts led to the isolation of 
three new analogues, precandidaspongiolide A (11), precandidaspongioldie B (12) and 
candidaspongiolide B 13 along with candidaspongiolide A (10) and tedanolide (6).19 
Candidaspongiolide A (10) and B (11) were isolated as an equilibrium mixture (A:B = 1.7:1) whereas 
precandidaspongiolide A (11) and B (12) were isolated as an equilibrium mixture (A:B = 4.5:1). 
Precandidaspngiolides A and B showed excellent selectivity against melanoma cell lines in the NCI 60-
cell-line screen. The LC50 values for 11/12 against melanoma cell lines were significantly lower than 
other tumour cell lines. Structurally candidaspongiolides are related to tedanolide (6) with 
modifications on the carbon chain at C11-C15. Interestingly, the myriaporones isolated from a 
bryozoan are structurally related to the southern hemisphere of tedanolides, have also been isolated 
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as  an equilibrium mixture.21 The general structure of the candidaspongiolides was determined by 
analyses of various 2D NMR and MS data sets. The acyl ester components were identified by GC-MS 
analysis of the derived fatty acid methyl esters. 
 
Fig. 1.7: Structures of candidaspongiolides 9-13. 
1.5. Structure Activity Relationship Studies on 13-Deoxytedanolide (7): 
The isolation of 13-deoxytedanolide (7) from sponge Mycaleadhaerens provided the natural product 
in substantial amounts (105 mg), whereas tedanolide (6) was obtained in a very less amount (2 mg). 
In an attempt to obtain not only more active and less toxic derivatives but also structure activity 
relationships (SARs) of tedanolide cyclotoxins, Fusetani et al. modified some functional groups as an 
epoxide, hydroxyls, ketones and olefins of 13-deoxytedanolide (7).22 A total of ten derivatives has 
been prepared and evaluated for cytotoxicity against P388 leukemia cells as well as for inhibitory 
effects on polypeptide elongation in yeast cell lysate. This information provided some important 
information for SARs. 
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When 13-deoxytedanolide (7) was exposed to CDCl3, a considerable amount of less polar compound 
14 was observed, confirmed by NMR studies (Scheme 1.1). This product could be generated by acid-
catalysed fragmentation and also it’s noteworthy that compound 14 was present as a mixture of the 
ketone 14 and hemiacetal 14a forms in a ratio of 3:2. 
 
 
Scheme 1.1: Proposed mechanism for the formation of furan 14 from 13-deoxytedanolide (7). 
 
Upon treatment of 13-deoxytedanolide (7) with NaBH4, the 11-keto group was selectively reduced to 
obtain a pair of diastereomers (15 and epi-15), catalytic hydrogenation of 7 over Pd-C afforded the 
tetrahydroderivative 16, hydrogenation over RhCl(PPh3)3 yielded 17 in which only the 
21-olefin was 
reduced (Scheme 1.2). The three free hydroxyl groups in 7 are tried to acetylated using 4-pentenyl 
chloride and acetic anhydride to provide 18-21. Oxidation with OsO4/NaIO4 cleaved the less hindered 
21-olefin afforded aldehyde 22.  
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Scheme 1.2: Derivatives of 13-deoxytedanolide (7) for SAR studies. 
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With the derivatives 14-22 obtained from the chemical transformations from 13-deoxytedanolide (7), 
the cytotoxicity and inhibitory activity against polypeptide elongation (Table 1.2). The IC50 values of 
their cytotoxicity against P-388 murine leukemia cells ranged from 14 pg/mL to higher than 5 µg/mL, 
while those of their polypeptide elongation inhibition from 0.15 µM to higher than 100 µM. Furan 
compound 14 lost both the activities, suggesting the importance of both or either of the C-15 keto 
group and/or the side chain. Compound 15 retained the activity similar to deoxytedanolide (7), this 
implies that oxygen atom at C(11) in keto form or hydroxyl form will act as hydrogen acceptor. epi-15 
has significant decrease in the activity emphasising the strict requirement for spatial alignment of the 
oxygen atom at C(11). The contribution of 8-olefin functionality to the activity was demonstrated by 
the significantly reduced activity of 16, while 21-olefin functionality is less important as judged by the 
fully retained activities of 17. The northern hemisphere and the 8-olefin may play a role for 
stabilizing the conformation of the southern hemisphere in the active form. Two hydroxyl groups in 
the northern hemisphere may not be incorporated in the pharmacophore, which was indicated by the 
decreased but still potent activity of mono-acylated derivatives 18 and 19. Dipentenoate 20 showed 
only weak or no activity. These bulky modifications may generate synergetic effect, to avoid its 
binding to the ribosome. The oxygen atom at C(17) may also contribute to the potent activity, which 
was revealed by the loss of polypeptide elongation inhibition of the derivative 21. Although 21 
showed potent cytotoxicity, retention of activity in acetates are frequently explained by hydrolysis of 
endogenous esterases. The significance of the hydrophobhic terminus was substantiated by reduced 
activity of 22, in which terminal aldehyde group was hydrated. The cytotoxicity and polypeptide 
elongation inhibition of these derivatives disclosed the structural features important for the potent 
cytotoxicity (Table 1.2). 
Compounds Cytotoxicity Polypeptide elongation inhibition 
 IC50 (ng/mL) IC50 (µM) 
7 0.064 0.15 
14 >5000 >100 
15 0.014 0.15 
epi-15 92 0.80 
16 49 1.5 
17 0.2 0.4 
18 20 0.75 
19 9.2 0.65 
20 500 >50 
21 8 >50 
22 >5000 15.0 
Table 1.2. Biological activity of 13-deoxytedanolide (7) and its derivatives. 
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1.6. 60S Ribosomal Subunit Target of 13-Deoxytedanolide (7): 
Since the discovery of tedanolides, inspite of their remarkable activity the modes of action remained 
unknown until 2005, for the first time Fusetani et al. had conducted studies on 13-deoxytedanolide 
(7) and elucidated.23 In this study, a search was performed on the target molecule of 13-
deoxytedanolide (7) by using radiolabeled analogues 23 and epi-23 (Figure 1.8). From the budding 
yeast Saccharomyces cerevisiae cell lysate, 60S large ribosomal subunit was identified as the target of 
13-deoxytedanolide (7), and showed that compound 7 strongly inhibited polypeptide synthesis. 
Furthermore, 13-deoxytedanolide (7) was shown to share an unknown binding site on the 60S large 
ribosomal subunit with pederin.24 
 
Fig. 1.8: Chemical structures of radiolabeled ligands from 13-deoxytedanolide (7). 
Two radiolabeled analogues [11-3H]-(11S)-deoxydihydrotedanolide 23 and epi-23 were synthesized by 
treatment with [3H]-NaBH4. Compounds 7 and 23 inhibited growth of S.cervisiae while 24 showed 
weaker growth inhibition. To identify the 13-deoxytedanolide (7) binding protein, the cell lysate of 
S.cervisiae was incubated with radio-labeled 13-deoxydihydrotedanolides and tested whether the 
radioactivity was detected in the fraction trapped on the glass filter. Binding activity of these 
compounds correlated well with their anti-yeast activities, suggesting the presence of specific 
macromolecular target in the yeast. Although many protein synthesis inhibitory natural products are 
known to bind to the prokaryotic large subunit and inhibit the peptide elongation, 13-
deoxytedanolide (7) is the first macrolide that binds to the eukaryotic ribosome. Macrolide 
antibiotics, for example erythromycin and carbomycin, inhibit protein synthesis by binding to the 50S 
large subunit of prokaryotic ribosomes, but do not bind to the eukaryotic ribosomes. This difference 
may be due to the size of rings; 12- to 16- membered rings in prokaryotic antibiotics versus 18-
membered rings in tedanolides.  
The radioligands 23 also bound to the purified salt washed 80S ribosome. Moreover, the radioligand 
23 bound to the 60S subunit with high affinity, but didn’t bind to the 40S subunit. The 60S subunit 
had only a high affinity binding site, although 13-deoxytedanolide showed a high-affinity binding and 
a low-affinity binding to the 80S ribosomal complex. The presence of the high-affinity binding 
suggested that a covalent bond formed between the ribosome and the macrolide. 
The strong binding of 13-deoxytedanolide (7) to the 60S subunit of the ribosome suggests that 7 
inhibits protein synthesis. By examining the effects of 7, 23, epi-23 on poly(U)-directed poly(Phe) 
synthesis in the yeast S30 fraction. Compounds 7 and 23 inhibited the reaction at the IC50 value of 
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0.15 µM. In contrast compounds 7 and 23 couldn’t inhibit the polypeptide synthesis in the cell lysate 
prepared from Escherichiacoli. 
Competitive binding assays were carried out using ribosomal antibiotics, namely, peptidyltransferase 
inhibitors, puromycin and anisomycin, which share a neighbouring binding site around the 
peptidyltransferase center, did not prevent the binding of the radioligand 23 to the ribosome. The 
traditional translocation inhibitor, pederin (Figure 1.9) was found to perturb the binding of the 
radioligand to the 60S ribosomal subunit. While cycloheximide, another translocation inhibitor did 
not inhibit it. Theopederin A and onnamide A, which are closely related to pederin24 (isolated from 
sponge Paederusfuscipes) also competed with 13-deoxytedanolide (7) for binding, thus indicating that 
the potent cyclotoxins of the pederin class share the binding site on the 60S large subunit common to 
13-deoxytedanolide (7). It is also expected that compound 7 will be an important tool for elucidating 
structure and function of eukaryotic ribosomes. 
 
Fig. 1.9: Chemical structures of pederin, theopederin A and onnamide A. 
Crystal structures of the 50S ribosomal subunit from Haloarculamarismortui complexed with the 
antibiotic 13-deoxytedanolide (7) have been reported by Moore and co-workers in 2007.25 13- 
Deoxytedanolide (7) binds to the E-site of the 50S subunit and thus appears to inhibit protein 
synthesis by competing with deacylated tRNAs for E site binding (Figure 1.10). The specificity of 13-
deoxytedanolide for eukaryotic ribosomes is explained by its extensive interactions with protein L44e, 
which is an E site component of archeal and eukaryotic ribosomes, but not of the eubacterial 
ribosomes. In addition, protein L28, which is unique to the eubacterial E site, overlaps the site 
occupied by 13-deoxytedanolide, precluding its binding to eubacterial ribosomes. Homology modeling 
of the 70S ribosomal subunit of Thermus thermophilus with 13-deoxytedanolide showed overlapping 
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of the 28L protein (gray) and the drug (yellow) (Figure 1.10). This explains the selectivity for 
eukaryotes and presumably archaea. 
 
Fig. 1.10: Homology modelling studies of 50S and 70S subunit with 13-deoxytedanolide (yellow) (7). 
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1.7. Myriaporones  Structural Similarity to C10-23 Fragment of Tedanolide: 
In the year 1995, Reinhart and co-workers isolated four novel polyketide-derived metabolites, 
myriaporones 24-27 from the Mediterranean bryozoan Myriaporatruncate (Figure 1.11).21, 26-27 
Bryozoans are a group of primitive colonial animals widely distributed throughout the worlds marine 
and fresh water environments. Among those metabolites isolated from marine bryozoans, bryostatins 
are the most exciting and promising compounds which exhibit pronounced cytotoxicity. 
 
Fig. 1.11. Structures of myriaporones 24-27. 
The structures and stereochemistry have been assigned from the analysis of spectroscopic data. The 
inseparable equilibrium mixture of myriapornes 3 (26) and 4 (27) showed 88% inhibition of L210 
murine leukemia cells at 0.2 µg/mL (IC50 value of 100 ng/mL). Additionally, cytofluorometry 
experiments showed that myriaporone 3/4 caused S-phase arrest. Myriaporone 2 (25) showed 70% 
inhibition against L210 murine leukemia cells at 5 µg/mL. Myriaporone 2 arises from the epoxide 
opening of by the C(7)-carbonyl in myriaporone 1 (24). 
The myriaporones are structurally nearly identical to the C10-23 portion of tedanolide (6). The C(16)-
alcohol is reminiscent of the candidaspongiolides. The myriaporones would then share the same 
mode of action as tedanolide and their simple structure renders them more attractive as drug 
candidates. Recent studies established that like tedanolide, myriaporone 3/4 is a potent protein 
synthesis inhibitor selective for eukaryotes.28 In order to provide enough material to facilitate these 
studies, research groups of Taylor and Cuevas were successful in achieving the total synthesis of 
myriaporones.29,30 
Tedanolide (6) and 13-deoxytedanolide (7) are the most studied members of the tedanolide family, 
they virtually exhibit the same biological activity. The only structural difference is the presence of an 
alcohol at the C(13) position, which corresponds to C5 position for the myriaporones. Few analogues 
were designed by Myriam Roy from Taylor group in order to study the structure activity relationships 
of myriaporones (Figure 1.12).31 C(16)-deoxymyriaporone 4 (28), C(5)-deoxymyriaporone 3/4 (29) and 
C(5,16)-dideoxymyriaporone (30) are the analogues lacking the hydroxyl groups as similar to the 
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difference in 6 and 7 (Figure 1.12).Analogues lacking the Z-double bond in myriaporones and to probe 
the role of equilibrium, C(16)-hydroxyl ether was masked as methyl ether. 
 
 
Fig. 1.12: Structures of derivatives of myriaporones 28-34. 
Preliminary biological results performed with HTC-116 and MF-7 exhibited significant loss of activity. 
Thus far, simplification made to myriaporone 3/4 failed to retain the biological activity (Figure 1.13). It 
was identified that C(10,11) epoxide, C(13,14) Z-olefin, alcohol at C(5) and its stereochemistry, C(16) 
alcohol in the open form and the oxidation state at C(3) in the close form are proven to be essential 
for the activity. 
1. Introduction  Tedanolides 
21 
 
 
Fig. 1.13: Myriaporones 3/4 26&27. 
 
1.8. Gephyronic acid  Pharmacophoric Link between two Classes of Natural Products: 
An antibiotic compound gephyronic acid (35) was isolated from the culture broth of the 
myxobacterium Archangiumgephyrastrain Ar 3895 in 1995 by Höfle and Reichenbach.32 It is an 
aliphatic acid and tends to form hemiacetal (Figure 1.14). Both forms inhibited growth of yeasts and 
molds (MIC 1 ~ 25µg/mL) and had a cytostatic effect on mammalian cell cultures (IC50 10 ~ 60 ng/mL). 
Gephyronic acid (35) is a specific inhibitor of eukaryotic protein synthesis showing an IC50 value of 1~2 
× 10-7mol/L in an in vitro translation assay. 
 
Fig. 1.14. Structure of gephyronic acid (35). 
A combination of high-field NMR analysis of the natural products resulted in a revision of the 
structure of gephyronic acid (35), including a full assignment of the relative and absolute 
stereochemistry was finally confirmed by total synthesis from Taylor group.33,34 
The structurally related polyketide natural products tedanolide (6), myriaporone 3/4 (27) and 
gephyronic acid (35) are promising bioactive compounds that have been found to be potent and 
selective eukaryotic protein synthesis inhibitors. Although the the mode of action of gephryronic acid 
(35) is not known.  
Recently, polyketide 35 was discussed as a pharmacophoric link to tedanoliode (6) and 13-
deoxytedanolide (7) on its proposed relative configuration.35 There is a significant structural 
similarities between the C8-C17 region of gephyronic acid, the C15-C15 region of myriaporones, and 
the C13-23 region of the tedanolides (Figure 1.15). Moreover, the closed form of gephyronic acid 
appears to map quite well to the pyran region of the pederin class of polyketides. Thus, combined 
with their common selective eukaryotic protein synthesis inhibitor activity, gephyronic acid (35) may 
represent a potential pharmacophoric link between structurally distinct classes of biologically active 
compounds.  
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Fig. 1.15: Structural relationships between eukaryotic protein synthesis inhibitors. 
Although the biological target of gephyronic acid (35) was known, the specific target remains 
unidentified. Various diastereomers of gephyronic acid were made in order to elucidate the structure 
activity relationships. These studies have provided the evidence for the epoxide C(12-13) in the 
western part of the molecule as well as the C3-C5 stereotriad and the C1-moeity in the eastern part 
to be the pharmacophoric subunits for the observed cytotoxicity (Figure 1.16).31 
 
Fig. 1.16: Phamracophoric subunits of gephyronic acid (35). 
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1.9. Polyketide Biosynthesis: 
The remarkable structural and functional diversity in polyketides biosynthetically arises from 
combinatorial utilization and template-directed elongation of only a few simple building blocks. 
Malonyl-CoA and methylmalonyl-CoA comprise the great bulk of monomer units incorporated during 
chain elongation (Figure 1.17). The chain starter units can be the thioesters of monoacyl groups as 
acetyl-, propionyl-, and benzyl-CoAs, or structural variants, such as malonamyl-CoA or 
methoxymalonyl-CoA.13 There are three types of polyketide synthases (PKS) type I PKS (large and 
highly modular proteins), type II PKS (aggregates of mono-functional proteins) and type III PKS (which 
don’t use ACP domains). Type I PKS can be iterative (repetition of the same module in a cyclic fashion) 
or modular (contains a sequence of separate modules and don’t repeat domains).  
 
Fig. 1.17: Structures of common acyl-CoA thioesters used for chain intitiation and elongation of PKSs. 
Several transformations are catalysed in the different modules. An example of best know polyketide, 
erythromycin will be discussed. To clarify the synthetic implication of the domain organisation, the 
PKS version is shown in the Figure 1.18. The structural genes responsible for the biosynthesis of first 
macrolide intermediate 6-deoxyerythronolide B (6-dEB) are three enormous open reading frames 
(ORFs), eryAI, eryAII and eryAIII coding for three gigantic multienzyme polypeptides, 6-
deoxyerythronolide B synthase (DEBS) 1, 2 and 3 respectively. The circles depict the domains and the 
linker regions are omitted. Each of the DEBS proteins contains two modules, each module contains 
the three domains require to catalyse one cycle of chain extension [ketosynthase (KS), acyltransferase 
(AT) and acyl carrier protein (ACP)] as well as variable set of domains [ketoreductase (KR), dehdratase 
(DH) and enoyl reductase (ER)]. Starting from ketosynthase and finishing with ACP is taken to be a 
modular unit. DEBS 1 is fronted by a loading didomain (AT and ACP) which accepts the started unit 
propionate from the propionyl-CoA, while DEBS 3 terminates with the thioesterase (TE) activity which 
is thought to catalyse the off-loading of the fully formed heptaketide intermediate 37 and cyclise to 
give 6-dEB 36.  
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 Fig. 1.18: Domain organization of the erythromycin polyketide synthase.13 
The post PKS process involves the conversion of the 6-deoxyerythronolide (36) to erythromycins A-D. 
This direct PKS product 37 then usually is cyclised and becomes the substrate for the enzymes that 
perform the post-PKS modifications. Among these modifications are methylations (performed by 
methyl transferases MT) and oxidations (epoxidation or alcohol insertions by cytochrome P450 
oxidase). In the case of erythromycins, C-6 erythronolide hydroxylase selectively introduces the 
hydroxyl group at C(6) position, TDP-mycarose glycosyltransferase attaches the L-mycarose at C(3) 
position and the amino sugar D-desosamine is then added to C(5) hydroxyl group with the aid of TDP-
desosamine glycosyltransferase gives rise to erthyromycin D. Eyrythromycin D later will be converted 
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to other erythromycins with the help of enzymes C-12 hydroxylase and O-methyl transferase (Figure 
1.19). 
Another example is the case of epothilone,36 the C(12-13) epoxide is installed by a cytochrome P450 
epoxidase found in epoK. 
 
Fig. 1.19: Post-PKS modifications in polyketide biosynthesis  
It is evident from the above stated examples that the post-PKS modifications are common in the 
synthesis of polyketides, there could be chance that the biosynthesis of the tedanolides would also 
include a direct PKS product, which would then undergo post-PKS modifications to give rise to the 
rare class of compounds with primary lactone linkage macrolides. 
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2. Objective: 
 
From the biosynthetic prospective of polyketides, macrolides with primary lactone linkage are rare in 
the nature. Tedanolides are one of the rare class of polyketides consisting this salient feature. From 
the proposed biosynthesis of tedanolide (6), it was envisioned that isotedanolide (38), a secondary 
lactone could be the synthetic precursor (Figure 2.1). In an effort to prove this proposal 
desepoxyisotedanolide (40) was chosen as our synthetic target. The main objective of my Ph.D. 
dissertation is to synthesize desepoxyisotedanolide (40). 
 
Fig. 2.1: Desepoxytedanolide (40) as a biosynthetic precursor of tedanolide (6). 
Additionally, we planned to investigate the isomerisation of desepoxytedanolide (40) to the 
desepoxytedanolide (41) in a chemical environment (Scheme 2.1). This will substantiate the proposed 
biosynthesis of the tedanolide (6) and also the biological tests of this derivative 40 could provide 
more insights into the structure activity relationships of tedanolides.  
 
 
Scheme 2.1:  Isomerisation of desepoxyisotedanolide (40). 
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In second part of my thesis, the scope of applying Kiyooka aldol reaction to a variety of aldehydes to 
generate tertiary alcohols in a stereoselective manner will be explored (Scheme 2.2). 
 
Scheme 2.2: Kiyooka aldol reaction 
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3. Previous work: 
 
Due to the challenging structural complexity along with promising biological activity of tedanolides, 
several groups had initiated the synthetic studies resulting in a variety of fragment synthesis and total 
synthesis of tedanolide (6) and 13-deoxytedanolide (7).37-45, 67, 79 No total synthesis had been reported 
till date for the comparitively more complex molecules tedanolide C (8) and candidaspongiolides (9-
13). In this chapter the synthetic work concerning the total synthesis of natural products (6&7) will be 
discussed.  
3.1. Smith’s Approach:  
      (A unified approach to tedanolide (6) and 13-deoxytedanolide (7)). 
Smith and co-workers were the first to accomplish the total synthesis of the 13- deoxytedanolide (7) 
in 200337 and followed it up later with the total synthesis of tedanolide (6) in 200738 using the unified 
approach from a common intermediate (Scheme 3.1). 
Inspired from the total synthesis of rapamycin,39 the Smith group used dithiane linchpin 43 as the 
common advanced intermediate for the synthesis of both tedanolides 6 and 7. 
 The retrosynthetic part is depicted below in the Scheme 3.1. Epoxidation of the double bond C(18-19) 
was performed at the later stage, disconnection at the macrolactone linkage unfolded the linear 
fragment 42a/42b. Further disconnection at C(11-12) linkage gave rise to a common fragment, 
dithiane 43, and an epoxide fragment 45 employed in the synthesis of tedanolide, whereas an alkyl 
halide 44 in the case of 13-deoxytedanolide (7). 
 
Scheme 3.1: Retrosynthetic approach towards tedanolide and 13-deoxytedanolide by Smith et al. 
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3.1.1. Construction of the Dithiane Fragment 46: 
Aldehyde 48 was foreseen as an ideal substrate for further conversions towards the synthesis of 
dithiane 46 (Scheme 3.2). This polypropionate motif was obtained by a series of aldol condensations 
beginning from (S)-glyceraldehyde acetonide 47 as the starting point in 11 steps. Aldehyde 48 was 
treated with the lithiated species of vinyl iodide 50 to obtain the essential carbon framework for the 
dithiane 43. Iodide 50 was obtained in 11 steps from the commercially available (S)-Roche ester 49. 
The dithiane 46 was achieved in a linear sequence of 13 steps starting from glyceraldehyde acetonide 
47 with an overall yield of 23%.40 
 
Scheme 3.2: Synthesis of dithiane 46. 
3.1.2 Construction of Iodide Fragment 44: 
 
Synthesis of the fragment 44 began with the known alcohol 51,41 Conversion to acetate 53, using 
standard transformations proceeded in an overall high yield (51% over 5 steps). Ozonolysis of 
terminal olefin followed by Roush crotylation42 afforded compound 54, subsequent hydroboration of 
the terminal olefin to the corresponding primary alcohol, followed by removal of the PMB group gave 
compound 55. Oxidation of the deprotected hydroxyl group to the aldehyde and immediate Witting 
olefination led to the desired Z-Olefin in very good selectivity (20:1). Finally, deprotection of the 
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acetyl group and conversion of the primary hydroxyl group to the alkyl iodide using 
methyltriphenoxyphosphonium iodide gave the iodide 44 (Scheme 3.3).  
 
 
Scheme 3.3: Synthesis of alkyl iodide 44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Previous Work Tedanolides 
31 
 
3.1.3. Synthesis of 13-Deoxytedanolide (7): 
Construction of SEM ether 56 from dithiane 46 was achieved over a sequence of 4 steps (Scheme 
3.4). Lithiated dianion of 56 was treated with iodide 44 to afford compound 57 in 75 % yield, 
providing the complete carbon framework necessary for the construction of 13-deoxytedanolide (7).  
 
Scheme 3.4: Synthesis of compound 57. 
Intermediate 57 was then conveniently converted to the corresponding aldehyde using Parikh-
Doering conditions,43 followed by treatment with SmI2 in the presence of -hydroxy ketone 58 to 
afford a diastereomeric mixture of ester 59, therefore effectively achieving oxidation at C(1) via an 
Evans-Tischenko reduction (Scheme 3.5).44 Removal of the acetonide group using standard conditions 
also led to the loss of the diethylisoproplysilyl (DEIPS) group and hydrolysis at elevated temperature 
provided the free carboxylic acid necessary for the macrolactonisation, which was achieved using 
Yamaguchi conditions45 to provide macrolactone 60. Selective protection of the less sterically 
hindered allylic hydroxyl group was achieved with TESCl in DMF, subsequent removal of the PMB 
ether and the dithiane allowed for Dess-Martin oxidation of the resulting hydroxyl group to afford 
triketone 61. Removal of the TES ether and SEM ethers46 in the presence of TIPS group was achieved 
selectively in high yields and upon treatment of compound 62 with m-CPBA in the presence of 
NaHCO3
47 the desired epoxide was obtained with excellent stereoselectivtiy (>15:1) and an yield of 
48%. Finally removal of the TIPS group using TBAF and aq. DMPU led to 13-deoxytedanolide (7). 
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scheme 3.5: Synthesis of 13-deoxytedanolide (7). 
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3.1.4. Synthesis of Tedanolide (6) by Smith et al.: 
3.1.5. Construction of the Epoxide 63: 
Due to the lengthy first generation sequence leading to epoxide fragment 45 resulted in synthetic 
inefficiency. For the synthesis of tedanolide (6), Smith group developed a second generation strategy 
employing the alternative -stereoisomer of C(15) compared to 13-deoxytedanolide (7). This would 
be of no consequence since the C(15) hydroxyl would eventually be oxidized to ketone in the final 
product 6 (Scheme 3.6). Recognition of the allylic alcohol system at C(17) in compound 63 prompted 
the construction of this structural array in a stereo selective manner. It was envisioned that 
disconnection at the C(17-18) bond would result in vinyliodide 64 and aldehyde 65. 
 
Scheme 3.6: Retrosynthetic approach of epoxide 63. 
3.1.6. Construction of the Vinyliodide fragment 64:  
Literature known Roche aldehyde 67 was converted to alkyne 69 via Corey-Fuchs protocol48 in a yield 
of 83% (Scheme 3.7). In order to obtain the vinyl iodide moiety, stannylcupration of alkyne 69 
employing conditions of Pancrazi and coworkers,49 followed by iodination afforded the desired (E)-
trisubstitutedvinyliodide 70 as a single isomer. Thus fragment 70 was obtained in four steps with an 
overall yield of 69% from aldehyde 67. 
 
Scheme 3.7: Synthesis of vinyliodide 70. 
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3.1.7. Construction of the Aldehyde Fragment 65: 
Syn-aldol condensation employing the Evans’ crotonateimide50 of the literature known aldehyde 7151 
followed by reductive cleavage of the oxazolidinone furinished the homoallylic diol 72, establishing 
the C(15) and C(16) stereogenic centers with excellent stereoselectivity (Scheme 3.8). The resulting 
C(15) and C(29) hydroxyl groups were protected as a cyclic ketal 73. Ozonolysis of the terminal olefin 
in compound 73 provided the desired aldehyde 65. 
 
 
Scheme 3.8: Synthesis of aldehyde 65. 
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3.1.8. Construction of the C(12-23) Fragment 63: 
The coupling reaction between vinyliodide 70 and aldehyde 65 was achieved by metal-halogen 
exchange of vinyliodide 70 with t-BuLi in Et2O, followed by addition of aldehyde 65 to furnish the 
desired adduct 74 as the major diastereomer (6:1) and a combined yield of 90%. The newly generated 
C(17) hydroxyl group in compound 74 was protected as SEM ether and the PMB group was oxidatively 
removed to afford the primary hydroxyl compound 75. The required (Z)-olefin was installed by 
oxidation of primary hydroxyl to aldehyde followed by Wittig ethylidenation to yield compound 76. 
Removal of the TBS groups and inturn conversion of the resulting hydroxyl groups to the desired 
epoxide was achieved by the Fraser-Reid12 protocol affording the epoxide (C12-13) fragment 63 
(Scheme 3.9).  
 
 
Scheme 3.9: Synthesis of epoxide 63. 
 
3.1.9. Coupling of Epoxide 63 and Dithiane 56: 
 
In order to assemble the complete carbon framework for the tedanolide (6), epoxide 63 was added to 
the lithiated species of dithiane 56 using Williams’ protocol53 (t-BuLi in a 10%HMPA/THF solution) to 
furnish diol 77 (Scheme 3.10). Diol 77 was subsequently protected with TBSOTf and the primary TBS 
group was selectively removed using HF-pyridne to afford hydroxy compound 78, conversion of the 
primary hydroxyl group to the ester 78 was achieved in similar fashion to deoxytedanolide (7),  acid 
catalyzed methanolysis of the C(15,29) acetonide in 79 furnished diol 80  and saponification using 
LiOH in dioxane/H2O at reflux provided the carboxylic acid, which was allowed for macrocyclisation 
employing the Yamaguchi protocol45 to afford the desired primary macrolactone 81.  
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Scheme 3.10: Synthesis of compound 81. 
In the final steps, the PMB group was removed oxidatively using DDQ to produce diol 82, followed by 
dithiane cleavage with PhI(CF3CO2)2 employing Stork protocol
54 and the Dess-Marin oxidation55 of two 
hydroxyl groups furnish triketone 83 (Scheme 3.11). SEM deprotection was carried out selectively in 
the presence of TIPS and TBS groups using the conditions employed by Kim (MgBr2, EtSH).
56 Hydroxyl-
directed epoxidation using m-CPBA buffered with NaHCO3 furnished the desired epoxide, Global 
deprotection was achieved using the Et3N•3HF and Et3N as described by Roush
57 completed the total 
synthesis of tedanolide (1). 
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Scheme 3.11: Synthesis of tedanolide (6). 
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3.2. Roush’s Approach: 
 
In planning the synthetic approach to tedanolide (6) and deoxytedanolide (7), the Roush group 
envisioned compound 84 as a common intermediate to synthesize both macrolides (Scheme 3.12).58 
Compound 84 would be assembled from the convergent aldol coupling of methyl ketone 85 and 
aldehyde 86. (R)-configuration was chosen for the C(15)-position of 86 due to the earlier studies 
demonstrating that the lithium enolates of methyl ketone 85 add to 2,3-anti aldehydes with greater 
Felkin selectivity compared to 2,3-syn aldehydes. Keeping in mind the fact that C(15) hydroxyl would 
eventually oxidized to a ketone. Both the C(1)-acid and C(29)-hydroxyl groups would be masked with 
an allyl group to allow for simultaneous deprotection preceding macrolactonisation. Deoxygenation 
of C(13)-hydroxyl group was planned on adduct 84 in order to achieve deoxytedanolide (7). A 
convergent route would assemble the C(1)-C(12) ketone 85 via the aldol reaction of ethyl ketone 87 
and aldehyde 88. 
 
Scheme 3.12: Retrosynthetic approach towards tedanolide and 13-deoxytedanolide by Roush et al. 
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3.2.1. Synthesis of Ethyl Ketone 87: 
 
The synthesis began with assymetric hydrogenation of -ketoester 89,59 followed by alkylation of the 
-hydroxyester under Frảter conditions60 to give 2,3-anti ester 90 (Scheme 3.13). Reduction of the 
ester followed by protection of 1,3-diol with 3,4-dimethoxybenzylidene acetal and regioselective 
reductive acetal opening using DIBAL-H afforded compound 91. The primary alcohol was oxidized 
using Swern protocol61 and the resulting aldehyde was treated with -silyloxyallylstannane 92 and 
BF3•Et2O to afford the corresponding 3,4-syn-4,5-syn-homoallylic alcohol. Methylation of the alcohol 
(MeOTf, 2,6-di-tert-butyl-4-methylpyridine) gave compound 93. Oxidation of the terminal olefin to 
aldehyde followed by oxidation62 provided the C(1)- carboxylic acid, which was converted to allylester 
94 under Mitsunobu conditons.63 DDQ-mediated benzyl ether cleavage followed by the Parikh-
Doering oxidation43 of the resulting alcohol afforded the ethyl ketone 87. 
 
 
Scheme 3.13: Synthesis of ethyl ketone 87. 
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3.2.2. Synthesis of Aldehyde 88: 
 
Aldehyde 88 was synthesized from readily available anti--hydroxy--methylbutyrate 95, which was 
converted to aldehyde 96 via ester reduction, dimethoxybenzylideneacetal formation, 
regioselectiveacetal reductive opening, and Swern oxidation of the resulting primary alcohol. Wittig 
olefination of 96 with stabilized ylide Ph3P=C(Me)CO2Et provided ,-unsaturated ester 97 (Scheme 
3.14). Reduction of ester 97 to allylic alcohol followed by Parikh-Doering oxidation43 furnished the 
aldehyde 88. 
 
  
Scheme 3.14: Synthesis of aldehyde 88. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Previous Work Tedanolides 
41 
 
3.2.3. Completion of Synthesis of C(1-12) Ketone 85: 
 
The stereoselective aldol coupling of ethyl ketone 87 and aldehyde 88 was achieved by using TiCl4 and 
i-Pr2NEt with a good diastereoselectivity and moderate yield by immediate treatment of the titanium 
enolate of 87 with aldehyde 88 (Scheme 3.15). The free hydroxyl group in compound 98 was 
protected as TBS ether and DDQ cleavage of dimethoxybenzyl ether followed by TPAP oxidation64 
provided ketone 85. 
 
 
Scheme 3.15: Synthesis of ketone 85. 
 
3.2.4. Synthesis of C(13-23) Aldehyde 86: 
 
Wittig olefination of literature known aldehyde 6765 with stabilized ylide Ph3P=C(Me)CO2Et furnished 
the corresponding ,-unsaturated ester, reduction to the alcohol using DIBAL-H and subsequent 
Sharpless epoxidation66 of the allylic alcohol followed by Parikh-Doering oxidation afforded the 
epoxyaldehyde 101 (Scheme 3.16). Evans aldol reaction of 101 with chiral crotonate imide 102,50 
followed by silylation of the newly formed alcohol and reduction of the acyl oxazolidinone provided 
an alcohol functionality which was protected with 2-bromoethylcarbonate (BEC) to provide 
compound 103.  Oxidative cleavage of the terminal olefin in 103 furnished an aldehyde, which was 
converted to 105 via asymmetric crotylboration with (S,S)-104.42 The newly generated alcohol in 105 
was masked as TES ether and dihydroxylation of the terminal olefin followed by protection of diols as 
two -methoxy-acetate esters provided 106. The C(21)-C(22) (Z)-olefin was installed upon oxidative 
cleavage of PMB ether using DDQ, followed by oxidation of the primary alcohol and Wittig olefination 
of the resulting aldehyde. Treatment of 107 with allyl alcohol and MeMgBr, transesterified the BEC 
group to an Alloc group and also cleaved both the -methoxyacetate groups. The resulting diol was 
converted to aldehyde 87 using Pb(OAc)4. 
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Scheme 3.16: Synthesis of aldehyde 86. 
 
3.2.5. Synthesis of 13-Deoxytedanolide (7) by Roush et al.: 
The aldol reaction between ketone 85 and aldehyde 86 using LiHMDS provided 84 as a single 
diastereomer in moderate yield (Scheme 3.17). Upon cleavage of the C(15) TES ether, the secondary 
alcohol spontaneously cyclized onto the C(11) carbonyl to form a hemiketal 107, which proved to be 
unreactive towards oxidants (DMP, TPAP/NMO, SO3•pyrdine, PDC). Deoxygenation at C(13) in 
compound 107 was performed using pentafluorophenylthiocarbonate and subsequent treatment 
with triethylborane and tributyltinhydride afforded 108.  Dess-Martin periodinane oxidation on this 
mixture provided triketone 109. Cleavage of the allyl ester and allyl carbonate was achieved by 
treatment with Pd(PPh3)4 and tributyltinhydride in a single step, Yonemitsu-modified Yamaguchi 
lactonization45 followed by removal of the TBS groups furnished 13-deoxytedanolide (7). 
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Scheme 3.17: Synthesis of 13-deoxytedanolide (7) by Roush et al. 
 
3.2.6.  Synthesis of Tedanolide (6) by Roush et al.: 
 
For the synthesis of tedanolide (6), aldehyde 110 was targeted as a coupling partner for ketone 85 
which maintained the (S)-configuration at C(15)-position but lacked the epoxide (Scheme 3.18). A late 
stage C(17)-hydroxyl directed epoxidation of the C(18-19) olefin was envisioned similar to the 
Kalesse67 and Smith38 syntheses of tedanolide. Appropriate protecting groups were chosen in order to 
facilitate macrolactonisation.  
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Scheme 3.18: Retrosynthesis of aldehyde fragment 110. 
 
The C(13-23) framework of aldehyde 110 was achieved via the anti-aldol reaction of aldehyde 111 
and ketone 112 using conditions developed by Paterson,68 which presented similarities to the work 
done in the synthesis of tedanolide by the Kalesse group.67a Both aldehyde 111 and ketone 112 can be 
synthesized from the commercially available Roche ester (Scheme 3.19). Formation of aldehyde 111 
started from the trityl protected aldehyde 113. Wittig olefination followed by cleavage of trityl group 
using mild acidic conditions provided alcohol 114. Swern oxidation of alcohol 114 to the aldehyde 
followed by Wittig olefination with the stabilized ylide Ph3P=C(Me)CO2Et gave the ,-unsaturated 
ester 115. Reduction of ester 115 and subsequent oxidation with MnO2 provided aldehyde 111. 
 
 
 
Scheme 3.19: Synthesis of aldehyde 111. 
 
Ketone 112 was prepared from the DMPM-protected aldehyde 116 (Scheme 3.20). Addition of the 
lithium enolate of tert-butyl acetate to aldehyde 116 resulted in a -hydroxy ester, which underwent 
reduction to a 1,3-diol. Selective silylation of primary hydroxyl group and oxidation of the secondary 
alcohol furnished ketone 112. 
 
 
Scheme 3.20: Synthesis of ketone 112. 
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Ketone 112 and aldehyde 111 were coupled by Paterson’s aldol conditions68 leading to aldol product 
117 as the major diastereomer in a ratio of 80:20 (Scheme 3.21). Redcution of -hydroxy ketone 117 
to the syn-1,3-diol with DIBAL-H and selective silylation of the allylic alcohol gave TES ether 118. The 
dimethoxy benzyl ether of compound 118 was transferred on to the secondary alcohol via 
benzylideneacetal formation followed by regioselctive acetal reductive opening with DIBAL-H. The 
resulting primary alcohol in 119 was oxidized using Dess-Martin Periodinane to furnish aldehyde 110. 
 
 
Scheme 3.21: Synthesis of aldehyde 110. 
 
Addition of the lithium enolate of ketone 85 to aldehyde 110 provided the Felkin adduct 120 in 77% 
yield with 3:1 diastereomeric selectivity (Scheme 3.22). Protection of the newly formed C(13)-alcohol 
using SEMCl and DIPEA at 50 °C provided the SEM ether in quantitative yield. Under mild acidic 
conditions (PPTS/MeOH), the primary TBS group along with the C(17)-TES ether was cleaved to 
provide diol 121. Finally, the liberation of carboxylic acid functionality allowed for macrolactonisation 
to take place under the Yonemitsu modification of the Yamaguchi protocol.45 The cyclisation was 
completely selective at the primary alcohol, and the free hydroxyl group at C(17) position was 
protected as SEM ether to obtain macrolactone 122. Treatment of 122 with DDQ liberated the C(15)-
alcohol which was subsequently oxidized using Dess-Martin periodinane to afford the triketone 123. 
Removal of the two SEM groups was achieved using MgBr2 and ethane thiol in Et2O,
56 followed by 
directed epoxidation of the C(18-19) double bond with m-CPBA41b to afford a single epoxide 
diastereomer. Finally the TBS groups are removed using Et3N buffered HF•Et3N
69 to provide 
tedanolide (6). 
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Scheme 3.22: Synthesis of tedanolide (6) by Roush et al.  
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3.3. Loh’s Contribution towards Fragment Synthesis of Tedanolide (6): 
 
Loh’s group contributed valuable inputs towards the synthesis of tedanolide (6).41b, 70 Although the 
total synthesis of tedanolide (6) couldn’t be accomplished, the initial inputs on synthesis of individual 
fragments provided a very detailed information for other groups who were working on tedanolide at 
that point of time.57-58, 67  Loh and co-workers envisioned the synthesis of the carbon skeletal 
framework of tedanolide (6) through the aldol reaction between two key fragments, diketoester 125 
C(1-12) and aldehyde 126 C(13-23) (Scheme 3.23). 
 
 
Scheme 3.23: Loh’s retrosynthetic approach of tedanolide (6). 
 
3.3.1. Synthesis of Diketoester Fragment C(1-12) 125: 
 
The first key fragment diketoester 125, would be derived from the syn-selective boron-mediated aldol 
coupling of fragments ketoester 127 and ,-unstaruated aldehyde 128 (Scheme 3.24).70a  
 
 
Scheme 3.24: Syn-selective aldol coupling. 
 
The synthesis of aldehyde 128 began from the Roche ester 49 (Scheme 3.25), protection of primary 
alcohol with TBDPS group, followed by conversion to Weinreb amide to afford compound 129. 
Treatment of Weinreb amide 129 with methylmagnesium bromide yielded the corresponding methyl 
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ketone, further reduced to a mixture of diastereomeric alcohols and then protected as PMB ether 
130. Liberation of the primary alcohol followed by Dess-Martin periodinane oxidation to the 
corresponding aldehyde and treatment with stablisied Wittig ylide Ph3P=CCH3CO2Et afforded ,-
unstaruated ester 131 with a (E:Z, 94:6) diasteromeric ratio in favour of desired product. Reduction of 
the ester 131 to the corresponding allylic alcohol followed by oxidation to the desired aldehyde 128 
was achieved using Dess-Martin periodinane. 
 
Scheme 3.25: Synthesis of aldehyde 128. 
 
Once the synthesis of aldehyde 128 was achieved, efforts focused on the preparation of the keto-
ester, aldol coupling partner 127. Synthesis of ethyl ketone 127 started with Wittig reaction of 
literature known Roche aldehyde 132 with stabilized Wittig ylide t-BuO2CCH=PPh3. Sharpless 
asymmetric dihydroxylation66 using AD-mix-incorporated the C(2) and C(3) hydroxyl groups in a 
diastereomeric ratio of 6:1 in favour of the desired compound 134. C(2) and C(3)-hydroxyl groups 
were then protected as TBS and methyl ethers respectively. The PMB group in compound 135 was 
removed using aqueous DDQ, followed by oxidation using Dess-Martin periodinane provided 
aldehyde 136. Grignard reaction of aldehyde 136 with ethylmagnesium bromide at 78 °C provided a 
diastereomeric mixture of alcohols which are subsequently oxidized to the corresponding ketone to 
yield the desired ethylketone aldol coupling partner 127 (Scheme 3.26). 
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Scheme 3.26: Synthesis of ethylketone 127. 
 
In order to complete the fragment synthesis enal 128 was treated with ethyketone 127 in a syn-
selective boron-mediated aldol reaction to give compound 137 with good stereoselectivity (94:6). The 
newly generated hydroxyl group was protected as TBS ether and deprotection of the PMB group 
followed by Dess-Martin periodinane oxidation provided the C(1-12) diketoester fragment 125 
(Scheme 3.27).  
 
 
 Scheme 3.27: Synthesis of diketoester 125. 
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3.3.2.  Synthesis of Aldehyde Fragment C(13-23) 126: 
 
The synthesis of the second key fragment aldehyde 126,70b was based upon two advanced 
intermediates, ketone 13870b and aldehyde 13968c (Scheme 3.28). These two fragments were reacted 
in a boron-mediated aldol reaction using Paterson’s conditions68 to afford a mixture of diastereomers 
(85:15) in favour of desired product 140. The C(16)-ketone group was selectively reduced to a syn-diol 
as a mixture of diastereomers (>20:1) using Et2BOMe/NaBH4 and converted to p-methoxybenzylidene 
acetal 141 using DDQ. Installation of the Z-double bond at C(21-22) was achieved by removal of 
TBDPS group followed by Dess-Martin periodinane oxidation and Wittig olefination of the resulting 
aldehyde with stabilised Wittig ylide Ph3P=CCH3 to afford Z,E-diene 142 as the major product (dr 
>10:1). Selective reductive acetal opening using DIBAL-H followed by Dess-Martin oxidation yielded 
the desired aldehyde 126.  
 
 
Scheme 3.28: Synthesis of aldehyde 126. 
 
Having both the key fragments diketoester 125 and aldehyde 128 in hand, the crucial aldol reaction 
required to effect the generation of the desired C(13) center of the tedanolide skeleton was 
performed70b (Scheme 3.29). Various aldol reagents were tested to achieve higher selectivity of the 
newly formed C(13)-carbinol center (Table 3.1). The lithium and sodium enolates of methyl ketone 
125, gave moderate stereoselectivities favouring the desired diastereomer 143. Addition of HMPA 
further decreased the diastereoselectivity. Reaction with dibutylboron and 9-BBN enolates of methyl 
ketone 125 provided similar results as lithium enolate, while dicyclohexylboron enolate gave a slight 
improvement in diastereoselectivity in favour of desired isomer 143. Enolization employing (+)-
Ipc2BCl afforded better selectivities in moderate yields. An aldol reaction with TiCl4 gave a mixture of 
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aldol products. In addition, the ester 125 and aldehyde 126 were recovered with satisfactory yields 
without any epimerisation.  
 
 
Scheme 3.29: Aldol coupling of fragments 125 and 126. 
a
 Table 3.1: Aldol reaction of keto ester 125 and aldehyde 126. 
Combined isolated yields of 143and 144 after silica gel chromatography. 
b
Ratio was deteremined from 
1
H NMR of the purified diastereomers in a mixture 
 
In conclusion, the Loh group developed convergent routes to synthesize both ketoester 125 and 
aldehyde 126, and demonstrated their synthetic viability for an aldol coupling. Having accomplished 
the construction of the C(1-23) carbon backbone of the tedanolide, they failed to finish the total 
synthesis of the tedanolide (6). 
 
 
Entry Conditions Yielda 
(%) 
143:144b Recovered (%) 
    125            126 
1 LiHMDS, 78 °C, THF 26 68:32 66 59 
2 NaHMDS, 78 °C, THF 30 64:36 57 43 
3 LiHMDS, 9% HMPA, 78 °C, THF 27 53:47 54 29 
4 n-Bu2BOTf, Et3N, 78 °C, CH2Cl2 24 66:34 79 53 
5 (c-hex)2BCl, Et3N, Et2O, 0 °C, 1h then 126, 78 to 
20 °C 
47 74:26 59 1 
6 9-BBNOTf, Et3N, Et2O, 78 to 20°C 52 60:40 14 6 
7 ()-Ipc2BCl, Et3N, Et2O, 0 °C, 1h then 126, 78 to 
20 °C 
19 15:85 62 56 
8 ()-Ipc2BCl, Et3N, Et2O, 0 °C, 1h then 126, 78 to 
20 °C 
34 83:17 37 17 
9 TiCl4, i-Pr2EtN, CH2Cl2, 78 °C 24 41:59 46 0 
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3.4. Yonemitsu’s Approach towards the Synthesis of Tedanolide (6):  
 
As a result of extensive studies based on the conformational analysis by molecular mechanics (MM) 
caluculations of the macrolactone in tedanolide (6), the Yonemitsu group designed a seco-acid 
derivative suitable for effective macrolactonization. Key notes suggested that the aldol structures in 
compound 6 are not all arranged antiperiplanar in order to avoid decomposition or dehydration; the 
two pairs of carbonyl groups (C1-C11, C5-C15) are situated opposite to each other, to maintain 
stability of the 18-membered lactone; In order to maintain the conformational stability in the acyclic 
intermediates all the aldol groups were to be replaced by the protected diol functionality, and then 
be oxidised back to the ketones after the formation of the 18-membered macrolactone. Taking all 
these aspects into consideration, Yonemitsu et al. proposed two structures 145 and 146 as promising 
intermediary lactone and the corresponding seco-acid which would eventually lead to the synthesis 
of tedanolide (6) (Scheme 3.30).71 
 
 
Scheme 3.30: Resulting structures of conformational studies on tedanoldie (6) by Yonemitsu et al. 
 
Retrosynthetically, compound 146 would be synthesized by coupling between fragments C(1-12)  147 
and C(13-23) 148. Inturn, these could be obtained from precursors C(1-7) 149, C(8-11) 150, C(13-17) 
151 and C(18-21) 152, derived from (R) and (S)-Roche esters (Scheme 3.31).72 
3. Previous Work Tedanolides 
53 
 
 
 
Scheme 3.31: Retrosynthetic approach towards tedanolide (6). 
 
3.4.1. Synthesis of C(1-12) Fragment Methylketone 147: 
 
With the established retrosynthetic pathway the following task involved the synthesis of 
methylketone 147, which was based upon the coupling of two fragments vinyliodide 150 and 
aldehyde 149, both obtained from the common starting material Roche aldehyde 153 (Scheme 3.32). 
Wittig reaction of aldehyde 153 with a stabilised ylide, followed by reduction provided allyl alcohol 
154. Subsequent Sharpless asymmetric epoxidation73 followed by regioselective ring opening with 
vinylcopper reagent afforded 1,3-diol 155. Several functional group manipulations lead to compound 
156, which underwent dihydroxylation of the terminal double bond, followed by periodate cleavage 
and homologation of the resulting aldehyde to afford unsaturated species 157. The ,-unsaturated 
ester 157 was subjected to Sharpless asymmetric dihydroxylation66 using AD-mix-to afford diol 158 
in excellent yield and diastereoselectivity (>99 % de). Treatment of diol 158 with DDQ under 
anhydrous condition followed by C(2)-hydroxyl protection with methoxymethyl chloride provided 
compound 159, which underwent reduction of the ester and protection of the resulting primary 
hydroxyl group with pivaloyl chloride followed by TBS group removal and subsequent oxidation to 
aldehyde using Dess-Martin perdiodinane gave compound 149 quantitatively. 
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Scheme 3.32: Synthesis of aldehyde 149. 
 
The synthesis of aldol coupling partner iodoalkene 150 was achieved by hydrozirconation74 of alkyne 
160 using the Schwartz reagent (Scheme 3.33). Alkyne 160 in turn was prepared from Roche aldehyde 
153 via dibromoalkene following the Corey-Fuchs protocol.48   
 
 
Scheme 3.33: Synthesis of iodoalkene 150. 
 
The lithiated species of iodoalkene 150 was then allowed to react with aldehyde 149 to obtain the 
expected Felkin adduct 161 and its isomer in a ratio of 3.6:1 (Scheme 3.34). The newly generated 
C(7)-hydroxyl was protected as methoxymethyl (MOM) ether, to which TBDPS group cleavage  and 
oxidation of the resulting primary alcohol resulted in aldehyde 162.  Aldehyde 162 was treated with 
methyllithium in order to introduce the C(12) methyl group, and the protection of the C(1)-hydroxyl 
group followed by the oxidation of the C(11)-secondary alcohol afforded methyl ketone 147. 
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Scheme 3.34: Synthesis of methylketone 147. 
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3.4.2. Synthesis of C(13-23) Fragment Aldehyde 148: 
 
Aldehyde 148 was obtained from coupling of two fragments aldehyde 151 and Iodoalkene 152. 
Iodoalkene 152 was synthesized in similar fashion to alkene 150 using the enantiomer of Roche 
aldehyde 153. Although aldehyde 151 was synthesized by two different routes, both utilizing the 
Roche aldehyde 153 as starting point, the second route proved to be more efficient with and is 
depicted below (Scheme 3.35). Evans’ asymmetric aldol reaction50 on aldehyde 153 gave the product 
163 in very good selectivites (dr = 95:5), Evans’ auxiliary was removed by using standard conditions 
and the resulting 1,3-diol was protected as dimethoxyphenyl acetal to afford compound 164. 
Selective reductive acetal opening using DIBAL-H followed by protection of the primary hydroxyl 
group and treatment of the terminal double bond with OsO4 and NaIO4 provided aldehyde 151. 
 
 
 
 
Scheme 3.35: Synthesis of aldehyde 151. 
 
 
Aldehyde 151 was then treated with the lithiated species of the iodoalkene 152 resulting in poor 
diasteroselectivity (1:7.5) in favor of the undesired product (Scheme 3.36). The newly generated 
hydroxyl group was oxidized to ketone 165. Removal of the TBS group followed by stereoselective 
reduction of the ketone provided the desired alcohol C(17/) and then both hydroxyl groups are 
protected as diacetate 166. Installation of the double bond at C(21-22) was achieved by selective 
protection of the C(13)-alcohol as DMPM acetal followed by the oxidation of the C(21)-alcohol to the 
corresponding aldehyde, which was treated with a ylide prepared from ethyltriphenylphosphonium 
bromide to afford the Z-olefin 168 with 15:1 selectivity. Reductive acetal opening and oxidation of the 
primary alcohol provided aldehyde 148. 
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Scheme 3.36: Synthesis of aldehyde 148. 
 
The aldol condensation between the lithium enolate of ketone 147 and aldehyde 148 resulted in a 
poor diastereoselectivity (1:1.9) in favour of Felkin product 169 (Scheme 3.37). Removal of TES group 
afforded the corresponding primary alcohol, which is further converted to the carboxylic acid 146 
under standard conditions. TBS group removal followed by macrolactonisation using Yamaguchi 
conditions45 afforded the macrolactone 145. On the whole, Yonemitsu and co-workers established a 
convergent route for individual fragment synthesis, successfully obtained the macrolactone 145, but 
the total synthesis of tedanoldie (6) was not accomplished. 
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Scheme 3.37: Synthesis of macrolactone 145. 
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3.5.  Kalesse’s Approach: 
The total synthesis of tedanolide (6) was first accomplished in our group in the year 2006,67b In the 
process of synthesizing the tedanolide (6), a late stage C(17)-hydroxyl directed epoxidation at 
C(18,19) was planned in order to circumvent the problems that are reported by Roush et al. during 
the total synthesis of deoxytedanolide (7).58 Macrolactone cleavage would give rise to compound 170 
(Scheme 3.38), which was envisioned as the substrate constituting the complete carbon framework 
necessary for the target molecule (6), in which C(29)- hydroxyl bearing MMTr group and allyl ester on 
C(1) can be selectively liberated to undergo macrolactonisation.  
The retrosynthetic analysis (Scheme 3.38) dissected compound 170 such that the aldol reaction 
between C(12) and C(13) serves as a juncture between the key intermediates 171 and 172. (S)-
configuration was chosen for the C(15)-hydroxyl group and C(1)-carboxylic acid was masked as allyl 
ester.  
Scheme 3.38: Retrosynthetic approach towards tedanolide (6) by Kalesse et al.. 
3.5.1. Synthesis of Methyl Ketone C(1-12) 171:  
 
The synthesis  of the ketone fragment C(1-12) 171 was carried out in our group by J. Hassfeld and U. 
Eggert.75-76 Throughout these studies, the scope of aldol coupling of methyl ketone 171 with the 2,3-
syn model aldehydes was explored and various conditions for macrolactonisation towards the 18-
membered ring. The synthesis involved the vinylogous Mukaiyama aldol reaction (VMAR) as the key 
step, in which four-carbon chain with three contiguous stereo centers, was introduced with high 
enantiomeric and diastereomeric selectivities. 
  
The retrosynthetic approach of the ketone fragment 171 is depicted below in the Scheme 3.39. 
Compound 171 could be achieved from the dihydroxylation of the unsaturated ester 173. The 
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hydroxyl groups at C(2) and C(3) position are introduced using Sharpless asymmetric 
dihydroxylation,30,37 obtaining the desired stereochemistry. Ester 177 could be achieved from a 
vinylogous Mukaiyama aldol reaction of the aldehyde 174. The vinylogous Mukaiyama aldol reaction 
on aldehyde 174 using the ketene acetal 175 could provide the ,-unsaturated ester 173, bearing 
the complete carbon framework for the fragment. Aldehyde 174 could be obtained from a syn-
selective Evans aldol reaction50 of aldehyde 176, which in turn could be obtained from the 
crotylboration of the acetaldehyde using the Brown protocol.77 
 
 
Scheme 3.39: Retrosynthesis of methyl ketone 171. 
 
3.5.2.  Synthesis of Aldehyde C(13-23) 179:  
 
The synthesis of aldehyde fragment 179 was reported by G. Erhlich, J. Hassfeld and U. Eggert (Scheme 
3.40).78 Two separate synthesis of the aldehyde fragment were developed. In the first approach, anti-
selective aldol reaction was planned at the C(15-16) bond between the intermediates 178 and 132. 
Hydroxy compound 178 was in turn built by an aldol reaction between ethyl acetate and aldehyde 
111. 
 
 
 Scheme 3.40: First generation approach of aldehyde 179. 
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Aldehyde 111 could be obtained from the ester 115, which inturn could be obtained from E-Wittig 
olefination of the aldehyde generated from compound 180. The Z-olefin olefin 180 could be obtained 
from the aldehyde generated from the alcohol 181, which is obtained from the commercially 
available Roche ester 182 (Scheme 3.41). 
 
 
Scheme 3.41: Retro synthetic approach of aldehyde 111. 
 
The first generation synthesis of the aldehyde 179, commenced with the treatment of aldehyde 111 
was treated with the lithiated species of ethyl acetate, followed by DIBAL-H reduction, TBS-protection 
of the primary group and oxidation of the secondary alcohol to provide compound 184 (Scheme 5.5). 
Anti-selective aldol reaction with PMB-aldehyde 132 gave the desired Felkin-product 185 in 2:1 
diastereomeric ratio. Subsequently, the PMB group was oxidized to PMP acetal using DDQ, and the 
TBS group was removed using HF-pyridine. Chelation controlled reduction of the ketone in the 
presence of Zn(BH4)2 provided allyl alcohol 186 with the desired stereochemistry. To finalise the 
synthesis, protection of the primary and allyl alcohol functionalities, followed by reductive acetal 
opening and oxidation furnished the aldehyde 179.  
 
 
 
Scheme 3.42: First generation synthesis of aldehyde 179. 
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The first generation synthesis of C13-23 aldehyde presented above had its drawbacks, due to the 
relatively long number of linear steps and occasional uncontrolled migration of protecting groups. 
This led to development of second generation synthesis of aldehyde 172, using a more convergent 
anti-selective aldol coupling between C(16) and C(17) (Scheme 3.43). Ketone 138 was planned as the 
coupling partner for the aldol reaction. 
 
 
Scheme 3.43: Second generation approach of aldehyde 172. 
 
Ketone 138 was prepared in 4 steps from the PMB Roche aldehyde 132, addition of lithium enolate of 
ethyl acetate to aldehyde 132 resulted in a -hydroxy ester that was reduced to a 1,3-diol (Scheme 
3.44). Subsequently selective silylation of primary hydroxyl group and oxidation of the secondary 
alcohol furnished the ketone 138. Paterson aldol reaction of ketone 138 with aldehyde 111 gave the 
desired diastereomer 187 in 2:1 ratio. The ketone functionality in 187 stereoselectively reduced with 
DIBAL-H to the alcohol in high selectivity. Following functional group exchange, the allylic alcohol was 
selectively protected as TBS ether and the PMB group was transferred on to the secondary hydroxyl 
via a sequence of benzylideneacetal formation followed by regioselctive acetal reductive opening 
with DIBAL-H. The resulting primary alcohol was oxidized to aldehyde 172 using TPAP/NMO. 
 
 
Scheme 3.44: Synthesis of aldehyde 172. 
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3.5.3. Synthesis of Tedanolide by Kalesse et al.(6): 
 
Having established the routes for both fragments, the focus turned towards the completion of 
tedanolide (6). The crucial aldol coupling between the ketone 171 and aldehyde 172 was optimized 
after careful screening of different bases. KHMDS proved to be the most suitable base for the 
enolisation of the methyl ketone functionality and thereby achieved the highest diasteroselectivity in 
favour of Felkin product 189 (dr 7:1) (Scheme 3.45).  
 
 
Scheme 3.45: Aldol coupling of ketone 171 and aldehyde 172. 
 
The resulting C(13)-hydroxyl group was protected as TBS ether in order to avoid any lactonisation at 
this position (Scheme 3.46). The moderate yield observed for this protection was attributed firstly, to 
considerable amount of retro-aldol reaction and the secondly to the cleavage of the MMTr group 
under these reaction conditions. Finally the MMTr group was removed using a mild acid 
hexafluoroisopropanol. Palladium-catalyzed allyl ester saponification followed by macrolactonisation 
under Mitsunobu conditions63 led to the desired macrolactone 198. The C(5) and C(15) hydroxyl 
groups are liberated and oxidized to their respective ketones. The global deprotection was achieved 
by following the protocol utilized by Roush in the total synthesis of deoxytedanolide57 (Et3N•HF in 
Et3N). The final epoxidation of the C(18-19) double bond was achieved using excess of m-CPBA and 
NaHCO3 at low temperatures to furnish tedanolide (6). 
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Scheme 3.46: Synthesis of tedanolide (6). 
 
 
In conclusion, the total synthesis of tedanolides achieved by several groups were discussed in 
detail additionally valuable contributions from Yonemitsu and Loh groups for individual 
fragment synthesis have been highlighted. A few other research groups79 had tried to 
synthesize to make this class of natural product however, they were not successful in 
accomplishing the total synthesis of tedanolides. 
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4. Synthetic Part: 
4.1. Synthesis of Isotedanolide: 
The tedanolide family of natural products is a rare example of macrolactones formed by primary 
linkage (Figure 4.1). The biosynthesis of these polyketides is elusive and is thought that the presence 
of the primary hydroxyl group in the tedanolide could arise from the post polyketide synthases (PKS) 
modifications.80 
 
Fig. 4.1: Structures of tedanolides 6 and 7. 
Due to the belief that the oxygenation at C(29) along with the C(2)-hydroxyl occur as post-PKS 
modifications, it is thought that the C(18-19) epoxide and the C(3) methyl ether may also arise from 
this process, the direct product of PKS biosynthesis is likely to be the 18-membered lactone (39) 
(Scheme 4.1). This species (39) would then act as a substrate for cytochrome of P450 oxidase, and a 
methyl transferase, which would then produce isotedanolide (38).35 
 
Scheme 4.1: Proposed biosynthesis of tedanolide (6). 
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The synthesis of desepoxyisotedanolide (40) was initiated in order to probe the proposed 
biosynthesis of tedanolide.35 The synthesis of desepoxyisotedanolide (40) followed by the 
isomerisation under chemical conditions to desepoxytedanolide (41) was the objective of this project 
(Scheme 4.2). Based on the literature precedence and the research carried out by several work 
groups, the synthesis of desepoxyisotedanolide (40) was designed. 
 
Scheme 4.2: Isomerisation of desepoxyisotedanolide (40). 
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4.1.1. Retrosynthesis of Desepoxyisotedanolide (40): 
The synthetic route was designed similar to that of the total synthesis of tedanolide (6), followed 
earlier in our group.67 Cleavage of macrolatone would provide the linear fragment 192 consisting of 
the complete carbon frame work for desepoxyisotedanolide (40) (Scheme 4.3). The linear fragment 
192 could be built upon the base-induced substrate controlled-aldol reaction of ketone 193 and 
aldehyde 194. Selective liberation of the C(17)-allyl hydroxyl group, keeping the C(29)-hydroxyl group 
protected and cyclisation to the eighteen-membered secondary lactone would furnish the desired 
secondary macrolactone. A series of oxidations will provide us desepoxyisotedanolide (40). 
 
 
 
Scheme 4.3: Retrosynthetic approach towards desepoxyisotedanolide (40). 
 
Appropriate selection of the protecting groups for the hydroxyl group was the major challenge 
throughout the synthesis of desepoxyisotedanolide (40). An advanced stage intermediate with 
minimal protecting groups for the ketone part was required in order to avoid problems at later 
stages. Ketone 193, earlier reported in our group,81 containing a ketone at the C(6) position was 
chosen as a possible coupling partner for the key aldol condensation. It was envisioned that an 
alternative protecting group strategy was required at the C(17)-hydroxyl group of aldehyde 194 
coupling partner, which would allow for deprotection under milder conditions. From our earlier 
experiences during the synthesis of tedanolide (6),67 monomethoxytrityl group (MMTr) was selectively 
removed in the presence of TBS group under mild acidic conditions. Keeping this in mind, initially 
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aldehyde 194, bearing the MMTr group at the C(17)-hydroxyl and TBS group at  the C(29)-primary 
hydroxyl while retaining the C(15)-hydroxyl as PMB ether, was envisioned as an aldol coupling partner 
to the ketone 193 in an aldol reaction. 
 
4.1.2. Synthesis of Keto C(1-12) Fragment 193: 
The synthesis of methyl ketone 193 began with Brown’s crotylboration77 of commercially available 
acetaldehyde to afford homoallylic alcohol 195 (Scheme 4.4). The reaction proceeded in good 
yieldresulting in high diastereo- and enantioselectivity.  
 
 
Scheme 4.4: Crotylboration of acetaldehyde. 
 
The synthesis of (Ipc)2BOMe was achieved from commercially available -pinene 196, which readily 
undergoes hydroboration at 0 °C to form diisopinocampheyldiborane 12 (Scheme 4.5). The best 
conditions to form optically pure Ipc2BH involved the use of relatively stable boranemethylsufide and 
15% excess -pinene, in order to reduce the dissociation of diisopinocampheyldiborane. 
Methanolysis of Ipc2BH 197, at 0 °C produced the methoxy-isopinocampheylborane 198. 
 
 
 
Scheme 4.5: Synthesis of methoxy-isopinocampheylborane 198. 
 
The reaction of allyllic organometallic reagents with aldehydes affords the corresponding homoallyl 
alcohols. This transformation generates two new stereo centers and potentially four stereoisomeric 
products. The crotyl-borane derivatives generally exist as an interconvertible mixture of isomers 
which adds to the aldehyde to afford a mixture of regioisomers. The fast equilibration of pure (E)- and 
(Z)-crotylboron derivatives 199 and 201 via a simple borotropic rearrangement involves the 1-
methylallyl compound 200 as an intermediate (Scheme 4.7). 
 
 
Scheme 4.6: Equilibration of crotylboranes. 
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The rate of isomerization of these intermediates varies greatly with the nature of the other boron 
substituents. In addition, allyldialkylboranes react readily at 78 °C and the optical purity achieved is 
considerably greater at low reaction temperatures. Synthetic access to the (Z)-
crotyldiisopinocampheylborane 203 was achieved using Schlosser’sprocedure (Scheme 4.7).82 
Conversion of (Z)-butene to (Z)-crotylpotassium 202 was delivered by using a mixture of n-butylithium 
and potassium tert-butoxide in THF at 45 °C, followed by treatment with borane-
methoxydiisopinocampheylborane 198 at 78 °C. This afforded complex 203, which was exposed to 
boron trifluoride etherate to generate trialkylborane 204, which upon treatment with the 
acetaldehyde, yielded the erythro-3-methyl-4-pent-2-ol 195 in 99% diastereoselectivity and 96% 
enantioselectivity.  
 
Scheme 4.7: Synthesis of compound 195. 
 
It is believed that the asymmetriccrotylboration proceeds via an intital complexation of the carbonyl 
oxygen with boron, followed by a transfer of the crotyl group from boron to the carbonyl carbon by a 
mechanism involving a six-membered transition state (Figure 4.2). In the allyllboration of the 
aldehydes, depending on the nature of the -pinene [(+) or (-)], it was proposed that one of two 
possible six-membered transistion states (205 or 206) predominates, determined by the geometry of 
the asymmetric isopinocampheyl group, and therefore deciding the absolute configuration of the 
alcohol products. 
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Fig. 4.2: Transition states for crotylboration. 
 
The homoallylic alcohol 195 was protected as PMB ether, followed by ozonolysis of the terminal 
olefin 177 to the aldehyde, which was treated insitu with stabilized Wittig ylide PPh3=CH3CO2Et to 
yield thecorresponding E-,-unsaturated ester 208 in good yield and selectivity (Scheme 4.8).  
 
 
 
Scheme 4.8: Synthesis of -unsaturated ester 208. 
 
Ester 208 was reduced to the allyl alcohol 209 using DIBAL-H and the oxidation of the allylic alcohol 
was conveniently carried out in the presence of manganesedioxide at room temperature, to afford 
aldehyde 176 (Scheme 4.9). 
 
 
 
Scheme 4.9: Synthesis of -unsaturated aldehyde 176. 
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In a syn-selective Evans’ aldol reaction,50 aldehyde 176 was converted to aldol adduct 211 in very 
good yield and high diastereoselectivity (>20:1) (Scheme 4.10). 
 
 
Scheme 4.10: Synthesis of aldoladduct 211. 
 
The aldol adduct 211 was then treated with N,O-dimethyl hydroxylamine in the presence of Lewis 
acid trimethylaluminium to cleave the chiral auxiliary and afford amide 212 (Scheme 4.11). The free 
hydroxyl group was protected as TBS-ether under standard conditions to afford amide 213. 
 
 
 
Scheme 4.11: Synthesis of amide 213. 
 
The addition of trimethylaluminium to the amine hydrochloride generates an active aluminium 
intermediate 214,83 which upon reacting with aldol adduct 211 affords amide 212 (Scheme 4.12). 
 
 
Scheme 4.12: Transamination using lewis acid species 214. 
 
Amide 213 was reduced selectively to aldehyde 174 using DIBAL-H at 78 °C, and then immediately 
used in the vinylogous Mukaiyama aldol reaction (VMAR) to afford the ,-unsaturated ester 215 
(Scheme 4.13).  
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Scheme 4.13: Synthesis of ester 216. 
 
Aldehyde 174 was added to a solution of trispentafluorophenylborane (TPPB) in diethylether at 78 
°C, followed by the addition of a mixture of isopropanol and ketene acetal 175 over a period of two 
hours at the same temperature.The reaction proceeded in 80% yield of the syn-aldol product 216 (dr 
> 20:1). The (Z)-3,4-double bond geometry in ketene acetal 175 plays an important role in 
determining the regio- and stereo-selectivity of the reaction (Scheme 4.14). A detailed description of 
the vinylogous Mukaiyama aldol reaction with these ketene acetals was done in our group by Jorma 
Hassfeld.76, 84 When the E- and Z-ketene acetals were subjected to VMAR conditions with TPPB and 
isobutyraldehyde (Scheme 4.14), interestingly the E-configured ketene acetal 219 resulted in low 
yields and poor regioselectivity, favouring the undesired -alklyated product 220 in substantial 
amounts. In contrast, the Z-ketene acetal 175 delivered in high yields and exclusively -akylated 
product 222. 
 
Scheme 4.14: VMAR reactions using E- and Z-ketene acetals. 
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In the open-chain transition state it can be seen that for the E-ketene acetal 219, one substituent is 
always on the same side of the R group of the aldehyde and that the -position is accessible to 
alkylation (Figure 4.3). In the transition state involving the Z-ketene acetal 176, both substituents on 
the double bond are directed away from the R group of the aldehyde. At the same time, the Z-
configuration prevents -alkylation by increased steric hindrance through the adjacent methyl group. 
 
 
Fig. 4.3: Proposed transition states for the VMAR reaction. 
 
The yield and selectivity of the reaction also depends on the Lewis acid tris(pentaphenylborane) 
(TPPB) (Scheme 4.15).The bulkiness of the phenyl groupsresults in increased steric hindrance leading 
to higher diastereoselectivity. It was noted that either the monohydrate or the etherate of TPPB were 
suitableLewis acidsin this reaction. However, neat TPPB lead to decomposition. Isopropanol was 
added to the reaction as the scavenger to trap the reactive ‘’R3Si’’ species. When the reaction was 
carried out in the absence of isopropanol, two syn-aldol products are observed, one with newly 
formed unprotected hydroxyl 222 and the other as TBS protected 223 with a decrease in 
diastereoselectivity to 4.5:1. 
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Scheme 4.15: Silyl species competing as a Lewis acid. 
 
The newly formed hydroxyl group in the ,-unsaturated ester 216 was protected as triethylsilyl 
ether and then subjected to Sharpless asymmetric dihydroxylation66 to afford diol 224 (Scheme 4.16).  
 
 
Scheme 4.16: Synthesis of diol 224. 
 
The dihydroxylation reaction proceeded in good yield with high diasteroselectivity in the ratio of 20:1 
in favor of the desired product 224. This presented a mismatched case of AD-mix-, giving rise to the 
product, the transition states are depicted below (Figure 4.4).72, 85 In the case of olefinic compounds 
with chiral centers, diastereoselective face-selectivity of OsO4 is governed by the conformation of the 
olefins. Two favorable conformations of compound 173, (A and B) are predictable, A is the 
conformation controlled by the 1,3-allylic strain, whereas in the B-conformation, a large group is 
situated in the antiperiplanar position to the double bond. Face selectivity of ,-unsaturated esters 
by AD-mix has been well studied,66, 86 and the reaction on the re-si face can be achieved with AD-mix-
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, but not AD-mix-. Our case is a mismatched one, where the result clearly shows that the 
conformation of 173 changed from B to A during the reaction with AD-mix-. 
 
Fig. 4.4: Transition states for dihydroxylation. 
 
The C(2)-hydroxyl group in diol 224 was selectively protected as TBS-ether using TBSCl/imidazole in 
dimethylformamide and the C(3)-hydroxyl was subsequently protected as methyl ether using 
Meerwein salt in the presence of proton sponge (Scheme 4.17).87 In order to avoid a potentially 
problematic late stage hydrolysis of the methyl ester functionality , methyl ester 226 was treated with 
dibutylstannanechloride oxide88 at 160 °C in allyl alcohol for 4 days to provide allylester 227. 
 
 
Scheme 4.17: Synthesis of allylester 227. 
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The C(6)-TES ether wasremoved under mildlyacidic conditions using PPTS in a mixture of methanol and 
THF (Scheme 4.18). The free hydroxyl group was immediately oxidised to the corresponding ketone using 
Dess-Martin periodinane/pyridine in CH2Cl2 in order to avoid the formation of six-membered lactone 
230. Finally, the PMB group was removed using DDQ and the secondary hydroxyl group was oxidised 
with TPAP/NMO to afford ketone 193.89 
 
 
Scheme 4.18: Synthesis of ketone 193. 
 
4.1.3. Synthesis of Aldehyde Fragment C(13-23) 194: 
The aldehyde fragment would be built upon coupling of the two keto fragments, ketone 48 and ,-
unsaturated aldehyde 49 (Scheme 4.19). Anti-selective Paterson aldol reaction was planned in order 
to achieve the desired stereochemistry at C(16,17). Both these fragments would be quickly accessed 
from commercially available Roche ester 181, following the research work carried out by Gunnar 
Ehrlich in our group.90 
 
Scheme 4.19: Retrosynthesis of aldehyde 194. 
 
Synthesis of ketone 138 began with the PMB-protection of the primary hydroxyl functionality in 
Roche ester 181, followed by reduction of the ester group to primary alcohol 232 (Scheme 4.20). 
Employing the Swern protocol,61 the primary hydroxyl group was oxidised to aldehyde 132, which was 
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immediately used in an aldol reaction with the lithiated species of ethylacetate to provide a 
diastereomeric mixture of alcohol 233. The ester group was reduced using DIBAL-H to diol 234, then 
selective protection of the primary hydroxyl group as TBS-ether followed by oxidation of the 
secondary hydroxyl group provided ketone 138. 
 
 
Scheme 4.20: Synthesis of ketone 138. 
 
The synthesis of aldehyde 111 began from the commercially available Roche ester 181 (Scheme 4.21). 
Protection of the hydroxyl group with acid labile trityl group, followed by reduction of the ester 
afforded alcohol 236. The installation of the Z-double bond was achieved by employing the Swern 
oxidation of alcohol 236 to provide aldehyde 113, which was immediately used in the Wittig reaction. 
Ethyltriphenylphosphonium bromide was initially treated with n-BuLi to generate the ylide, followed 
by treatment with aldehyde 113 to afford the Z-olefin 237 in good diastereoselectivity (9:1). Removal 
of the trityl group was done under mild acid conditions involving PPTS in a mixture of 
methanol/dichloromethane and the resulting volatile alcohol 114 was distilled and subjected to 
Swern protocol to yield aldehyde 238, which proved to be highly epimerisable91 at room temperature 
when allowed to stand for prolonged time. Aldehyde 238 was immediately treated with stabilised 
ylide 207 even before quenching the Swern oxidation reaction at 78 °C. The Wittig reaction 
produced ,unsaturated ester 115 with high diastereoselectivity (95:5). Ester 58 was reduced to 
alyllic alcohol using DIBAL-H and converted to aldehyde 111 using MnO2. 
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Scheme 4.21: Synthesis of aldehyde 111. 
The reaction between ketone 138 and aldehyde 111 was performed employing the Paterson 
conditions,68 which involved the initial addition of ketone 138 to a mixture of triethylamine and the 
Lewis acid chloroddicyclohexylborane at 78 °C to form an enolate, which was allowed to stand for 16 
h at 2 °C in order to obtain the E-enolate, resulting in the desired anti-selectivity (3:1) in product 239 
(Scheme 4.22). The diastereomers were easlily separated using column chromatography.  
 
Scheme 4.22: Paterson aldol reaction of ketone 138. 
The stereo-differentiation operating in these anti-aldol reactions is remarkable and can be traced to 
the relative steric and electronic properties of the substituents-H, Me and CH2OPMB at the adjacent 
stereocenter. A chair-like transition state TS-1 was proposed, responsible for the high level of 
aldehyde –face selectivity (Figure 4.5). This minimises the (1,3)-allylic strain with the E-enolalkoxy 
group and has the methyl group pointing outwards and the PMB-methyl group directed in towards 
the aldehyde. This preference for TS-1 (si-face attack) over TS-2 (re-face attack) is considered to have 
an electronic origin, possibly with TS-2 destabilised by lone-pair repulsion22 between the oxygen 
atoms. 
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Fig. 4.5: Proposed transition states for Paterson aldol reaction. 
The major aldol product 239 was immediately subjected to reduction using DIBAL-H, since the 
appearance of the retro-aldol products were observed upon long standing of compound 239 (Scheme 
4.23). The stereoselective reduction to diol 240 proceeded in high yield and high diastereoselectivity 
(dr 98:2). According to our synthetic plan a very mild protecting group, which can be cleaved in 
presence of all other protecting groups must be installed at the C(17)-allylic hydroxyl group. The initial 
plan involved thepresence of monomethoxytrityl group (MMTr) at this position, but unfortunately 
this protection was unsuccessful. 
 
 
Scheme 4.23: Synthesis of compound 241. 
As the monomethoxytrityl group protection failed (Table 4.1, entries 1-4), installation of alloc group 
on the C(17) hydroxyl functionality was attempted, so that both the C(1)-allyl ester and the alloc 
group could be removed in a single step. Unfortunately, the alloc group protection was not successful 
(Table 4.1, entries 5-8). In addition, it was also considered that the presence of this alloc ether could 
increase the chances of elimination at this position at a later stage of the synthesis. The search then 
switched back to silyl protecting groups. During the synthesis of the southern fragment of tedanolide 
(6), the Roush group installed the TES group at this C(17)-hydroxyl group.57 It is known from literature 
that the TES group can be cleaved under mild acidic conditions in the presence of TBS group. Keeping 
this in mind, the C(17)-hydroxyl group was selectively protected by treatment with triethylsilyl 
chloride at 78 °C (Table 4.1, entry 9). 
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Table 4.1: Protection of C(17)-hydoxyl group with various protecting groups. 
 
Compound 243 was converted to the PMP acetal 244 using DDQ under anhydrous conditions, 
followed by reductive acetal opening from the less hindered side using DIBAL-H provided the the 
primary alcohol 245 (Scheme 4.24). Dess Martin oxidation55 of the alcohol provided the 
corresponding aldehyde 246. 
Entry Substrate Conditions Comments 
1 240 MMTrCl (1.5 eq), Et3N (3.0 eq), 
CH2Cl2, rt, 16 h 
No product 241 observed, starting 
material retained no further 
progress with excess of MMTrCl and 
Et3N. 
2 240 MMTrCl (1.5 eq), Et3N (3.0 eq), 
DMAP (0.3 eq), CH2Cl2, rt, 16 h 
Only starting material observed. 
3 240 MMTrCl (1.3 eq), pyridine/CH2Cl2, rt, 
16 h 
Only starting material observed. 
4 240 MMTrCl (2.5 eq), imidazole (4.0 eq), 
CH2Cl2, rt, 16 h 
Only starting material observed. 
5 240 AllocCl (1.5 eq), Et3N (2.0 eq), 
CH2Cl2, rt, 16 h 
Only starting material observed. 
6 240 AllocCl (1.5 eq), pyridine (2.0 eq), 
CH2Cl2, rt, 16 h 
Product 242 (25%) isolated but lot of 
starting material retained. 
7 240 AllocCl (3.0 eq), imidazole (4.0 eq), 
CH2Cl2, rt, 16 h 
Only starting material observed. 
8 240 AllocCl (5.5 eq), pyridine (6.5 eq), 
CH2Cl2, rt, 16 h 
Product 242 (30%) isolated but lot of 
starting material retained. 
9 240 TESCl, 2,6-lutidine, DMAP, CH2Cl2, 
78 °C, 3 h 
 Product 243 obtained, 80% yield, 
selective monoprotection at C(17)-
position 
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Scheme 4.24: Synthesis of aldehyde 246. 
 
4.1.4. Coupling of the Fragments 193 and 246: 
Aldol reaction between the fragments was done using the conditions provided by the Roush group,57, 
58 as both the ketone and aldehyde fragments used by the Roush group are similar to the fragments 
which are used in this synthesis of tedanolide (6). Ketone 193 was treated with lithium 
hexamethyldisilazane at 78 °C, allowed to enolisation for 30 mins, aldehyde 246 was slowly added 
drop wise to the reaction mixture and the reaction was quenched after 15 minutes (Scheme 4.25). 
 
Scheme 4.25: Synthesis of compound 247. 
Initial purifications using column chromatography separated the aldol products 247 (dr 2.5:1), 
unreacted ketone 193 and the aldehyde 246 were recovered without any epimerization. The 
purification of the diastereomersfrom the aldol reaction using normal chromatography was not 
successful, they are purified with the aid of HPLC on a normal phase column employing EtOAc and 
heptane as eluent.  
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The newly formed stereocenter C(13)-hydroxyl group in compound 247 was initially tried to protect 
as TBS-ether, so that all the TBS ethers can be cleaved in a single step together at the later stage, but 
the protection was not successful at room temperature, and at higher temperatures silyl group 
migration was reported by the Roush group.58 After looking at the different protecting groups we 
needed a protecting group which should survive the TES groupdeprotection conditions and at the 
same time the protecting group should be able to remove in presence of primary TBS group. SEM 
group provided the right combination under these circumstances, as Roush et al. used the SEM group 
at the C(13)-position.58 So, the C(13)-hydroxyl group was protected as SEM ether using SEM chloride 
and Hünig’s base in tetrahydrofuran (Scheme 4.26).  
 
 
Scheme 4.26: Synthesis of compound 248. 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2: Trial with different protecting groups on compound 248. 
 
The stage was set to do the macrolactonisation, the C(17)-TES group was tried to remove using PPTS 
in a solution of methanol and THF at room temperature, After two hours it was observed only the TES 
group was removed selectively in presence of primary TBS group. Extended reaction times lead to the 
deprotection of the primary TBS group as well, so the reaction was quenched at this point and the 
starting material was recovered. C(1)-carboxylic acid was liberated using the literature known 
procedure with Pd(PPh3)4 or Pd(PPh3)2Cl2 and tributyltinhydride in dichloromethane (Scheme 4.27).
92 
The reaction proceeded very smoothly and the crude acid was passed through a silica gel bed, initially 
eluted with hexanes to get rid of tin impurities and then elution with ethyl acetate gave the semi-
crude acid, which was used immediately in the reaction for the macrloactonisation. After screening a 
No Conditions on substrate 247 Yield Comments 
1 TBSOTf, 2,6-lutidine, CH2Cl2, 16 h, 0 ˚C to rt -- No Reaction, SM 
recovered 
2 TBSOTf, 2,6-lutidine, CH2Cl2, 16 h, 0 ˚C to 50 °C -- No Reaction, SM 
recovered 
3 TMSOTf, 2,6-lutidine, CH2Cl2, 16 h , 0 ˚C to rt -- No Reaction, SM 
recovered 
4 SEMCl, DIPEA, TBAI, THF, 72 h, 0 ˚C to  50 °C 90% -- 
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few macrolatonisation conditions (Shiina,93 Evans Mukaiyama,94 and Yamaguchi-Yonemitsu) the best 
yields were obtained by using the modified procedure of Yamaguchi protocol45 in dry benzene.  
 
Scheme 4.27 Synthesis of compound 251. 
No. Conditions Yield Comments 
1 2-methyl-6-nitrobenzoicanhydride, 
DMAP, toluene, THF, 24 h, rt. 
-- SM decomposed, No desired product 
observed. 
2 2-bromo-1-methyl pyridine, Et3N, 
CH2Cl2, 24 h, rt. 
-- SM decomposed, No desired product 
observed. 
3 2,4,6-trichlorobenzoyl chloride, DIPEA,  
DMAP, CH2Cl2, rt, 52 h. 
18 % No trace of acid, no other major spots. 
4 2,4,6-trichlorobenzoyl chloride, DIPEA,  
DMAP, toluene, 110 °C, 16 h. 
10 % TLC showed several spots. 
5 2,4,6-trichlorobenzoyl chloride, DIPEA,  
DMAP, toluene, 110 °C, 5 h. 
10 % TLC showed several spots. 
6 2,4,6-trichlorobenzoyl chloride, Et3N, 
DMAP, benzene, rt. 
45 % DMAP was added after 1h of the 
anhydride formation. 
Table 4.3: Trial with different conditons for macrolactonisation on compound 250. 
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4.1.5. Removal of the PMB group at C(15)-Position before Macrolactonisation: 
Trials were made to liberate the C(15)-hydroxyl group prior to macrolactonisation in order to see the 
competition of the C(15) and C(17)-hydroxyl groups participation in the macrolactonisation. Intially 
compound 248 was treated with PPTS for the TES group deprotection, which went smoothly to afford 
alcohol 252 (Scheme 4.28). When compound 252 was tried to react with DDQ to remove PMB group 
on the C(15)-hydroxyl group, C(17)-hydroxyl group was oxidized to the respective ketone 253. Other 
method using ceric ammonium nitrate was unsuccessful resulting in retention of starting material. 
Hydrogenation and strong Lewis acid conditons cannot be employed on the substrate 252 due to the 
presence of double bonds and silyl protecting groups (TBS and SEM). 
 
 
Scheme 4.28: Deprotection of PMB group prior to macrolactonisation. 
 
In an effort to remove the C(15)-PMB group prior to the C(17)-TES group, compound 248 treated with 
DDQ and the reaction was sluggish, it went for completion at room temperature over a period of 24 h 
to yield alcohol 254. The task of removing the TES group was performed using mild acidic conditions 
(PPTS, MeOH/THF), resulted in a messy reaction indicating the presence of lactol 255 (Scheme 4.29). 
Basic conditions (HF•pyridine) employed to deprotect the TES ether, it was observed that both the 
C(29) and C(17)-silyl ethers are deprotected within short period of time giving rise to triol 256. 
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Scheme 4.29: Deprotection of PMB group prior to macrolactonisation. 
 
It has proved to be highly challenging and unsuccessful to deprotect the C(17)-TES group selectively 
when the C(15)-hydroxyl group was unmasked. With these results the focus was shifted back to 
original route to do macrolactonisation in first place and then the removal of PMB group. 
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4.1.6. End Game: 
The next steps towards completion of the total synthesis of desepoxyisotedanolide (40) began with 
removal of the PMB group in compound 251. It was carried out using 2,3-Dichloro-5,6-dicyano-1,4-
benzoquinone in a mixture of dichloromethane and pH7 buffer (Scheme 4.30). The reaction 
proceeded smoothly to completion and the resulting alcohol is oxidized to ketone 258 using Dess-
Martin periodinane55 and sodium bicarbonate.  
 
Scheme 4.30: Synthesis of triketone 258. 
 
 
Cleavage of the SEM ether at the C(13)-hydroxyl in compound 258 was performed using a mild Lewis 
acid (MgBr2) and excess of ethane thiol (Scheme 4.31).
56 Global deprotection of the TBS group was 
achieved using the conditions earlier used in the synthesis of tedanolide (6)57 (HF•Et3N, Et3N in 
CH3CN). The reaction proceeded to completion over a period of 3 days to provide 
desepoxyisotedanolide (40).  
 
 
 
Scheme 4.31: Synthesis of desepoxyisotedanolide (40). 
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During the purification of desepoxyisotedanolide (40), compound 40a was observed as a minor product 
(Figure 4.6). From the 13C NMR, only three peaks were observed for carbonyl compounds, which 
indicates the lack of carbonly group C(5), a new peak was observed at  108.2, which is clearly indicating 
the presence of  5-membered lactol. After a detailed 2D NMR studies (COSY and HMBC), C(5)-carbon has 
clearly HMBC contacts with H-4, H-6, H-7 and methyl groups at C4 and C6.  
 
 
Fig 4.6: Isomers of desepoxyisotedanolide 40, 40a. 
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 4.1.7. Formation of the 14-Membered Macrolactone 260:  
Compound 247 was treated with mild acid PPTS in MeOH and THF to deprotectC(17)-TES ether, When 
the linear fragment 261 was tried to lactonise to form the 18-membered lactone, it was envisioned 
that the C(17)-allylic hydroxyl group could be more reactive to form the macrolactone. Initially 
Yamaguchi lactonisation45 conditions were used, unfortunately no product was observed. 
Shiinaprotocol94 with 2-methyl-6-nitrobenzoic acid anhydride produced the lactonised product 80 
(Scheme 4.32). After a detailed two-dimensional NMR studies, the structure was confirmed as a 14-
membered lactone 260. The lactone C(1)-carbonyl group has clearly indicated the HMBC contacts 
with H-13 proton along with H-2 and H-3 protons. This clearly suggested that the C(13)-hydroxyl 
group is very active than the C(17)-hydroxyl group in the macrolactonisation. This indicated that the 
C(13)-hydroxyl group should be masked with a protecting group in order to avoid the fromation of 
undesired macrolactone 260. 
 
 
Scheme 4.32: Synthesis of macrolactone 260. 
This structure was further confirmed by a chemical transformation, converting C(17)-allylic alcohol in 
compound 260 to the ketone using MnO2, which can only selectively oxidise the allylic and benzylic 
alcohols. When compound 260 was treated with MnO2, it was clearly observed by Mass spectrometry 
that product 262 has formed (Scheme 4.33). 
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Scheme 4.33: Oxidation of macrolactone 260. 
The formation of the 14-membered lactone was also observed earlier in the synthesis of tedanolide (6) 
by Kalesse and Roush groups (Scheme 4.34). The C(29)-hydroxyl group was expected to be much more 
reactive , so the macrolactonisation reaction was carried out in the presence of free C(13)-hydroxyl 
group by the Kalesse group,67a Only 14-membered lactone was observed instead of the 18-membered 
lactone. When Roush group had similar results,57, 58 efforts were made to transesterify the 14-membered 
lactone to the desired 18-membered lactone, but even in the presence of strong Lewis acid like Ti(OiPr)4 
14-membered lactone couldn’t be isomerized. 
 
Scheme 4.34: Earlier results for the 14-membered macrolactone. 
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In conclusion, it is again confirmed that 14-membered lactone is more favoured in compared to 18-
membered lactone in macrolactonisation. It is essential to block the C(14)-hydroxyl group in order to 
achieve the tedanolides. It is also noteworthy, that this 14-membered macrolactone could be a 
potential biosynthetic intermediate in the process of tedanolide. Efforts were made in our group 
earlier by Nina Diaz91 to synthesize this 14-membered macrolide, unfortunately it was not successful 
and the synthesis of the macrolide couldn’t be accomplished. 
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4.2. Biological activity of Desepoxyisotedanolide (40) in comparision to Tedanolide (6): 
 
The biological studies on desepoxyisotedanolide (40) were performed at the Helmholtz Centre for 
Infection Research (HZI) at Braunschweig. Biological tests were performed on mouse fibroplasts (L-
929), cervical carcinoma (KB-3-1) and rat kangaroo kidney cells (PtK2); and the IC50 and IC90 values 
have been obtained.  
 
 
 
Figure 4.7: IC50 values against L929 mouse fibroplasts of tedanolide and desepoxyisotedanolide. 
 
The biological data have revealed that the desepoxyisotedanolide (40) is one fold less active than  
natural product tedanolide (6) but still exhibiting potent cytotoxicity. Fusetani et al. had reported that 
13-deoxytedanolide (7) inhibits peptide elongation by binding to the 60S large subunit of the S. 
cerevisiae ribosome. Moore et al. in their experiments of binding 13-deoxytedanolide (7) to the 
Haloarcula marismortui zu 50S subunit provided the structural explanations for the relative activities 
of tedanolide. The decrease in the biological activity of desepoxytedanolide (40) could be attributed 
to the lack of groups that normally do hydrogen bonding the C(18-19) epoxide as well as C(17)-
hydroxyl group. Additionally, affinity to the ribosome may be further decreased by the alterations in 
confirmation, as explained by Moore et al. in the case of derivatives of 13-deoxytedanolide.  
 
Biological activites of desepoxytedanolide (40) in comparison with tedanolide (6) against different cell 
lines are shown below in the Table 4.4. 
Table 4.4: Biological activity of tedanolides in differernt cell lines. 
n.d = not determined 
 
 
Cell lines Tedanolide (6) Desepoxytedanolide 
(41) 
Desepoxyisotedanolide 
(40) 
L929 Mouse connective 
tissue 
0.05 0.5 65 
PtK2 Potoroo kidney n.d n.d 600 
KB-3-1 Cervix 
carcinoma 
0.2 n.d 25 
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4.3. Transesterification Experiments: 
 
Having been accomplished the total synthesis of the desepoxyisotedanolide (40), our focus was 
shifted to see the possibility of transesterification to desepoxytedanolide (41) (Scheme 4.35). Few 
attempts were made to explore this transformation under mild acidic and basic conditions (Table 4.4). 
 
Scheme 4.35: Trials to isomerise of desepoxytedanolide (40). 
A mild Lewis acid, bis(n-butyldichlorotin)oxide was initially tried at room temperature and at 80 °C, 
there was no progress in reaction. In  a refluxing solution of toluene, led to decomposition (Table 4.5). 
Mild basic conditions (DMAP, Et3N, K2CO3) in (CDCl3, CHCl3 and DMF) haven’t produced any progress 
in reaction. Neutral conditions (DMAP•HCl in CHCl3, refluxing CHCl3) also failed to isomerize.  
 
 
 
 
 
 
 
 
    Table 4.5: Trials to isomerize desepoxyisotedanolide to desepoxytedanolide. 
In 2000, two new members of amphidionolides were isolated, amphidinolide G and H (Scheme 
4.36).95 These two natural products are isomers at the macrolactone linkage and interestingly found 
to be interconvertible in the presence of K2CO3 in ethanol at 4 °C.  
No. Conditions Yield Comments 
1 (nBu2SnClO)2, toluene, rt -- No reaction 
2 (nBu2SnClO)2, toluene, 80 °C -- No reaction 
3 (nBu2SnClO)2, toluene, 
reflux 
-- Decomposed 
4 Et3N, DMAP, CDCl3, rt -- No reaction 
5 K2CO3, CDCl3, rt -- No reaction 
6 DMAP•HCl, CHCl3, rt -- No reaction 
7 CHCl3, reflux -- No reaction 
8 K2CO3, DMF, rt -- No reaction 
9 K2CO3, EtOH, rt -- No reaction 
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Scheme 4.36: Transesterification of amphidinolides H and G. 
No success has been achieved even employing these conditions in the case of desepoxyisotednaolide 
(40). Unfortunaley, efforts to isomerisation were unsuccessful, it could be possible that this 
transesterfication may require a special biological environment to convert to desepoxytedanolide 
(41).  
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4.4. Synthesis of Simplified Tedanolide Analogues:  
          Connecting Tedanolide to Myriaporones and Gephyronic acid: 
 
The myriaporones were first reported in 1994 by Rinehart et al. Extractions from the bryozoan 
Myriaporatruncata in the west Mediterranean Sea led to four novel structures myriaporones 1-4 (24-
27) (Figure 4.7).26, 27 Out of which, myriaporone 3 and its inseparable hemiacetal isomer myriaporone 
4, exhibited an IC50 value of 100 ng/mL in L-1210 murine leukemia cells. Initial structure elucidation 
was done using spectroscopic analysis and later confirmed by total synthesis in Taylor group29 and 
Cuevas group30 independently. 
A similar natural product gephyronic acid 35 isolated from the myxobacterium Archangiumgephyra at 
HZI braunschweig by Höfle, Reichenbach and co-workers in 1995.32 Initial biological studies revealed 
selective inhibition of the eukaryotic protein synthesis. It exhibits an IC50 value of 10 ng/mL against 
cervix carcinoma and human myelogenous leukemia (K-562) cell lines. Structural similarities between 
myriaporone, gephyronic acid and the C10-C23 region of tedanolide having similar mode of action35 
prompted us to prepare the simplified analogues along the lines of our synthesis of the southern 
hemisphere of tedanolides.96 
 
Fig. 4.7: Tedanoldes and myriaporones. 
Intermediate 263 was the crucial intermediate served as a building block during the synthesis of 
tedanolide (6) (Scheme 4.37). This intermediate was chosen as a starting point for the simplified 
analogues. 
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Scheme 4.37: Southern fragment of tedanolide as precursor for simplified tedanolide analogue. 
Acetate group was incorporated at the primary hydroxyl group as a substitute for the macrolactone 
linkage, p-methoxybenzyl (PMB) could participate in hydrophobic interactions comparable to the 
eastern fragment of tedanolide. Additionally the importance of the epoxide on these simplified 
analogues was explored. These compounds were obtained from the intermediate 263 (Scheme 4.38), 
TBS group removal followed by selective protection of the primary hydroxyl group as acetate 265. 
Epoxide 266 was obtained using Henbest oxidation using m-CPBA/NaHCO3. 
 
 
Scheme 4.38: Synthesis of simplified tedanolide analogues. 
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These simplified tedanolide analogues were investigated for biological activities in mammalian cell 
lines, the test results revealed that these biologically active compounds are approximately one order 
of magnitude less than desirable for promising drug candidates (Figure 4.8). The data indicated that 
incorporation of the acetyl groups, has a more pronounced effect on the biological activity of these 
derivatives, while epoxidation has only little contribution. These results will potentially provide access 
to a new target and provides a promising starting point for further optimization.  
 
Fig. 4.8: IC50 values of an MTT assay with L-929 mouse fibroblasts and KB-3-1 cervix carcinoma cell line respectively. 
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4.5. Kiyooka Aldol Reaction: A Methodology for the Generation of the Chiral Quaternary 
Center 
Chiral lewis acid mediated reactions have been recognized as useful tools for the stereo-selective 
formation of the C-C bonds. Aldol reaction of the silyl ketene acetals with aldehydes are literature 
known,97 Kiyooka and co-workers had reported the chiral boranes 268 promoted reactions of silyl 
ketene acetals 267 with aldehydes (Scheme 4.39).98 These reactions yielded different products 
depending on the type of the silyl group used in the ketene acetals with high enantioselectivity.  
 
Scheme 4.39: Kiyooka aldol reaction using the chiral borane as chiral lewis acid 
The chiral borane reagents 271 were prepared by treating the sulfonamides obtained from the 
corresponding amino-acids and sulfuryl chlorides with an equimolar amount of BH3•THF complex.
99 
Changing the triaalkylsilyl group of the silyl ketene acetal from trimethylsilyl (TMS) to tert-
butyldimethylsilyl (TBS) group has a dramatic effect on the reaction course (Scheme 4.40). 
Condensation of the the TBS ketene acetal with aldehyde in presence of the chiral borane gave 
surprisingly the diastereomeric hydroxyacetal 272.  
 
Scheme 4.40: Kiyooka aldol reaction using the TBS ketene acetal 
This acetal 272 would rise apparently from the reduction of an intermediate ester by hydride transfer 
from the promoter 271. High enantioselectivities were observed for ketene acetals 270a compared to 
270b. A mechanism which accounts for the formation of the compounds 272 is shown below (Figure 
4.9). It features a cyclic transition state 273, coordination of the boron atom of the borane with the 
oxygen atom of the carbonyl group would lower the energy of the activation for the nucleophilic 
attack and concurrently facilitate desilylation. The stability of 274 would be enhanced if the trialkylsily 
group were TBS rather than TMS. Reduction of the ester group of the transient complex 274 by 
intramolecular hydride transfer from the borane and retransfer of the TBS group would form the 
acetal complex 275. 
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Fig. 4.9: Proposed mechanism for the Kiyooka aldol reaction with TBS ketene acetal. 
Since the advent of the Kiyooka aldol reaction, lot of work has been done in creating stereoselecitve 
quaternary centers using this methodology. One of the noteworthy work was done by Hayashi and 
co-workers, a tetrasubstituted ketene acetal was used for the pivotal step in the synthesis of 
azaspirene.100 However in this case, MgBr2•Et2O proved to the best lewis acid in order to get better 
yields and enantioselectivity. Our experience with the Kiyooka aldol reaction as the ideal 
transformation to establish a secondary alcohol next to a quaternary center was based on the 
synthesis of a simplified disorazole analog.101 
In the synthesis of the diastereomeric analogue of the tedanolide C 276, to generate one additional 
stereocenter at C-17 in the southwest fragment 277, a Kiyooka aldol reaction between aldehyde 279 
and ketene acetal 278 was performed (Scheme 4.41).102 
 
Scheme 4.41: Kiyooka aldol reaction in the synthesis of diastereomeric analogue of tedanolide C. 
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To make this methodology a more general protocol for the generation of a variety of tertiary alcohols, 
few aldehydes we reacted under these reaction conditions to check the enantioselectivity and 
diastereoselectivity of the products. Benzaldehyde, cinnamaldehyde and valeraldehyde are allowed 
to react under these conditions and it was observed that the diastereomeric ratio ranges from 6:1 to 
10:1 and the enantiomeric ratio was higher than 10:1 (Scheme 4.42).103 
 
 
 
 
 
 
 
Scheme 4.42: Kiyooka protocol using different aldehydes. 
The diastereoselectivity of the quaternary center could be explained from the proposed transition 
states T1 and T2 (Figure 4.10). In transition state 1 (T1), the alkyl chain (R) is having less syn pentane 
interactions compared to transition state (T2).  
 
 
Fig. 4.10: Proposed transition states for the Kiyooka aldol reaction. 
 
 
entry 
 
Starting 
material 
 
Product 
 
yield 
(%) 
 
dr 
 
er 
1 282,  
R = Phenyl 
285 83 6:1 >10:1 
2 283,   
R = Cinnamyl 
286 80 10:1 >10:1 
3 284, 
R = Valeryl 
287 40 10:1 >10:1 
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5. Conclusion and Outlook: 
5.1. Conclusion: 
In the first part of my thesis, the total synthesis of despeoxyisotedanolie (40) was described (Scheme 
5.1). Interestingly desepoxyisotedanolide (40) was also found out to be biologically active but not at 
the same concentration of desepoxytedanolide (41) and tedanolide (6) (Figure 5.1). With these 
results, it is evident that the presence of epoxide is contributing to higher biological activity. It could 
be also important to have this special feature of having primary lactone linkage for this superior 
activity of tedanolides. 
 
Fig 5.1: Biological activity of desepoxyisotedanolide (40) in comparision to tedanolide (6).  
The synthesis of desepoxyisotedanolide (40) was carried out in a similar fashion to synthesis of 
tedanolide (6). The synthesis of methyl ketone 193 (northern hemisphere) was achieved starting from 
Brown- crotylboration of acetaldehyde following a sequence of 18 steps. The synthesis involved a 
Evans syn aldol reaction, vinylogous Mukaiyama aldol reaction and a Sharpless asymmetric 
dihydroxylation as key steps. The vinylogous Mukaiyama aldol reaction proved to be the most 
economical step with generating 4 carbon atoms with great stereocontrol for the 4,5 all syn-product 
(Scheme 5.1). 
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Scheme 5.1: Synthesis of methyl ketone 193.  
 
The synthesis of aldehyde C(13-23) fragment 246 involved a key reaction of anti-selective Paterson 
aldol reaction between ketone 138 and aldehyde 111 (Scheme 5.2).  
 
 
 
Scheme 5.2: Synthesis of aldehyde 246.  
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Both the fragments 193 and 246 are coupled by a substrate controlled aldol reaction to provide the 
total carbon frame work C(1-23) for desepoxytedanolide (40) (Scheme 5.3). 
 
 
 
 
Scheme 5.3: Aldol coupling of ketone 193 and aldehyde 246. 
 
Compound 247 was converted to desepoxyisotedanolide (40) in a sequence involving Yamaguchi 
macrolactonisation, followed by oxidation of C(15)–hydroxyl group and global deprotection of the 
silyl groups (Scheme 5.4). 
 
 
Scheme 5.4: Synthesis of desepoxyisotedanolide (40). 
 
During the course of synthesis of desepoxyisotedanolide (40) a 14-membered lactone 260 was 
exclusively formed when the C(14)-hydroxyl group along with C(17)-hydroxyl group were allowed to 
participate in macrolactonisation under the Shiina protocol (Scheme 5.5).  
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Scheme 5.5: Formation of 14-membered lactone 260. 
 
Trials were made to see the isomerization of the desepoxyisotedanolide (40) to desepoxytedanolide 
(41) using very mild conditions; unfortunately it was not successful (Scheme 5.6). 
  
 
 
 
Scheme 5.6: Transesterification of desepoxyisotedanolide (40). 
 
Few truncated analogues of the C(13-23) aldehyde fragment of tedanolides were made in order to 
evaluate their biological activity (Figure 5.2). These analogues were found to be active but two fold 
less compared to the tedanolides.  
 
 
 
Fig 5.2: Simplified analogues of tedanolides. 
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In another part of this thesis, the Kiyooka aldol reaction was used as a protocol to generate tertiary 
alcohols in a stereo selective manner. This method was tested on a variety of aldehydes and proven 
to be successful (Scheme 5.7).  
 
 
 
Scheme 5.7: Kiyooka aldol reaction. 
 
5.2. Outlook: 
From biosynthetical aspect, the synthesis of the 14-membered lactone 288 could be a precursor for 
tedanolides. Removal of PMB group followed by oxidation at C(15) position and finally global 
deprotection of all silyl groups using different conditions could provide the macrolactone 288 
(Scheme 5.8). This could provide the access to investigate the spontaneous isomerization of the 
lactones. 
 
 
  
Scheme 5.8: Synthesis towards lactone 288. 
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6. Experimentals 
6.1. Equipment and Devices: 
 
1H-NMR spectra are measured on “Bruker WP-200 SY”, “Bruker AM-400” and “Bruker AM-500” 
spectrometers. As the inner standard a rest signal of a deuterated solvent.1 As a solvent 
deuterochloroform (CDCl3), DMSO-d6 (CD3SOCD3), deuterobenzene (C6D6) and deuteromethanol 
(CD3OD) were used. The chemical shifts are given in ppm on the δ-scale. The coupling constants are 
measured in hertz (Hz). The multiplets are labeled as: s = singlet, d = doublet, t = triplet, q = quartet, 
qui = quintet, sxt = sextet, sep = septet, m = multiplet, dd = doublet of doublets, dt = doublet of 
triplets, dq = doublet of quartets, br = bright, o = overlapping. 
13C-NMR spectra are measured on “Bruker AM-400” at 100 MHz. As a solvent deuterochloroform 
(CDCl3), DMSO-d6 (CD3SOCD3) and deuteromethanol (CD3OD) were used. 
 
Mass Spectra (MS-ESI) are presented as a m/z-ratio, the signal intensity is given in % compared to the 
intensity of the most intensive pick. 
 
Optical rotation [α] was measured on a “Perkin-Elmer 341” polarimeter for light with λ = 589 nm, l = 
1 dm, c is additionally given.   
  
Bulb-to-bulb distillation was done on a „Büchi GKR 50” device. 
 
Flash Chromatographic purification was done on „J.T. Baker Silica gel“ (40-60 µm, Pours 60Å) under a 
slight pressure.  
 
Analytical Thin Layer Chromatography (TLC) was done on 5 x 7,5 cm “Merk 60 F 254” aluminium 
plates covered with a silica gel layer (0,2 mm) and the spots were visualized with UV lamp (254 nm), 
additionally “Vanillin”, “Cer”,  or “Permanganate” were used to stain the TLC’s. Eluent is usually given. 
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High Performance Liquid Chromatography (HPLC) For non-polar compounds was done on a normal 
phase column (NP 250/21, Nucleosil 100-7) using Ethyl acetate and Heptane as eluent.  
For polar compounds, reverse phase was used to carried out purification on column (Nucleodur C18 
ISIS, 5 µm) using acetonitrile and water as eluent. 
 
Solvents and Reagents Reactions were performed under nitrogen/argon atmosphere. Solvents used 
in the reactions were purified by standard procedures. Tetrahydrofuran was refluxed over 
sodium/benzophenone and distilled; dichloromethane was refluxed over calcium hydride and 
distilled. Solvents used for column chromatography are distilled. Reagents and anhydrous solvents 
(DMSO, DMF, CH3CN, Diethyl ether) were purchased commercially and use without any purification. 
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6.2. Preparation of Reagents 
(+)-Methoxydiisopinocampheylborane 198[104] 
 
 
 
To a solution of ()--pinene (20.0 g, 146.78 mmol, 98%ee) in THF (19 mL) was added borane 
dimethylsufide complex (6.10 mL, 60.77 mmol). The temperature was maintained below 20-25 °C 
using ice bath during the addition.  Stirring was continued for further 15 min after the completion of 
addition, ice bath was removed, stirring was stopped and left overnight at room temperature. White 
solids precipitated out of the solution, THF layer was syringed out under nitrogen. White crystalline 
solids are washed with dry pentane (2 × 15 mL) and dried under vacuum. Diisopinocampheylborane 
was obtained as white crystalline solid (13.76 g, 79%). This solid is stable for a month under inert 
atmosphere at 0 °C. 
 
To the obtained solids was added dry Et2O (50 mL) and cooled to 0 °C. Pre-cooled methanol (2.30 mL, 
56.71 mmol) was added slowly dropwise over a period of 20 min. This reaction is highly exothermic 
with the evolution of hydrogen. Stirring was continued for further 15 min to obtain a clear solution, 
solvent removed under vacuum without exposing to air for complete dryness. ()-
Methoxydiisopinocampheylborane (14.64 g) was obtained as white solid quantitatively, which was 
used in next step without any characterization. 
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(1-ethoxycarbonylethylidene)triphenylphosphorane 207[105] 
 
 
 
To a solution of ethyl-2-bromopropionate (10.0 g, 55.24 mmol) in toluene (20 mL) was added 
triphenylphosphine (14.48 g, 55.24 mmol). Reaction mixture was heated at 70 °C for a period of 16 h. 
White solids precipitated out, reaction mixture cooled to 50 °C and distilled water (100 mL) was 
added, stirred until the solids are completely dissolved. Phases are separated, aqueous layer 
extracted with MTBE (2 × 30 mL). Aqueous layer then cooled and NaOH was added, initially light 
yellow solids precipitated out and then turned into yellow fluorescent solids. These solids are filtered 
out, washed with distilled water (2 × 50 mL), dried under vacuum. Wittig ylide (15.20 g, 52%) was 
obtained as yellow solid. 
Melting point: 158 °C. 
 
bis(n-Butyldichlorotin)oxide[88] 
 
 
 
Dibutyltin dichloride (2.00g, 6.58 mmol) was dissolved in ethanol (15 mL) and an equivalent amount 
of pyridine (0.64 g, 0.66 mL, 8.09 mmol) in ethanol (6 mL) was added. Addition of few drops of water 
(~1 mL) resulted in a white precipate, the reaction mixture was refluxed for 10 min and a clear 
solution obtained. Upon cooling to room temperature bis(n-butyldichlorotin)oxide (1.00 g) 
crystallized as white solid. 
Melting point: 105-107 °C. 
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p-Methoxybenzylchloride[106] 
 
To a solution of p-methoxybenzylalcohol (12.0 mL, 96.40 mmol) in CH2Cl2 (300 mL), was added a 
mixture of thionylchloride (8.76 mL, 120.05 mmol) and benzotriazole (14.35 g, 120.05 mmol) in CH2Cl2 
(50 mL) dropwise slowly at 0 °C. Reaction mixture stirred for further 10 minutes, the precipitated 
solids are filtered off and washed with CH2Cl2 (2 × 20 mL). The filtrate was concentrated in vacuo to 
yield p-methoxybenzylchloride (15.0 g) in quantitative. This product was directly used in the next 
reaction without further purification. 
 
1H-NMR (200 MHz, CDCl3):  7.30 (d, Har, 2H, J = 7.0 Hz), 6.75 (d, Har, 2H, J = 7.0 Hz), 4.35 (s, CH2Cl, 
2H), 3.65 (s, ArOCH3, 3H). 
 
p-Methoxybenzyltrichloroacetimidate 231[107] 
 
 
To the sodium hydride (0.68 g, 16.92 mmol, 60% dispersion in oil) in Et2O (46 mL) was added p-
methoxybenzylalcohol (23.58 g, 170.70 mmol) in Et2O (46 mL) dropwise and stirred for 1 h at room 
temperature. Reaction mixture cooled to 0 °C, trichloroacetonitrile (24.48 g, 170.70 mmol) in Et2O (46 
mL) was added over a period of 10 minutes. Subsequently reaction mixture warmed to room 
temperature and stirred for 30 minutes. Reaction mixture was quenched with methanol (0.6 mL) and 
the solvent was removed in vacuo, again methanol (0.6 mL) and hexane (100 mL) was added 
successively, then filtered over Celite and the filtrate was concentrated in vacuo to obtain p-
methoxybenzyltrichloroacetimidate (41.0 g, 95%) as yellow oil. 
1H-NMR (200 MHz, CDCl3):  8.40 (brs, NH, 1H), 7.41 (m, Har, 2H), 6.95 (m, Har, 2H), 3.86 (s, CH3, 3H). 
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(R)-()-Benzyl-3-propionyl-2-oxazolidinone (Evans Auxiliary) 210[108] 
 
To an ice-cold methanol (76 mL) was added acetyl chloride (12.54 mL, 174.74 mmol) over a period of 
10 min. D-Phenylalanine (10.0 g, 60.53 mmol) was added to the reaction, which initially produced a 
cloudy solution and became clear solution in 10 min. Reaction left stirring for 16 h at room 
temperature, solvents were removed in vacuo to obtain white solids. To the obtained solids in 
distilled water (300 mL), NaHCO3 (25.0 g, 297.6 mmol) was added slowly portion wise and then 
ethylchloroformate (6.84 mL, 71.58 mmol) was added dropwise at room temperature and stirred for 
4 h. Reaction mixture was extracted with ethyl acetate (2 × 350 mL), combined organic layers are 
dried over Na2SO4, filtered and concentrated in vacuo under reduced pressure. 
The obtained product was taken in a mixture of ethanol/THF (2:1, 150 mL), to this was added calcium 
chloride (11.50 g, 103.64 mmol) and sodium borohydride (8.30 g, 219.4 mmol) successively in 
portions. Apparatus was fixed with condenser and stirred for 16 h at room temperature. Reaction 
mixture was slowly poured into aq. citric acid (200 mL, 1M), stirred for 20 min and extracted with 
EtOAc (3 × 125 mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in 
vacuo. The obtained residue passed through short silica gel column using pet ether: EtOAc (2:1), the 
fractions containing compound are concentrated in vacuo and the product stored at 25 °C to 
crystallize for 16 h. 
To the obtained solid was added potassium carbonate (10.0 g, 72.35 mmol) and toluene (15 mL)  and 
the resulting mixture was stirred on rotavap at 90 °C (50 mbar) for 4 h. A mixture of ethanol/water 
(1:1, 75 mL) was added, the organic phase was separated, aqueous layer was extracted with EtOAc 
and combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. Obtained 
residue was kept at 25 °C to crystallize for 16 h. 8.20 g of the oxazolidine was obtained. 
To the above obtained oxazolidine (8.20 g, 46.20 mmol) in THF (150 mL) was added n-BuLi (18.5 mL, 
46.25 mmol, 2.5M in hexanes) at 78 °C slowly dropwise. Freshly distilled propionyl chloride (4.30 mL, 
46.20 mmol) was added dropwise to the reaction mixture slowly, after the completion of addition, 
stirring was continued for another 30 minutes at 78 °C. Reaction mixture was quenched with 
saturated aq. NH4Cl (30 mL), the solvent was removed in vacuo and extracted with CH2Cl2 (3 × 50 mL), 
the combined organic layers are washed with aq. NaOH (30 mL, 1M) and saturated aq. NaCl (30 mL), 
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dried over Na2SO4, filtered and concentrated in vacuo. Obtained residue was cooled at 25 °C to 
crystallize to obtain (R)-()-benzyl-3-propionyl-2-oxazolidinone as white solid. 
1H-NMR (200 MHz, CDCl3):  7.22-7.42 (m, Har, 5H), 4.64-4.76 (m, H-6, 1H), 4.17-4.30 (m, H-5, 2H), 
3.35 (dd, H-2, 3J = 13.3 Hz, 3J  = 3.3 Hz, 1H), 2.88-3.08 (m, H-7, 2H), 2.79 (q, H-2, 3J = 13.4 Hz, 3J = 9.6 
Hz, 1H), 1.25 (t, H-1, 3J = 7.3 Hz, 3H). 
 
]23D =  63.0 (c 0.99, CHCl3) 
 
Tris(pentafluorophenyl)borane (TPPB)[110] 
 
 
 
To the magnesium turnings (2.50 g) in Et2O (174 mL) was added slowly dropwise 
pentafluorobromobenzene (12.98 mL, 25.72 g, 100 mmol) until the reaction mixture becomes turbid, 
once the turbidity was observed addition was stopped and reaction mixture was cooled to 0 °C. The 
remaining amount of pentafluorobromobenzene was added slowly dropwise so that the reaction 
mixture shouldn’t boil. In another flask borontrifluoride etherate was taken in toluene (70 mL) and 
cooled to 0 °C. The Grignard generated was slowly added using syringe to the borontrifluoride 
etherate in toluene at 0 °C and then warmed to room temperature. Around 100 mL of solvent was 
removed under reduced pressure. Reaction mixture was heated at 100 °C for 1 h and then 
concentrated under reduced pressure for complete dryness. The obtained brown residue was filtered 
using schlenk filter apparatus under nitrogen atmosphere using hexane (200 mL) and Et2O (200 mL). 
The filtrate was kept for crystallization at 25 °C for 16 h. The filtrate was concentrated under 
vacuum, tried to purify by Kugel-Rohr distillation (100 °C/1 m bar). 
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6.3. Ketone Fragment C(1-12): 
 
6.3.1 Homoallyl alcohol 195 
 
 
 
To a stirred suspension (78 °C) of potassium-tert-butoxide (9.79 g, 87.26 mmol, dried at 60 °C/0.3 
mbar overnight) in THF (56 mL) was added cis-butene (14.0 mL, 155.83 mmol) via double-tipped 
needle. n-BuLi (34.0 mL, 2.5M in hexanes, 87.26 mmol) was added over 10 min. After the complete 
addition, the reaction mixture was warmed to 25 °C for 30 min and recooled to 78 °C. A solution of 
(+)-Methoxydiisopinocampheylborane (35.0 g, 110.64 mmol) in Et2O (74 mL) was added slowly. After 
the resulting solution was stirred for 30 min, Borontrifluoride etherate (14.0 mL, 110.64 mmol) was 
added slowly dropwise, followed by drop wise addition of acetaldehyde (7.04 mL, 124.66 mmol) in 
Et2O (8 mL). After 3 h, the reaction was quenched with aq. NaOH (95 mL, 2M) and 30% aq. H2O2 (27 
mL), warmed to room temperature and then heated to reflux for 1 h. The organic layer was separated 
and the aqueous layer was extracted with Et2O (50 mL). The combined organic layers were washed 
with distilled water (150 mL) and brine (150 mL), dried over MgSO4 and filtered. After evaporation of 
a major amount of solvent in vacuo (500 mbar, 40 °C water bath), the residual liquid was carefully 
fractionated to give alcohol 195 (9.00 g, crude) (bp 50-72 °C/90 mbar). This contains residual THF and 
pinenol. 
 
1H-NMR (400 MHz, CDCl3):  5.63-5.73 (m, H-2, 1H), 4.99-5.03 (m, H-1, 1H), 4.96-4.99 (m, H-1’, 1H), 
3.58 (dd, J = 15.6, 10.1 Hz, H-5, 1H), 2.08-2.21 (m, H-3, 1H), 1.28-1.39 (bs, -OH, 1H), 1.05 (d, J = 6.4 Hz, 
H-4, 3H), 0.93 (d, J = 6.9 Hz, H-6,  3H). 
 
13C-NMR (100 MHz, CDCl3): 140.6, 115.7, 70.9, 44.9, 20.0, 14.8. 
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6.3.2 PMB-ether 177 
 
 
 
Sodium hydride (5.54 g, 60% in mineral oil, 116.87 mmol) was washed with pentane (2 × 35 mL), 
DMSO (140 mL) was added and the suspension was stirred at room temperature for 1 h. Crude 
alcohol 195 from the above step in THF (20 mL) was added over 10 min. The yellowish mixture was 
cooled to 0 °C and p-methoxybenzylchloride (11.31 mL, 86.1 mmol) was added slowly. The mixture 
was warmed to room temperature and stirred for 16 h. Brine (300 mL) was added and the mixture 
was extracted with MTBE (4 × 100 mL). The combined organic layers are dried over MgSO4 and 
evaporated in vacuo. Silica gel chromatography (pet ether-EtOAc, 5:1) afforded PMB ether 177 (13.0 
g, 60% over two steps) as a colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.28 (d, J = 8.7 Hz, HAr, 2H), 6.88 (d, J = 8.7 Hz, HAr, 2H), 5.75-5.93 (m, H-
2, 1H), 5.04-5.09 (m, H-1, 1H), 5.01-5.04 (m, H-1’, 1H), 4.53 (d, J = 11.4 Hz, H-7, 1H), 4.42 (d, J = 11.4 
Hz, H-7’, 1H), 3.81 (s, Ar-OCH3, 3H), 3.36 (p, J = 6.2 Hz, H-5, 1H), 2.31-2.47 (m, H-3, 1H), 1.13 (d, J = 6.2 
Hz, H-4, 3H), 1.05 (d, J = 6.8 Hz, H-6, 3H). 
 
13C -NMR (100 MHz, CDCl3): 159.1, 140.9, 131.3, 129.2, 114.5, 113.8, 78.2, 70.4, 55.4, 43.1, 16.8, 
16.0. 
 
HRMS (ESI) calculated for C14H20O2Na ([M+Na]+): 243.1361, found 243.1331. 
 
 
 
 
 
6. Experimentals 
114 
 
6.3.3 ,-Unsaturated ester 208 
 
 
 
A stream of ozone in oxygen (50 L/h) was passed through a solution containing olefin 177 (13.0 g, 
59.0 mmol) and sudan red III (cat.) in CH2Cl2 (110 mL) at 78 °C. Ozone gas was bubbled until the color 
of the solution turned from red to gray. Excess of Ozone was purged with oxygen and then with 
argon, triphenylphosphine (23.21 g, 88.50 mmol) was added and the stirring was continued at 78 °C 
for 1 h. and warmed to room temperature. (1-ethoxycarbonylethylidene)triphenylphosphorane 207 
(64.19 g, 177.0 mmol) was added. After 16 h, the solvents were removed in vacuo. The residue was 
filtered through a short pad of silica using (pet ether-EtOAc, 2:1) and the solvent was evaporated. 
Silica gel chromatography (pet ether-EtOAc, 15:1) afforded ester 208 (9.20 g, 56%) of ester as a 
colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.26 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 6.62 (dd, J = 
10.3, 1.4 Hz, H-5, 1H), 4.54 (d, J = 11.3 Hz, H-10, 1H), 4.38 (d, J = 11.3 Hz, H-10’, 1H), 4.19 (q, J = 7.1 Hz, 
H-1, 1H), 3.80 (s, Ar-OCH3, 3H), 3.37 (p, J = 6.2 Hz, H-8, 1H), 2.64 (dp, J = 10.3, 6.8 Hz, H-6, 1H), 1.85 (d, 
J = 1.4 Hz, H-4, 3H), 1.30 (t, J = 7.1 Hz, H-11, 3H), 1.14 (d, J = 6.2 Hz, H-7, 3H), 1.06 (d, J = 6.7 Hz, H-9, 
3H). 
 
13C -NMR (100 MHz, CDCl3): 168.4, 159.2, 144.2, 130.9, 129.4, 127.7, 113.9, 78.0, 70.8, 60.6, 55.4, 
39.6, 17.4, 16.2, 14.4, 12.8. 
 
HRMS (ESI) calculated for C18H26O4Na ([M+Na]+): 329.1729, found 329.1731 
]23D =  7.8 (c 1.2, CHCl3) 
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6.3.4 Allyl alcohol 209 
 
 
 
To a stirred solution (78 °C) of ester 208 (9.30 g, 30.35 mmol) in CH2Cl2 (200 mL) was added DIBAL-H 
(91 mL, 1M in CH2Cl2, 91.05 mmol) dropwise. After 1 h of stirring, MTBE (220 mL) was added rapidly 
and the mixture was warmed to room temperature. Dropwise addition of distilled water (9 mL) led to 
the formation of a colorless gel. Upon addition of aq. NaOH (18 mL, 2N) and additional distilled water 
(9 mL), a white solid precipitated. The resulting suspension was then dried over MgSO4, filtered and 
evaporated in vacuo. Silica gel chromatography (pet ether-EtOAc, 4:1) afforded the desired alcohol 
209 (7.90 g, 95%) as colorless liquid.  
 
1H-NMR (400 MHz, CDCl3): 7.26 (d, J = 8.6 Hz, HAr, 2H), 6.87 (d, J = 8.6 Hz, HAr, 2H), 5.25 (dd, J = 9.8, 
1.0 Hz, H-4,1H), 4.53 (d, J = 11.3 Hz, H-9, 1H), 4.37 (d, J = 11.3 Hz, H-9’, 1H), 3.96 (s, H-1, 2H), 3.79 (s, 
Ar-OCH3, 3H), 3.29 (p, J = 6.3 Hz, H-7, 1H), 2.55 (dp, J = 9.8, 6.8 Hz, H-5, 1H), 1.71 (bs, -OH, 1H), 1.67 
(d, J = 0.9 Hz, H-3, 3H), 1.13 (d, J = 6.2 Hz, H-6, 3H), 1.00 (d, J = 6.7 Hz, H-8, 3H). 
 
13C -NMR (100 MHz, CDCl3): 159.1, 134.9, 131.1, 129.3, 128.6, 113.8, 78.8, 70.6, 68.9, 55.4, 38.2, 
17.2, 14.2. 
 
HRMS (ESI) calculated for C16H24O3Na ([M+Na]+): 287.1623, found 287.1620 
[]23D = 10.4 (c 1.9, CHCl3). 
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6.3.5 ,-Unsaturated aldehyde 176 
 
 
 
Activated MnO2 (71.5 g, 417.0 mmol) was suspended in CH2Cl2 (250 mL). Alcohol 209 (5.30 g, 20.80 
mmol) in CH2Cl2 (30 mL) was added at room temperature and stirred for 1 h. The mixture was filtered 
through a pad of Celite, washed with CH2Cl2 (250 mL) and the filtrate evaporated under vacuo to 
afford pure aldehyde 176 (5.00 g, 95%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3): 9.38 (s, H-1, 1H), 7.25 (d, J = 7.7 Hz, HAr, 2H), 6.87 (d, J = 8.6 Hz, HAr, 2H), 
6.37 (dd, J = 10.1, 1.1 Hz, H-4, 1H), 4.56 (d, J = 11.3 Hz, H-9, 1H), 4.37 (d, J = 11.3 Hz, H-9’, 1H), 3.80 (s, 
Ar-OCH3, 3H), 3.45 (p, J = 6.2 Hz, H-7, 1H), 2.84 (dp, J = 10.1, 6.7 Hz, H-5, 1H), 1.76 (d, J = 1.1 Hz, H-3, 
3H), 1.17 (d, J = 6.2 Hz, H-6, 3H), 1.10 (d, J = 6.8 Hz, H-8, 3H). 
 
13C -NMR (100 MHz, CDCl3): 195.6, 159.3, 156.6, 139.0, 130.7, 129.4, 113.9, 77.3, 70.7, 55.4, 39.6, 
17.1, 15.7, 9.6. 
 
HRMS (ESI) calculated for C16H22O3Na ([M+Na]+): 285.1467, found 285.1466 
]23D = 22.0 (c 0.9, CHCl3). 
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6.3.6 Evans’ aldol 211 
 
 
To a stirred solution (78 °C) of (R)-()-benzyl-3-propionyl-2-oxazolidinone 210 (1.65 g, 7.06 mmol) in 
CH2Cl2 (20 mL) was added di(n-butyl)boryl(trifluoromethane)sulfonate (8.43 mL, 1M in CH2Cl2, 8.44 
mmol) and triethylamine (1.29 mL, 9.19 mmol). The mixture was warmed to 0 °C, stirred for 1 h and 
then cooled to 78 °C again. A solution of aldehyde 176 (1.80 g, 6.86 mmol) in CH2Cl2 (10 mL) was 
added dropwise over 5 min. After 20 min, the reaction was warmed to 0 °C and stirred for 1 h. The 
reaction was quenched by dropwise addition of pH7 phosphate buffer (7.5 mL), methanol (22.5 mL) 
and a mixture of methanol and 30% aq. H2O2 (2:1, 22.5 mL) and stirred for 1 h. Distilled water (20 ml) 
was added, the organic layer was separated and the aqueous layer was extracted with MTBE (4 × 20 
mL). The combined organic layers are washed with brine (30 mL), dried over MgSO4, filtered and 
evaporated in vacuo. Silica gel chromatography (pet ether-EtOAc, 4:1) afforded aldol 211 (3.00 g, 
89%) as a colorless gel. 
 
1H-NMR (400 MHz, CDCl3):  7.28-7.36 (m, HAr, 3H), 7.25 (d, J = 8.5 Hz, HAr, 2H), 7.20 (d, J = 6.9 Hz, HAr,  
2H), 6.86 (d, J = 8.6 Hz, HAr, 2H), 5.39 (d, J = 10.0 Hz, H-10, 1H), 4.61-4.72 (m, H-3, 1H), 4.51 (d, J = 11.3 
Hz, H-15, 1H), 4.37 (d, J = 10.4 Hz, H-15’, 1H), 4.29-4.36 (m, H-7, 1H), 4.14 (d, J = 5.2 Hz, H-1, 1H), 4.00 
(qd, J = 6.9, 4.3 Hz, H-13, 1H), 3.80 (s, Ar-OCH3, 1H), 3.28-3.35 (m, BnCH2, 1H), 3.25 (dd, J = 13.2, 3.1 
Hz, H-5, 1H), 2.78 (dd, J = 13.4, 9.5 Hz, BnCH2, 1H), 2.51-2.62 (m, H-12, 1H), 1.64 (s, H-9, 3H), 1.58 (bs, 
-OH, 1H), 1.19 (d, J = 7.0 Hz, H-6, 3H), 1.11 (d, J = 6.2 Hz, H-14, 3H), 1.01 (d, J = 6.7 Hz, H-11, 3H). 
 
13C -NMR (100 MHz, CDCl3): 176.9, 159.2, 153.1, 135.3, 133.6, 131.2, 129.6, 129.4, 129.1, 127.5, 
79.1, 75.8, 70.7, 66.2, 55.4, 40.7, 38.4, 37.9, 17.6, 17.3, 13.7, 11.1. 
 
HRMS (ESI) calculated for C29H37NO6Na ([M+Na]+): 518.2516, found 518.2516 
]23D = 28.2 (c 1.2, CHCl3). 
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6.3.7 Weinreb amide 212 
 
 
 
To a stirred suspension (0 °C) of N,O-dimethylhydroxylamine hydrochloride (0.62 g, 6.34 mmol) in 
CH2Cl2 (10 mL) was added trimethylaluminium (3.17 mL, 2M in heptane, 6.34 mmol) over 5 min. The 
mixture was warmed to room temperature and stirred for 1 h. After 1 h, the clear solution was cooled 
to 20C and compound 211 (1.50 g, 3.02 mmol) in CH2Cl2 (5 mL) was added dropwise for 5 min. The 
reaction was allowed to warm to room temperature over a period of 5 h and was stirred 16 h at rt.  
The mixture was transferred via syringe to a second flask containing a vigorously stirred solution of 
tartaric acid (20 mL, 1M) at 0 °C. After 1.5 h, distilled water (30 mL) was added and the aqueous layer 
was extracted with CH2Cl2 (3 × 25 mL). The combined organic layers are washed with brine (30 mL), 
dried over MgSO4, filtered and evaporated in vacuo. The crude product purified by silica gel column 
chromatography (pet ether-ethyl acetate, 3:1) afforded compound 212 (1.00 g, 87%) as a colorless 
liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.27 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.40 (d, J = 10.0 Hz, H-9, 
1H), 4.53 (d, J = 11.2 Hz, H-14, 1H), 4.36 (d, J = 11.2 Hz, H-14’, 1H), 4.25 (d, J = 2.9 Hz, H-6, 1H), 3.79 (s, 
Ar-OCH3, 3H), 3.70 (s, H-1, 3H), 3.68-3.71 (m, H-12, 1H), 3.26 (dd, J = 7.9, 6.2 Hz, H-4, 1H), 3.18 (s, H-2, 
3H), 3.07 (bs, -OH, 1H), 2.39-2.61 (m, H-10, 1H), 1.61 (s, H-7, 3H), 1.12 (d, J = 6.1 Hz, H-5, 3H), 1.09 (d, 
J = 7.1 Hz, H-13, 3H), 1.02 (d, J = 6.6 Hz, H-11, 3H). 
 
13C -NMR (100 MHz, CDCl3): 177.8,159.1, 132.8, 131.3, 129.7, 129.4, 113.8, 79.2, 75.6, 70.8, 61.7, 
55.4, 39.0, 17.7, 13.9, 10.7. 
 
HRMS (ESI) calculated for C21H33NO5Na ([M+Na]+): 402.2256, found 402.2259 
]23D = 3.18 (c 2.2, CHCl3). 
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6.3.8 TBS-Weinreb amide 213 
 
 
 
To a stirred solution (0 °C) of amide 212 (5.30 g, 13.96 mmol) in CH2Cl2 (68 mL) was slowly added 2,6-
Lutidine (2.76 mL) and tert-Butyldimethylsilyltrifluoromethane sulfonate (4.20 mL). The mixture was 
warmed to room temperature and stirred for 1 h. The reaction was quenched with methanol (2 mL), 
diluted with CH2Cl2 (240 mL) and successively washed with saturated aq. NaHCO3 (60 mL), aq. NaHSO3 
(3 × 60 mL) and brine (60 mL), dried over MgSO4 and evaporated in vacuo. The crude product was 
purified by silica gel column chromatography (pet ether- EtOAc, 5:1) to afford compound 213 (5.60 g, 
81%) as a colorless liquid. 
 
1H-NMR (400 MHz, CDCl3): 7.28 (m, d, J = 8.5 Hz, HAr, 2H), 6.86 (d, J = 8.5 Hz, HAr, 1H), 5.09 (d, J = 
10.0 Hz, H-9, 1H), 4.50 (d, J = 11.1 Hz, H-14, 1H), 4.33 (d, J = 11.1 Hz, H-14’, 1H), 4.14 (d, J = 9.4 Hz, H-
6, 1H), 3.80 (s, Ar-OCH3, 3H), 3.62 (s, H-1, 3H), 3.15 (dd, J = 7.9, 6.3 Hz, H-4&H-12, 2H), 3.06 (s, H-2, 
3H), 2.41 (dd, J = 15.7, 8.9 Hz, H-10, 1H), 1.60 (s, H-8, 3H), 1.18 (d, J = 6.7 Hz, H-5, 3H), 1.02 (d, J = 6.1 
Hz, H-13,  3H), 0.98 (d, J = 6.6 Hz,H-11, 3H), 0.88 (s, Si(CH3)3, 9H), 0.05 (s, SiCH3, 1H), -0.02 (s, SiCH3, 
1H). 
 
13C -NMR (100 MHz, CDCl3): 175.7, 159.1, 135.1, 131.3, 129.4, 113.8, 80.7, 79.4, 70.8, 61.6, 55.4, 
40.0, 39.2, 31.8, 25.9, 18.3, 17.6, 17.3, 15.4, 11.3, -4.3, -4.8. 
 
HRMS (ESI) calculated for C27H47NO5SiNa ([M+Na]+): 516.3121, found 516.3122 
]23D = 11.6 (c 2.5, CHCl3). 
 
 
 
 
 
6. Experimentals 
120 
 
6.3.9 Aldehyde 174 
 
 
To a stirred solution (78 °C) of amide 213 (0.82 g, 1.66 mmol) in THF (8 mL) was added DIBAL-H (4.16 
mL, 1M in CH2Cl2, 4.16 mmol) over 20 min. Upon complete addition, the reaction was stirred for 
further 15 min. Excess DIBAL-H was quenched by the addition of acetone (0.3 mL). The reaction 
mixture was transferred via syringe to a second flask containing a vigorously stirred mixture of (23 °C) 
of aq. tartaric acid (16 mL, 1M) and pet ether (15 mL) stirred for 1 h. The organic layer was separated 
and the aqueous layer was extracted with MTBE (3 × 25 mL). The combined organic layers are washed 
with brine (25 mL), dried over MgSO4, filtered and evaporated in vacuo. Silica gel chromatography 
(pet ether-EtOAc, 5:1) afforded aldehyde 174 (0.64 g, 89%) as a colorless liquid. 
 
1H-NMR (400 MHz, CDCl3): 9.64 (d, J = 2.1 Hz, H-1, 1H), 7.26 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 
Hz, HAr, 2H), 5.22 (d, J = 10.0 Hz, H-7, 1H), 4.52 (d, J = 11.2 Hz, H-11, 1H), 4.33 (d, J = 11.2 Hz, H-11’, 
1H), 4.21 (d, J = 6.7 Hz, H-4, 1H), 3.80 (s, Ar-OCH3, 3H), 3.14 – 3.31 (m, H-10, 1H), 2.52 – 2.62 (m, H-2, 
1H), 2.43 – 2.52 (m, H-8, 1H)1.60 (d, J = 1.3 Hz, H-6, 3H), 1.09 (d, J = 6.2 Hz, H-12, 3H), 1.04 (d, J = 6.8 
Hz, H-9, 3H), 1.00 (d, J = 6.7 Hz, H-3, 3H), 0.88 (s, Si(CH3)3, 9H), 0.04 (s, SiCH3, 3H), -0.01 (s, SiCH3, 3H). 
 
13C -NMR (100 MHz, CDCl3): 204.5, 159.1, 135.0, 131.2, 130.9, 129.3, 113.8, 78.8, 78.5, 70.6, 55.4, 
51.2, 38.7, 25.9, 18.3, 17.5, 16.9, 12.5, 9.7, -4.3, -5.0. 
 
HRMS (ESI) calculated for C25H42O4SiNa ([M+Na]+): 457.2750, found 457.2747 
[]23D = 14.88 (c 1.8, CHCl3). 
 
 
 
 
 
 
6. Experimentals 
121 
 
6.3.10 Ketene acetal 175 
 
 
 
To a solution of diisopropylamine (7.0 mL, 49.3 mmol) in THF (30 mL) was added n-BuLi (2.5M in 
hexanes, 19.75 mL, 49.0 mmol) at 0 °C over a period of 10 minutes. The resulting solution was cooled 
to 78 °C, with an interval of 15 minutes each DMPU (8.00 mL, 66.0 mmol), methyl-(E)-pent-2-enoate 
(5.00 g, 43.0 mmol) and TBSCl (8.10 g, 53.7 mmol) are added successively. After the completion of 
addition reaction mixture warmed to room temperature and stirred for additional 90 min. sat. aq. 
NaHCO3 solution (50 mL) was added, the phases are separated, aqueous phase extracted with MTBE 
(3 × 50 mL). Combined organic layers are washed with water (3 × 20 mL), dried over anhydrous 
Na2SO4, filtered and concentrated on vacuo. Crude compound was purified using distillation (90-100 
°C/0.7 mbar) to afford ketene acetal 175 (8.0 g, 82%) as a colorless oil.  
 
1H-NMR (400 MHz, CDCl3): 6.17 (td, J = 10.8, 1.7 Hz, H-3, 1H), 5.10 (dqd, J = 10.8, 6.9, 1.0 Hz, H-2, 
1H), 4.54 (dd, J = 10.7, 0.9 Hz, H-4, 1H), 3.60 (s, H-6 3H), 1.67 (dd, J = 6.9, 1.7 Hz, H-1, 3H), 0.95 (s, 
SiC(CH3)3, 9H), 0.17 (s, SiCH3, 7H). 
 
13C -NMR (100 MHz, CDCl3): 158.6,124.4, 116.6, 75.4, 54.9, 25.8, 18.3, -4.1, 13.3. 
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6.3.11 VMAR aldol product 216 
 
 
 
To a stirred solution (–78 °C) of tris(pentafluorophenyl)borane (1.50 g, 2.93 mmol) in Et2O (35 mL), 
aldehyde 15 (1.10 g, 2.53 mmol) in Et2O (8 mL) was added. Ketene acetal 175 (1.27 g, 5.56 mmol) and 
i-PrOH (0.21 mL, 2.77 mmol) were diluted with Et2O (8 mL) and added via syringe pump over 2 h. The 
mixture was allowed to warm to 50 °C over 30 min and was then evaporated in vacuo at room 
temperature. Silica gel chromatography (pet ether-EtOAc, 4:1) afforded ester 216 (1.10 g, 80%) as a 
colorless liquid.  
 
1H-NMR (400 MHz, CDCl3):  7.25 (d, J = 8.3 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 6.71 (dd, J = 15.7, 
9.3 Hz, H-2, 1H), 5.82 (dd, J = 15.7, 0.6 Hz, H-1, 1H), 5.23 (d, J = 9.9 Hz, H-8, 1H), 4.51 (d, J = 11.5 Hz, H-
16, 1H), 4.36 (d, J = 11.5 Hz, H-16’, 1H), 3.90 (d, J = 7.7 Hz, H-6, 1H), 3.80 (s, -OMe, 3H), 3.73 (s, Ar-
OCH3, 1H), 3.31-3.36 (m, H-10, 1H), 3.29 (d, J = 6.0 Hz, H-4, 1H), 2.62 (dt, J = 9.9, 6.7 Hz, H-9, 1H), 2.32-
2.51 (m, H-3, 1H), 2.03 (d, J = 4.7 Hz, -OH, 1H), 1.57-1.66 (m, H-5, 1H), 1.55 (d, J = 1.2 Hz, H-13, 3H), 
1.12 (d, J = 6.2 Hz, H-11, 3H), 1.00 (d, J = 6.6 Hz, H-5, 3H), 0.97 (d, J = 6.8 Hz, H-12, 3H), 0.88 (d, J = 2.2 
Hz, H-14, 3H), 0.88 (s, Si(CH3)3, 9H), 0.05 (s, SiCH3, 1H), -0.03 (s, SiCH3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  167.1, 159.2, 150.9, 136.3, 131.1, 129.8, 129.2, 121.0, 113.9, 82.5, 78.6, 
75.3, 70.5, 55.4, 51.6, 41.1, 39.9, 37.8, 26.0, 18.3, 17.2, 16.7, 16.6, 12.10, 8.2, -4.2, -4.9. 
 
HRMS (ESI) calculated for C31H52O6SiNa ([M+Na]+): 571.3431, found 571.3433 
 []23D = 8.0 (c 0.7, CHCl3). 
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6.3.12 TES-ether 173 
 
 
 
To a stirred solution (0 °C) of ester 216 (580 mg, 1.056 mmol) in CH2Cl2 (11 mL) was added 2,6-lutidine 
(0.32 mL, 2.754 mmol) and TESOTf (0.406 mL, 1.796 mmol) dropwise. After 15 min, the reaction was 
quenched by the addition of sat. aq. NaHCO3 (20 mL). The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 × 25 mL). The combined organic layers dried over MgSO4, 
filtered and evaporated in vacuo. Silica gel chromatography (pet ether-EtOAc, 15:1) afforded the 
ester 173 (660 mg, 0.303 mmol, 94%) as a colorless liquid. 
  
1H-NMR (400 MHz, CDCl3):  7.27 (d, J = 8.0 Hz, HAr, 2H), 6.94 (dd, J = 15.8, 7.6 Hz, H-4, 1H), 6.87 (d, J = 
8.7 Hz, HAr, 2H), 5.76 (dd, J = 15.8, 1.3 Hz, H-3, 1H), 5.16 (d, J = 9.8 Hz, H-13, 1H), 4.54 (d, J = 11.2 Hz, 
H-18, 1H), 4.37 (d, J = 11.2 Hz, H-18’, 1H), 3.80 (s, H-1, 3H), 3.76 (d, J = 8.8 Hz, H- 10, 1H), 3.73 (s, 
ArOCH3, 3H), 3.54 (dd, J = 5.7, 2.5 Hz, H-7, 1H), 3.25 (dq, J = 12.3, 6.1 Hz, H-16, 1H), 2.50 – 2.65 (m, H-
14, 1H), 2.36 – 2.51 (m, H-5, 1H), 1.62 – 1.76 (m, H-8, 1H), 1.52 (d, J = 1.1 Hz, H-12, 3H), 1.17 (d, J = 6.1 
Hz, H-17, 3H), 1.02 (d, J = 6.7 Hz, H-15, 3H), 0.91 – 0.99 (m, 12H), 0.88 – 0.83 (m, 12H), 0.60 (q, J = 7.9 
Hz, 6H), 0.01 (s, SiCH3, 3H), -0.05 (s, SiCH3, 3H).
 
 
13C-NMR (100 MHz, CDCl3):  167.2, 159.1, 152.4, 136.9, 131.3, 131.2, 129.2, 120.2, 113.8, 80.7, 78.9, 
75.0, 70.6, 55.4, 51.5, 42.4, 39.4, 39.0, 26.0, 18.4, 17.6, 17.1, 15.2, 12.0, 11.0, 7.2, 5.8, -4.1, -4.8. 
 
HRMS (ESI) calculated for C37H66O6Si2Na ([M+Na]+): 685.4296, found 685.4294 
 []23D =7.58 (c 1.1, CHCl3). 
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6.3.13 Diol 224 
 
 
 
To a stirred solution of AD-mix- (3.05 g) in t-BuOH-H2O (1:1, 20 mL) was added methanesulfonamide 
(160 mg, 1.719 mmol) at room temperature. The suspension was cooled to 0 °C and methyl ester 
173(1.10 g, 1.6589 mmol) was added in t-BuOH (5 mL). After 5 days, the reaction was quenched by 
the addition of Na2S2O3 (1.67 g), warmed to room temperature and stirred for 1 h. H2O (20 mL) was 
added, and the mixture was extracted with EtOAc (4 × 25 mL), dried over MgSO4, filtered and 
evaporated in vacuo. Silica gel chromatography (pet ether- EtOAc, 3:1) afforded diol 224 (0.75 g, 70%) 
as a mixture of diastereomers (d.r. 24:1). 
 
1H-NMR (400 MHz, CDCl3):  7.28 (d, , J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 5.17 (d, J = 9.8 
Hz, H-13, 1H), 4.51 (d, J = 11.8 Hz, H-18, 1H), 4.40 (d, J = 11.7 Hz, H-18’, 1H), 4.26 (dd, J = 5.5, 3.0 Hz, 
H-3, 1H), 3.80 (s, ArOCH3, 3H), 3.78 (s, H-1, 3H), 3.74 (d, J = 9.2 Hz, H-4, 1H), 3.61 (dd, J = 5.2, 2.0 Hz, 
H-10, 1H), 3.29 (p, J = 6.2 Hz, H-7, 1H), 3.14 (d, J = 5.5 Hz, H-16, 1H), 2.53-2.70 (m, H-14/-OH, 2H), 
1.72-1.84 (m, H-8/H-5, 2H), 1.58 (d, J = 1.0 Hz, H-12, 1H), 1.12 (d, J = 6.2 Hz, H-17, 1H), 0.94-0.98 (m, 
18H), 0.88 (s, Si(CH3)3, 9H), 0.63 (q, J = 7.8 Hz, 6H), 0.03 (s, SiCH3, 1H), -0.04 (s, SiCH3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  174.3, 159.2, 137.6, 130.9, 130.5, 129.3, 113.9, 81.3, 78.6, 73.5, 73.2, 
72.2, 70.4, 55.4, 52.7, 42.5, 39.6, 37.9, 26.0, 18.4, 17.2, 16.6, 11.8, 11.3, 10.7, 7.3, 5.8, -4.1, -4.8. 
 
HRMS (ESI) calculated for C31H52O8SiNa ([M+Na]+): 719.4350, found 719.4146 
[]23D = 12.88 (c 1.8, CHCl3). 
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6.3.14 Monohydroxy ester 225 
 
 
 
To a stirred solution (0 °C) of diol 224 (750 mg, 1.070 mmol) in DMF (20 mL) was added imidazole 
(437 mg, 6.420 mmol) and TBSCl (567 mg, 3.765 mmol). After 16 h, the reaction was quenched by the 
addition of sat. aq NH4Cl (20 mL) and the mixture was extracted with pet ether- EtOAc (5:1, 4 × 25 
mL). The combined organic layers were dried over MgSO4, filtered and evaporated in vacuo. Silica gel 
chromatography (pet ether- EtOAc, 8:1) afforded the desired ester 225 (830 mg, 95%) as a colorless 
liquid.  
 
1H-NMR (400 MHz, CDCl3):  7.27 (d, J = 7.0 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 5.12 (dd, J = 9.7, 
0.9 Hz, H-13, 1H), 4.54 (d, J = 11.5 Hz, H-18, 1H), 4.39 (d, J = 11.5 Hz, H-18’, 1H), 4.07 (d, J = 6.8 Hz, H-
3, 1H), 3.79-3.82 (m, H-10, 1H), 3.80 (s, ArOCH3,3H), 3.74 (d, J = 7.5 Hz, H-4, 1H), 3.71 (s, H-1, 3H), 3.54 
(d, J = 7.5 Hz, H-7, 1H), 3.23 (dq, J = 12.3, 6.1 Hz, H-16, 1H), 2.54-2.63 (m, H-14, 1H), 2.53 (d, J = 4.5 Hz, 
H-5, 1H), 1.86 (dq, J = 13.6, 6.7 Hz, H-8, 1H), 1.58 (d, J = 1.1 Hz, H-12, 3H), 1.15 (d, J = 6.2 Hz,H-17,  
3H), 1.00 (d, J = 6.7 Hz, H-15, 4H), 0.95 (m, 12H), 0.88-0.92 (m, 12H), 0.80-0.87 (m, 9H), 0.59 (dt, J = 
8.4, 4.7 Hz, 6H), 0.07 (s, SiCH3, 3H), 0.06 (s, SiCH3, 3H), 0.02 (s, SiCH3, 3H), -0.04 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  172.5, 159.1, 137.5, 131.3, 131.2, 129.2, 113.8, 81.6, 78.8, 75.9, 74.1, 
71.7, 70.5, 55.4, 52.0, 40.2, 38.7, 26.0, 25.9, 18.4, 18.4, 17.5, 17.2, 11.6, 10.4, 10.4, 7.3, 6.1, -4.1, -4.8, 
-4.9, -5.1. 
 
HRMS (ESI) calculated for C43H82O8Si3Na ([M+Na]+): 833.5215, found 833.5204 
[]23D = 2.2 (c 0.85, CHCl3). 
 
 
 
 
 
6. Experimentals 
126 
 
6.3.15 Methyl ester 226 
 
 
 
To a stirred solution of trimethyloxonium tetrafluoroborate (1.53 g, 10.89 mmol) in CH2Cl2 (21 mL) 
was added proton sponge (2.32 g, 10.83 mmol). The mixture was cooled to 0 °C and a solution of TBS-
ether 225 (560 mg, 0.690 mmol) in CH2Cl2 (5 mL) was added slowly. The reaction was protected from 
light and stirred for 24 h. The mixture was diluted with CH2Cl2 (100 mL), washed with sat. aq. NaHCO3 
(3 × 30 mL), dried over MgSO4, filtered and evaporated in vacuo. The residue was filtered through a 
short pad of silica gel with EtOAc and evaporated. Silica gel chromatography (petether-MTBE, 14:1) 
afforded ester 226 (495 mg, 87%) as a colorless liquid.  
 
1H-NMR (400 MHz, CDCl3):  7.26 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 5.18 (dd, J = 9.6, 
0.9 Hz, H-13, 1H), 4.53 (d, J = 11.2 Hz, H-18, 1H), 4.35 (d, J = 11.2 Hz, H-18’, 1H), 4.28 (d, J = 6.6 Hz, H-
3, 1H), 3.80 (s, ArOCH3, 3H), 3.79 (d, J = 9.0 Hz, H-10, 3H), 3.71 (s, H-1, 3H), 3.46 (d, J = 8.7 Hz, H-4, 
1H), 3.41 (s, OMe, 1H), 3.34 (dd, J = 6.6, 0.8 Hz, H-7, 1H), 3.22 (dq, J = 12.2, 6.1 Hz, H-16, 1H), 2.42- 
2.57 (m, H-14, 1H), 1.83 (dq, J = 13.4, 6.6 Hz, H-5, 1H), 1.62-1.68 (m, H-8, 1H), 1.60 (d, J = 1.0 Hz, H-12, 
3H), 1.16 (d, J = 6.1 Hz, H-17, 3H), 1.04 (d, J = 6.6 Hz, H-15, 3H), 0.95 (t, J = 7.9 Hz, SiCH2CH3, 9H), 0.90 
(s, SiC(CH3)3, 9H), 0.80-0.89 (m, 15H), 0.61 (qd, J = 7.9, 2.9 Hz, SiCH2, 6H), 0.07 (d, J = 3.1 Hz, SiCH3, 
6H), 0.03 (s, SiCH3, 3H), -0.03 (s, SiCH3, 3H), -0.03 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  172.6, 159.1, 136.9, 131.9, 131.2, 129.2, 113.8, 82.6, 81.3, 78.8, 75.4, 
74.4, 70.6, 60.5, 55.4, 51.8, 39.5, 39.3, 39.0, 26.0, 25.9, 18.4, 18.3, 17.9, 16.9, 11.7, 11.3, 10.1, 7.4, 
6.3, -4.1, -4.8, -5.0, -5.0. 
 
HRMS (ESI) calculated for C44H84O8Si3Na ([M+Na]+): 847.5368, found 847.5368 
[]23D = 4.64 (c 2.5, CHCl3). 
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6.3.16 Allyl ester 227 
 
 
 
A mixture of methyl ester 226 (220 mg, 0.266 mmol), bis[(dibutyl)chlorotin] oxide (72 mg, 0.13 mmol) 
and allyl alcohol (5 mL) was heated to 160 °C in a sealed tube under argon for 4 days. The excess allyl 
alcohol was evaporated and the residue was dissolved in MTBE and filtered through Celite. The 
solvent was concentrated in vacuo, and the crude product was purified by silica gel chromatography 
(pet ether- MTBE, 15:1) afforded ester 227 (200 mg, 90%) as a colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.26 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 5.92 (ddt, J = 
16.4, 10.3, 6.0 Hz, H-2, 1H), 5.36 (dq, J = 17.2, 1.4 Hz, H-1, 1H), 5.26 (ddd, J = 10.4, 2.4, 1.1 Hz, H-1’, 
1H), 5.18 (dd, J = 9.6, 0.9 Hz, H-15, 1H), 4.56-4.66 (m, H-3, 2H), 4.54 (d, J = 11.2 Hz, H-20, 1H), 4.35 (d, 
J = 11.2 Hz, H-20’, 1H), 4.28 (d, J = 6.7 Hz, H-5, 1H), 3.80 (s, ArOCH3, 3H), 3.76-3.80 (m, H-12, 1H), 3.46 
(d, J = 8.9 Hz, H-6, 1H), 3.41 (s, OMe, 3H), 3.31-3.37 (m, H-9, 1H), 3.23 (dq, J = 12.2, 6.1 Hz, H-18, 1H), 
2.42-2.57 (m, H-16,  1H), 1.75-1.87 (m, H-7, 1H), 1.65 (dt, J = 14.8, 7.6 Hz, H-10, 1H), 1.60 (s, H-12, 3H), 
1.16 (d, J = 6.1 Hz, H-19, 3H), 1.04 (d, J = 6.6 Hz, H-17, 1H), 0.95 (t, J = 7.9 Hz, SiCH2CH3, 9H), 0.90 (s, 
SiC(CH3)3, 9H), 0.87 (s, SiC(CH3)3, 9H), 0.85 (d, J = 6.9 Hz, H-8/H-11, 6H), 0.67 – 0.55 (m, SiCH2, 6H), 0.07 
(d, J = 3.7 Hz, SiCH3, 6H), 0.03 (s, SiCH3, 3H), -0.03 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  171.8, 159.1, 136.9, 131.9, 131.7, 131.3, 129.2, 119.4, 113.8, 82.7, 81.3, 
78.8, 75.7, 74.3, 70.7, 65.7, 60.7, 55.4, 39.5, 39.4, 39.1, 26.0, 25.9, 18.4, 18.0, 16.9, 11.8, 11.4, 10.1, 
7.4, 6.3, -4.1, -4.8, -4.9, -5.0. 
 
HRMS (ESI) calculated for C46H86O8Si3Na ([M+Na]+): 873.5528, found 873.5528 
 []23D = 2.0 (c 1.0, CHCl3). 
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6.3.17 Keto ester 228 
 
 
 
A solution of TES-ether 227 (160 mg, 0.190 mmol) and PPTS (88.4 mg, 0.351 mmol) in THF (1.16 mL) 
and MeOH (4.68 mL) was stirred at rt for 8 h. The solution was diluted with MTBE (100 mL), washed 
with H2O (10 mL), sat. aq. NaHCO3 (10 mL) and brine (10 mL). The organic layer was dried over 
Na2SO4, filtered and concentrated in vacuo. Without any further purification, the crude product was 
dissolved in CH2Cl2 (1.5 mL). The solution was cooled to 0 °C and pre-dried pyridine (73.3 L) and a 
solution of DMP in CH2Cl2 (15% w/w, 0.73 mL) was added dropwise. Resulting yellow solution was 
stirred for additional 30 min. Concentrated in vacuo at rt and was directly subjected to column 
chromatography (pet ether: EtOAc, 20: 1 → 12:1) to afford ketone 25 (100 mg, 72%). 
 
1H-NMR (400 MHz, CDCl3):  7.26 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 5.92 (ddt, J = 
16.4, 10.4, 6.0 Hz, H-2, 1H), 5.35 (dq, J = 17.2, 1.4 Hz, H-1, 1H), 5.29-5.22 (m, H-1’, 1H), 5.15 (d, J = 
10.0 Hz, H- 15, 1H), 4.72-4.55 (m, H-3, 2H), 4.52 (d, J = 11.2 Hz, H-20, 1H), 4.34 (d, J = 11.2 Hz, H-20’, 
1H), 4.20 (d, J = 5.4 Hz, H-5, 1H), 4.16 (d, J = 7.9 Hz, H-12, 1H), 3.95 (dd, J = 5.4, 2.7 Hz, H-7, 1H), 3.80 
(s, ArOCH3, 3H), 3.38 (s, OMe, 3H), 3.17 (dt, J = 12.2, 6.1 Hz, H-18, 1H), 2.98 (dq, J = 13.9, 6.9 Hz, H-16, 
1H), 2.65 (qd, J = 7.2, 2.7 Hz, H-7, 1H), 2.29-2.42 (m, H-10, 1H), 1.56 (d, J = 1.1 Hz, H-14, 3H), 1.21 (d, J 
= 7.3 Hz, H-19, 3H), 1.14 (d, J = 6.9 Hz, H-17, 3H), 1.04 (d, J = 6.1 Hz, H-8, 3H), 0.98 (d, J = 6.6 Hz, H-11, 
3H), 0.91 (s, SiC(CH3)3, 9H), 0.87 (s, SiC(CH3)3, 9H), 0.08 (s, SiCH3, 1H), 0.05 (s, SiCH3, 1H), 0.03 (s, SiCH3, 
1H), -0.03 (s, SiCH3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  213.9, 171.4, 159.1, 134.7, 131.8, 131.8, 131.2, 129.3, 119.3, 113.8, 
80.1, 79.8, 79.0, 75.5, 70.8, 65.7, 60.3, 55.4, 48.4, 47.8, 39.1, 26.0, 25.9, 18.5, 18.3, 18.0, 16.8, 14.6, 
12.0, 10.8, -4.3, -4.8, -4.9, -5.1. 
 
HRMS (ESI) calculated for C40H70O8Si2Na ([M+Na]+): 757.4507, found 757.4506 
[]23D = 9.33 (c 0.9, CHCl3). 
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6.3.18 Alcohol 229 
 
 
 
To a solution of PMB ether 228 (85 mg, 0.115 mmol) in CH2Cl2 (1 mL) was added pH7 phosphate 
buffer (38.3 l) and DDQ (32.8 mg, 0.144 mmol) at 0 °C. Stirred for additional 30 min, the mixture was 
diluted with MTBE (80 mL) and washed with sat. aq. NaHCO3 (4 × 15 mL) and brine (25 mL).  Organic 
layer dried over Na2SO4, filtered and concentrated in vacuo.  Crude product purified by column 
chromatography (pet ether: EtOAc, 12:1 → 5:1) to afford alcohol 229 (70 mg, 98%) as a colorless oil. 
Crude product was used in next step without any characterization. 
 
6.3.19 Methyl ketone 193  
 
 
 
A suspension of alcohol 229 (70 mg, 0.113 mmol), NMO (40 mg, 0.314 mmol) and 4 A° molecular 
sieves (35 mg) in CH2Cl2 (1 mL) was stirred at 0 °C for 30 min. TPAP (0.38 mg) was added and warmed 
to rt, stirred for additional 15 min. Concentrated in vacuo and purified by column chromatography 
(pet ether: EtOAc, 12:1) to afford diketone 193 (56 mg, 80%) as a colorless oil. 
 
1H-NMR (400 MHz, C6D6):  5.74 (ddt, J = 16.3, 10.4, 5.9 Hz, H-2, 1H), 5.37 (d, J = 9.7 Hz, H-15, 1H), 
5.15 (ddd, J = 17.2, 3.0, 1.5 Hz, H-1, 1H), 4.98 (dd, J = 10.4, 1.3 Hz, H-1’, 1H), 4.43-4.55 (m, H-3/H-5, 
3H), 4.41 (d, J = 7.4 Hz, H-12, 1H), 4.16 (dd, J = 5.7, 3.6 Hz, H-6, 1H), 3.43 (s, OMe, 3H), 3.10 (dq, J = 
9.6, 6.9 Hz, H-16, 1H), 2.99 (p, J = 7.0 Hz, H-10, 1H), 2.90 (qd, J = 7.2, 3.6 Hz, H-7, 1H), 1.91 (s, H-19, 
3H), 1.60 (d, J = 1.2 Hz, H-14, 3H), 1.30 (d, J = 7.2 Hz, H-8, 4H), 1.24 (d, J = 7.0 Hz, H-11, 3H), 1.03 (s, 
SiC(CH3)3, 9H), 1.01 (d, J = 6.9 Hz, H-17, 3H), 0.97 (s, SiC(CH3)3, 9H), 0.21 (s, SiCH3, 3H), 0.16 (s, SiCH3, 
3H), 0.10 (s, SiCH3, 3H), 0.00 (s, SiCH3, 3H). 
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13C-NMR (100 MHz, CDCl3):  212.6, 207.2, 171.4, 138.3, 132.2, 118.7, 81.2, 79.2, 75.5, 65.5, 60.3, 
49.1, 47.5, 46.9, 27.5, 26.1, 18.7, 18.4, 16.4, 14.0, 12.3, 11.3, -4.3, -4.6, -4.8, -4.8. 
 
HRMS (ESI) calculated for C32H60O7Si2Na ([M+Na]+): 635.3775, found 635.3772 
 []23D = 48.3 (c 0.8, CHCl3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6. Experimentals 
131 
 
6.4. Aldehyde Fragment C(17-23): 
 
6.4.1 Ester 288 
 
 
 
 
To the Roche ester 181 (8.00 g, 67.72 mmol) in CH2Cl2 (130 mL) was added trityl chloride (22.22 g, 
101.58 mmol) at room temperature. Triethylamine (15.14 mL, 108.35 mmol) was added dropwise 
slowly to the reaction mixture, after the addition reaction mixture turned yellow color and the solids 
precipitated out. Stirring was continued for 16 h at room temperature. Sat. aq. NaHCO3 (130 mL) was 
added and then stirred for 15 min. Organic layer separated and the aqueous layer was extracted with 
CH2Cl2 (2 × 30 mL). Combined organic layers are dried over Na2SO4, filtered and concentrated to yield 
compound 288 (27.0 g, quantitative) as yellow solid. The crude compound was used directly in the 
next step without further purification. 
 
1H-NMR (100 MHz, CDCl3):  7.46 – 7.56 (m, HAr, 6H), 7.33-7.42 (m, HAr, 6H), 7.24-7.35 (m, HAr, 3H), 
3.76 (s, H-6, 3H), 3.39 (dd, J = 8.7, 7.0 Hz, H-4, 1H), 3.27 (dd, J = 8.7, 5.8 Hz, H-4’, 1H), 2.74-2.89 (m, H-
2, 1H), 1.22 (d, J = 7.1 Hz, H-3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  175.5, 147.0, 144.0, 128.7, 128.0, 127.9, 127.8, 127.3, 127.0, 86.4, 65.4, 
51.7, 40.5, 14.1. 
 
HRMS (ESI) calculated for C21H24O3Na ([M+Na]+): 383.1623, found 383.1621 
[]23D = 5.4 (c 1.2, CHCl3). 
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6.4.2 Alcohol 236 
 
 
 
To the LiAlH4 (2.10 g, 55.33 mmol) in THF (50 mL) was added the crude ester 288 (27.0 g, 74.90 mmol) 
in THF (150 mL) dropwise at room temperature. After the completion of addition, reaction mixture 
was heated to 40 °C and stirred for 1 h. LiAlH4 (0.74 g, 19.55 mmol) was added in portions to the 
reaction over a period of 1 h. Stirred for additional 2 h at 40 °C. Reaction mixture cooled to room 
temperature and quenched carefully with dropwise addition of sat. aq. Na2SO4 solution. A thick gel 
obtained which was diluted with EtOAc (100 mL), filtered over Celite bed and washed with EtOAc (2 × 
50 mL). The combined filtrates are concentrated on vacuo and the crude compound was purified by 
silica gel column chromatography (pet ether- ethyl acetate, 4:1) to afford alcohol 236 (20.5 g, 91% 
over two steps) as white solid.   
 
1H-NMR (100 MHz, CDCl3):  7.45-7.53 (m, HAr, 6H), 7.32-7.42 (m, HAr, 6H), 7.23-7.32 (m, HAr, 3H), 
3.57-3.74 (m, H-1, 2H), 3.28 (dd, J = 9.1, 4.6 Hz, H-4, 1H), 3.09 (dd, J = 9.1, 7.7 Hz, H-4’, 1H), 2.39 (t, J = 
5.4 Hz, -OH, 1H), 1.99-2.08 (m, H-2, 1H), 0.91 (d, J = 7.0 Hz, H-3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  144.0, 128.7, 128.0, 127.2, 87.05, 67.9, 67.6, 36.1, 13.9. 
 
HRMS (ESI) calculated for C23H24O2Na ([M+Na]+): 355.1674, found 355.1673 
[]23D = 26.65 (c 0.99, CHCl3). 
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6.4.3 Aldehyde 113 
 
 
 
To a solution of Oxalyl chloride (4.28 mL, 45.0 mmol) in CH2Cl2 (90 mL) was added dimethyl sulfoxide 
(4.28 mL, 60.16 mmol) slowly dropwise at 78 °C and stirred for 30 minutes. Alcohol 236 (10.0 g, 
30.08 mmol) in CH2Cl2 (36 mL) was added dropwise to the reaction mixture at 78 °C and stirred for 1 
h. Triethylamine (21.0 mL, 150.40 mmol) was added drop wise to the reaction and warmed to room 
temperature which resulted in the precipitation of solids. Distilled water (100 mL) was added and 
stirred for 15 min. Organic layer was separated and the aqueous layer extracted with CH2Cl2 (2 × 30 
mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in vacuo. Crude 
compound was passed through a pad of silica using EtOAc and the fractions are concentrated to yield 
the aldehyde 113 (9.30 g, 91%).  This compound was used directly in the next step without any 
characterization. 
 
1H-NMR (100 MHz, CDCl3):  9.68 (d, J = 1.7 Hz, H-1, 1H), 7.39-7.43 (m, HAr, 6H), 7.21-7.33 (m, HAr, 
9H), 3.37 (dd, J = 9.2, 5.2 Hz, H-4, 1H), 3.33 (dd, J = 9.3, 6.5 Hz, H-4’, 1H), 2.56-2.65 (m, H-2, 1H), 1.12 
(d, J = 7.1 Hz, H-3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  204.3, 143.8, 128.8, 128.0, 127.2, 63.8, 47.2, 11.0. 
 
HRMS (ESI) calculated for C23H22O2Na ([M+Na]+): 353.1517, found 353.1516 
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6.4.4 Olefin 237 
 
 
 
Ethyltriphenylphosphonium bromide (16.52 g, 44.54 mmol) in THF (50 mL) was cooled to 78 °C. To 
this was added n-BuLi (16.70 mL, 2.5M in hexanes, 41.76 mmol) slowly drop wise, the solution turned 
into orange color, after the compete addition cooling bath was removed and stirred for 30 minutes at 
room temperature. Reaction mixture turned into dark red color and the majority of the solids went 
into solution. Reaction mixture was again cooled back to 78 °C and the aldehyde 30 (9.20 g, 27.84 
mmol) in THF (50 mL) was added quickly drop wise. Cool bath was removed and the reaction stirred 
at room temperature for 3 h. Distilled water (70 mL) was added to the reaction mixture carefully and 
stirred for 10 min, organic layer was separated and the aqueous layer was extracted with EtOAc (2 × 
30 mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in vacuo. Crude 
compound purified by silica gel column chromatography (pet ether- EtOAc, 10:1) to afford olefin 237 
(7.20 g, 76% over two steps) as a colorless gel. 
 
1H-NMR (400 MHz, CDCl3):  7.50 (dt, J = 8.3, 1.8 Hz,  HAr, 6H), 7.31-7.40 (m, HAr, 6H), 7.21-7.29 (m, 
HAr, 3H), 5.45-5.55 (m, H-3, 1H), 5.19-5.29 (m, H-2, 1H), 3.03 (ddd, J = 11.6, 8.6, 6.3 Hz, H-6, 1H), 2.93 
(ddd, J = 11.3, 8.6, 7.0 Hz, H-6’, 1H), 2.78-2.90 (m, H-4, 1H), 1.69 (dd, J = 6.8, 1.8 Hz, H-1, 3H), 1.05 (d, J 
= 6.6 Hz, H-5, 3H). 
 
13C-NMR (100 MHz, CDCl3):  144.6, 134.0, 128.9, 127.8, 126.9, 124.1, 86.3, 68.3, 32.5, 18.1, 13.3. 
 
[]23D = 31.63 (c 0.99, CHCl3) 
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6.4.5 Homoallyl alcohol 114 
 
 
 
To the Olefin 237 (8.50 g, 24.8 mmol) in a mixture of methanol- CH2Cl2 (54 mL, 1:2) was added p-
toluenesulfonicacid monohydrate (0.4 g) and stirred for 16 h at room temperature. Sat. aq. NaHCO3 
(50 mL) was added and stirred for 5 min, organic layer was separated and the aqueous layer was 
extracted with CH2Cl2 (2 × 20 mL). Combined organic layers are dried over Na2SO4, filtered and the 
solvent was distilled using vigourex column at atmospheric pressure, subsequently the remaining 
residue was purified by vacuum distillation at 100 °C at 10 m bar. The alcohol 114 was collected using 
liquid nitrogen cooling bath as colorless liquid (1.60 g, 64%). 
 
1H-NMR (400 MHz, CDCl3):  5.40-5.58 (m, H-3, 1H), 5.08 (ddd, J = 11.1, 9.5, 1.8 Hz, H-2, 1H), 3.34 
(ddd, J = 12.1, 7.8, 4.6 Hz, H-6, 1H), 3.28 (dd, J = 10.4, 7.6 Hz, H-6’, 1H), 2.55-2.68 (m, H-5/OH, 2H), 
1.57 (dd, J = 6.9, 1.8 Hz, H-1, 3H), 0.87 (d, J = 6.7 Hz, H-5, 3H). 
 
13C-NMR (100 MHz, CDCl3):  133.1, 125.5, 67.4, 34.2, 16.8, 13.0. 
6.4.6 Aldehyde 238 
 
 
To a solution of Oxalyl chloride (2.28 mL, 23.96 mmol) in CH2Cl2 (25 mL) was added DMSO (2.26 mL, 
31.94 mmol) slowly dropwise at 78 °C and stirred for 30 minutes. Alcohol 237 (1.60 g, 15.97 mmol) 
in CH2Cl2 (20 mL) was added dropwise to the reaction mixture at 78 °C and stirred for 1 h. 
Triethylamine (11.10 mL, 79.85 mmol) was added drop wise to the reaction and warmed to room 
temperature which resulted in the precipitation of solids. Distilled water (50 mL) was added and 
stirred for 10 min. Organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 
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30 mL). Combined organic layers are dried over Na2SO4, filtered, taken to next step without 
concentrating the solvent. 
 
6.4.7 Ester 115 
 
 
 
To the aldehyde 238 in dichloromethane from the above step was added Wittig ylide 207 (17.40 g, 
48.0 mmol) and stirred for 16 h at room temperature. Solvents removed on vacuo, the residue was 
passed through a pad of silica using (pet ether- EtOAc, 1:1). Crude compound purified by silica gel 
column chromatography (pet ether-EtOAc, 15:1) to afford olefin 115 (1.50 g, 33% over three steps) as 
a colorless oil.  
 
1H-NMR (400 MHz, CDCl3):  6.58 (dd, J = 9.6, 1.4 Hz, H-6, 1H), 5.35-5.51 (m, H-3, 1H), 5.26 (ddd, J = 
10.7, 9.0, 1.7 Hz, H-2, 1H), 4.16 (q, J = 7.1 Hz, H-10, 3H), 3.39-3.58 (m, H-4, 1H), 1.86 (d, J = 1.4 Hz, H-8, 
3H), 1.63 (dd, J = 6.8, 1.7 Hz, H-1, 4H), 1.28 (t, J = 7.1 Hz, H-11, 6H), 1.06 (d, J = 6.8 Hz, H-5, 4H). 
 
13C-NMR (100 MHz, CDCl3):  168.6, 145.8, 133.3, 125.9, 123.7, 60.6, 31.6, 20.7, 14.4, 13.1, 12.5. 
 
HRMS (ESI) calculated for C11H18O2 ([M]+): 182.1307, found 182.1309 
[]23D = 131.63 (c 0.99, CHCl3) 
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6.4.8 Allyl alcohol 289 
 
 
 
To a stirred solution (78 °C) of ester 115 (1.10 g, 6.03 mmol) in THF (37 mL) was added DIBAL-H 
(18.72 mL, 1M in CH2Cl2, 18.72 mmol) drop wise. Warmed to room temperature and stirred for 90 
min. MTBE (40 mL) was added rapidly, dropwise addition of distilled water (2.8 mL) led to the 
formation of a colorless gel. Upon addition of aq. NaOH (2.8 mL, 4M) and additional distilled water 
(5.2 mL), a white solid precipitated. The resulting suspension was then dried over MgSO4 then filtered 
and evaporated in vacuo. Silica gel chromatography (pet ether-EtOAc, 4:1) afforded the desired 
alcohol 289 (0.76 g, 90%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  5.29-5.42 (m, H-2, 1H), 5.20-5.29 (m, H-3/6, 2H), 3.95 (s, 2H), 3.32-3.45 
(m, H-4, 1H), 1.68 (d, J = 1.4 Hz, H-8, 3H), 1.63 (dd, J = 6.7, 1.6 Hz, H-1, 3H), 0.99 (d, J = 6.8 Hz, H-5, 
3H). 
 
13C-NMR (100 MHz, CDCl3): 135.4, 133.2, 131.0, 122.2, 69.1, 30.7, 21.7, 14.0, 13.2. 
HRMS (ESI) calculated for C9H16O ([M]+): 140.1201, found 140.1201 
[]23D = 73.16 (c 1.06, CHCl3). 
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6.4.9 Aldehyde 111 
 
 
 
Activated MnO2 (9.43 g, 108 mmol) was suspended in Et2O (25 mL) Alcohol 289 (0.76 g, 5.42 mmol) in 
Et2O (5 mL) was added at room temperature and stirred for 1 h. The mixture was filtered through a 
pad of celite, washed with Et2O (25 mL) and the filtrate evaporated under vacuo (50 m bar, 25 °C) to 
afford aldehyde 37 (0.72 g, 96%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  9.34 (d, J = 1.1 Hz, H-9, 1H), 6.22-6.34 (m, H-7, 1H), 5.39-5.52 (m, H-2, 
1H), 5.19-5.35 (m, H-3, 1H), 3.54-3.73 (m, H-4, 1H), 1.75 (t, J = 1.2 Hz, H-8, 3H), 1.57-1.69 (m, H-1, 3H), 
1.11 (dd, J = 6.8, 1.0 Hz, H-5, 3H). 
 
13C-NMR (100 MHz, CDCl3):  195.5, 157.8, 137.0, 132.2, 124.6, 31.7, 20.4, 13.0, 9.2. 
 
HRMS (ESI) calculated for C9H14O ([M]+): 137.0966, found 137.0957 
]23D = 120.35 (c 1.2, CHCl3) 
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6.5 PMB-Ketone Fragment C(13-16): 
 
6.5.1 Ester 290 
 
 
 
To the Roche ester 181 (10.0 g, 84.65 mmol) in CH2Cl2 (200 mL) was added p-
methoxybenzyltrichloroacetimiditate (25.65 g, 101.58 mmol) and CSA (0.50 g) at room temperature 
and stirred for 16 h. Methanol (30 mL) was added and stirred for 1 h, sat. aq. NaHCO3 (30 mL) was 
added and then the organic layer was separated. Aqueous layer was extracted with CH2Cl2 (2 × 20 
mL). Combined organic layers are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
Crude compound purified by silica gel column chromatography using (pet ether-EtOAC, 10:1), 
afforded ester 290 (20.3 g) as a yellow oil. 
 
1H-NMR (200 MHz, CDCl3):  7.22-7.34 (m, Har, 2H), 6.86-6.99 (m, Har, 2H), 4.50 (d, H-6,  
2J = 1.8 Hz, 
2H), 3.85 (s, H-7, ArOCH3, 3H), 3.73 (s, H-1, 3H), 3.68 (dd, H-5, 
2J = 9.1 Hz, 3J = 7.3 Hz, 1H), 3.50 (dd, H-
5, 2J  = 9.2 Hz, 3J = 5.9 Hz, 1H), 2.71-2.90 (m, H-3, 1H), 1.21 (d, H-4, 3J = 7.1 Hz, 3H). 
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6.5.2 Alcohol 232 
 
 
 
To the LiAlH4 (2.50 g, 66.82 mmol) in THF (150 mL) was added the ester 290 (21.3 g, 89.35 mmol) in 
THF (70 mL) dropwise at room temperature. After the completion of addition, reaction mixture was 
heated to 40 °C and stirred for 1 h. LiAlH4 (0.84 g, 22.45 mmol) was added in portions to the reaction 
over a period of 1 h. Stirring continued for further 2 h at 40 °C, reaction mixture cooled to room 
temperature and quenched carefully with drop wise addition of sat. aq. Na2SO4 solution. A thick gel 
obtained which was diluted with EtOAc (100 mL), filtered over Celite bed and washed with EtOAc (2 × 
50 mL). The combined filtrates are concentrated on vacuo and the crude compound was purified by 
silica gel column chromatography (pet ether-EtOAc, 4:1) to afford compound 232 (11.5 g, 65% over 
two steps) as yellow oil.   
1H-NMR (400 MHz, CDCl3):  7.24 (d, J = 8.7 Hz, HAr, 2H), 6.87 (d, J = 8.7 Hz, HAr, 2H), 4.43 (s, H-5, 2H), 
3.79 (s, ArOCH3, 3H), 3.53-3.61 (m, H-1, 1H), 3.49 (dd, J = 9.1, 4.8 Hz, H-4, 1H), 3.38 (dd, J = 9.1, 7.9 Hz, 
H-1’, 1H), 2.83 (s, -OH, 1H), 1.96-2.09 (m, H-2, 1H), 0.86 (d, J = 7.0 Hz, H-3, 1H). 
 
13C-NMR (100 MHz, CDCl3):  159.3, 130.2, 129.3, 113.9, 75.0, 73.0, 67.6, 55.3, 35.6, 13.6. 
 
HRMS (ESI) calculated for C12H18O3Na ([M+Na]+): 233.1154, found 233.1154 
[]23D = 8.28 (c 0.98, CHCl3). 
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6.5.3 Aldehyde 132 
 
 
 
To a solution of oxalyl chloride (1.36 mL, 14.26 mmol) in CH2Cl2 (30 mL) was added DMSO (1.35 mL, 
19.02 mmol) slowly drop wise at 78 °C and stirred for 30 minutes. Alcohol 232 (2.00 g, 9.51 mmol) in 
CH2Cl2 (20 mL) was added drop wise to the reaction mixture at 78 °C and stirred for 1 h. 
Triethylamine (6.64 mL, 47.55 mmol) was added drop wise to the reaction and warmed to room 
temperature which resulted in the precipitation of solids. Distilled water (40 mL) was added and 
stirred for 10 min. Organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 
20 mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in vacuo, crude 
compound was passed through a pad of silica using EtOAc and the fractions are concentrated to yield 
the aldehyde 132 (1.90 g, 95%).  This compound was used directly in the next step without any 
characterization. 
 
6.5.4 -Hydroxy ester 233 
 
 
 
To EtOAc (1.80 mL, 18.24 mmol) in THF (42 mL) was added lithium hexamethyldisilylazide (18.42 mL, 
1M in THF/ethylbenzene, 18. 24 mmol) dropwise at78 °C. Stirred for 40 min at this temp and 
aldehyde 132 (1.90 g, 9.12 mmol) in THF (10 mL) was added dropwise and stirred for 20 min. Sat. aq. 
NH4Cl (20 mL) was added and warmed to room temperature, distilled water (20 mL) was added and 
the organic layer separated, aqueous layer extracted with EtOAc (3 × 10 mL). Combined organic layers 
are dried over Na2SO4, filtered and concentrated on vacuo, crude compound was purified by silica gel 
column chromatography (pet ether-EtOAc, 4:1) to afford compound 233 (2.20 g, 81%) as yellow oil. 
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1H-NMR (400 MHz, CDCl3):  7.19-7.26 (m, HAr, 2H), 6.80-6.90 (m, HAr, 2H), 4.42 (s, H-9, 1H), 4.09-4.23 
(m, H-2/H-5, 3H), 3.80 (s, ArOCH3, 3H), 3.30-3.40 (m, H-8, 2H), 2.33-2.62 (m, H-4, 1H), 1.82-1.98 (m, H-
6, 1H), 1.25 (t, J = 7.1 Hz, 3H), 0.92 (d, J = 7.2 Hz, H-7, 1H). 
 
13C-NMR (100 MHz, CDCl3): 172.9, 172.8, 159.3, 159.2, 130.2, 130.1, 129.3, 129.3, 113.8, 73.4, 73.3, 
73.0, 73.0, 71.8, 69.9, 60.6, 55.3, 39.7, 39.1, 38.4, 38.0, 14.2, 13.7, 11.3. 
 
HRMS (ESI) calculated for C16H24O5Na ([M+Na]+): 319.1521, found 319.1520 
 
6.5.5 Diol 234  
 
 
 
To a stirred solution (78 °C) of ester 233 (2.10 g, 7.08 mmol) in CH2Cl2 (200 mL) was added DIBAL-H 
(22.0 mL, 1M in CH2Cl2, 22.0 mmol) dropwise. Warmed to room temperature and stirred for 90 min. 
MTBE (40 mL) was added rapidly, drop wise addition of distilled water (2 mL) led to the formation of a 
colorless gel. Upon addition of aq. NaOH (2 mL, 4N) and additional distilled water (4.0 mL), a white 
solid precipitated. The resulting suspension was then dried over MgSO4 then filtered and evaporated 
in vacuo. Silica gel chromatography (pet ether-EtOAc, 1:1) afforded the diol 234 (1.60 g, 88%) as 
colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.10-7.23 (m, HAr, 2H), 6.77 (d, J = 8.3 Hz, HAr, 2H), 4.33 (d, J = 5.0 Hz, H-
7, 2H), 3.62-3.75 (m, ArOCH3/H-3/H-1, 6H), 3.46 (dt, J = 28.9, 2.8 Hz, H-6, 1H), 3.27-3.39 (m, H-6’, 1H), 
1.72-1.95 (m, H-4, 1H), 1.71-1.36 (m, H-2, 2H), 0.78 (dd, J = 26.4, 7.0 Hz, H-5, 1H). 
 
13C-NMR (100 MHz, CDCl3): 159.4, 130.0, 129.7, 129.5, 129.4, 127.0, 114.0, 114.0, 113.9, 77.4, 75.2, 
74.9, 74.2, 73.9, 73.3, 73.2, 62.2, 61.8, 61.5, 55.4, 40.6, 38.6, 38.4, 36.1, 35.1, 13.7, 11.5. 
 
HRMS (ESI) calculated for C14H22O4Na ([M+Na]+): 277.1416, found 277.1418 
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6.5.6 Alcohol 235 
 
 
 
To the diol 234 (1.50 g, 5.89 mmol) in CH2Cl2 (30 mL) was added imidazole (0.60 g, 8.83 mmol) and 
TBSCl (0.97 g, 6.48 mmol) at 0 °C. White solids precipitated out, reaction stirred for 15 min. Distilled 
water (30 mL) was added, organic layer separated and the aqueous layer extracted with CH2Cl2 (2 × 
10 mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in vacuo, crude 
compound was purified by silica gel column chromatography (pet ether-EtOAc, 5:1) to afford 
compound 235 (1.80 g, 88%) as yellow oil. 
 
1H-NMR (400 MHz, CDCl3):  7.25 (d, J = 8.3 Hz, HAr, 2H), 6.87 (d, J = 8.6 Hz, HAr, 2H), 3.76-3.96 (m, H-
3/H-1, 3H), 3.79 (s, ArOCH3, 3H), 3.37-3.57 (m, H-6, 2H), 1.79-1.92 (m, H-4, 1H), 1.51-1.77 (m, H-2, 
2H), 0.93 (dd, J = 7.0, 3.7 Hz, H-5, 2H), 0.90 (s, SiC(CH3)3, 9H), 0.07 (s, SiCH3,  6H). 
 
13C-NMR (100 MHz, CDCl3): 159.3, 159.25, 130.6, 130.5, 129.31, 129.3, 113.9, 74.3, 73.7, 73.03, 
73.01, 72.7, 62.5, 62.2, 55.4, 39.0, 38.8, 36.5, 36.3, 26.0, 18.3, 13.9, 11.5, -5.32, -5.31. 
 
HRMS (ESI) calculated for C20H36O4SiNa ([M+Na]+): 391.2281, found 391.2282 
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6.5.7 Ketone 138 
 
 
 
To a solution of oxalyl chloride (0.69 mL, 7.35 mmol) in CH2Cl2 (15 mL) was added DMSO (0.69 mL, 
9.76 mmol) slowly dropwise at 78 °C and stirred for 30 minutes. Alcohol 235 (1.80 g, 4.83 mmol) in 
CH2Cl2 (20 mL) was added drop wise to the reaction mixture at 78 °C and stirred for 1 h. 
Triethylamine (3.41 mL, 24.41 mmol) was added drop wise to the reaction and warmed to room 
temperature which resulted in the precipitation of solids. Distilled water (30 mL) was added and 
stirred for 15 min. Organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 × 
15 mL). Combined organic layers are dried over anhydrous Na2SO4, filtered and concentrated in 
vacuo, crude compound was crude compound was purified by silica gel column chromatography (pet 
ether- EtOAc, 6:1) to afford compound 138 (1.44 g, 80%) as yellow oil. 
 
1H-NMR (400 MHz, CDCl3):  7.13 (d, J = 8.6 Hz, HAr, 2H), 6.77 (d, J = 8.6 Hz, HAr, 1H), 4.32 (d, J = 3.9 Hz, 
H-7, 2H), 3.79 (td, J = 6.4, 2.5 Hz, H-1, 2H), 3.70 (s, ArOCH3, 3H), 3.51 (dd, J = 9.1, 7.5 Hz, H-6, 1H), 3.34 
(dd, J = 9.2, 5.7 Hz, H-6’, 1H), 2.78 (td, J = 7.2, 5.8 Hz,  H-4, 1H), 2.60 (td, J = 6.4, 3.7 Hz, H-2, 1H), 0.98 
(d, J = 7.1 Hz, H-5, 3H), 0.78 (s, SiC(CH3)3, 9H), -0.05 (s, SiCH3,  6H). 
 
13C-NMR (100 MHz, CDCl3): 211.8, 159.3, 130.3, 129.3, 128.4, 113.8, 73.0, 71.8, 58.7, 55.4, 47.1, 
44.9, 26.0, 18.3, 13.2, -5.3. 
 
HRMS (ESI) calculated for C20H34O4SiNa ([M+Na]+): 389.2124, found 389.2126 
[]23D = 3.94 (c 1.15, CHCl3) 
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6.6 Aldehyde C(13-23) 
 
6.6.1 Paterson aldol product 239  
 
 
To a solution of dicyclohexylboron monochloride (1M in Et2O, 2.74 mL, 2.74 mmol) in Et2O (5.6 mL) at 
78 °C was added triethylamine (0.43 mL, 3.03 mmol) over a period of 15 min and stirred for another 
20 min at this temperature. Ketone 138 (690 mg, 1.88 mmol) in Et2O (3 mL) was added dropwise over 
a period of 15 min at 78 °C and stirred for another 30 minutes at this temperature, Warmed to 0 °C 
and stored at this temperature for 16 h. Aldehyde 111 (200 mg, 1.44 mmol) was added dropwise over 
a period of 15 minutes at 78 °C and stirred for another 30 minutes. Quenched with methanol (2 mL) 
and H2O (2 mL) and warmed to room temperature, organic layer separated and the aqueous layer 
was extracted with MTBE (4 x 5 mL). Organic layers are dried over Na2SO4, filtered and concentrated 
in vacuo. Crude compound was purified by column chromatography (pet ether: EtOAc, 4:1) to obtain 
aldol product 239 (690 mg, 70%) as colorless oil. 
 
1H-NMR (400 MHz, CDCl3):  7.22 (d, J = 8.7 Hz, HAr, 1H), 6.86 (d, J = 8.7 Hz, HAr, 1H), 5.32 (dqd, J = 9.2, 
6.7, 0.7 Hz, H-3, 1H), 5.24 (dd, J = 6.1, 2.9 Hz, H-6, 1H), 5.15-5.22 (m, H-2, 1H), 4.44 (d, J = 11.7 Hz, H-
16, 1H), 4.40 (d, J = 11.7 Hz, H-16’, 1H), 4.20 (dd, J = 7.9, 4.7 Hz, H-9, 1H), 3.80 (s, ArOCH3, 3H), 3.70 
(dd, J = 6.1, 2.9 Hz, H-15, 1H), 3.67 (dd, J = 6.1, 4.0 Hz, H-11, 1H), 3.53 (dd, J = 10.1, 5.1 Hz, H-11’, 1H), 
3.36-3.42 (m, H-4, 1H), 3.35 (dd, J = 7.5, 4.8 Hz, H-15’, 1H), 3.04-3.17 (m, H-10/OH, 2H), 3.00 (d, J = 4.9 
Hz, H-13, 1H), 1.66 (d, J = 1.3 Hz, H-8,  3H), 1.63 (dd, J = 6.7, 1.7 Hz, H-1, 3H), 1.08 (d, J = 7.0 Hz, H-5, 
3H), 1.00 (d, J = 6.7 Hz, H-4, 3H), 0.84 (s, Si(CH3)3, 9H), -0.02 (s, SiCH3, 3H), -0.03 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3): 215.9, 159.4, 134.9, 132.9, 132.8,  129.9, 129.5, 121.9, 113.9, 75.9, 73.0, 
71.6, 62.6, 57.3, 55.4, 46.7, 30.5, 25.9, 21.4, 18.3, 13.5, 13.1, 11.7, -5.4, -5.5. 
 
HRMS (ESI) calculated for C29H48O5NaSi ([M+Na]+): 527.3169, found 527.3172 
[]23D = + 21.17 (c =1.7 in CHCl3). 
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6.6.2 Diol 240 
 
 
To the compound 239 (50 mg, 0.09 mmol) in THF (2.5 mL) was added DIBAL-H dropwise at 78 °C, 
stirred for another 2 h. Sat. aq. sodium potassium tartarate (1.5 mL) was added dropwise, warmed to 
room temperature slowly, extracted with MTBE (3 x 4 mL), dried over Na2SO4, filtered and 
concentrated in vacuo. Crude compound purified by silica gel column chromatography (pet ether: 
EtOAc, 5:1) to obtain diol 240 (45 mg, 90%) as colorless oil. 
 
1H-NMR (400 MHz, CDCl3):  7.23 (d, J = 8.6 Hz, HAr, 1H), 6.88 (d, J = 8.7 Hz, HAr, 1H), 5.30 (dt, J = 13.5, 
5.4 Hz, H-3/6, 2H), 5.20 (ddd, J = 10.8, 9.3, 1.6 Hz, H-2, 1H), 4.47 (d, J = 11.6 Hz, H-16, 1H), 4.42 (d, J = 
11.6 Hz, H-16’, 1H), 4.29 (d, J = 9.6 Hz, H-9/OH, 2H), 4.23 (dd, J = 8.2, 1.9 Hz, H-12, 1H), 3.81 (s, 
ArOCH3, 3H), 3.74 (bs, OH, 1H), 3.58 (dd, J = 9.0, 4.1 Hz, H-11, 1H), 3.51-3.56 (m, H-11’, 1H), 3.48 (dd, J 
= 10.4, 3.2 Hz, H-15, 1H), 3.40 (d, J = 8.9 Hz, H-15’, 1H), 3.35-3.39 (m, H-4, 1H), 2.02-2.13 (m, H-13, 
1H), 1.72-1.81 (m, H-10, 1H), 1.62-1.71 (m, H-1/6, 6H), 1.03 (d, J = 1.5 Hz, H-5, 3H), 1.01 (d, J = 1.2 Hz, 
H-14, 3H), 0.84 (s, Si(CH3)3, 9H), -0.04 (s, SiCH3, 3H), -0.04 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  159.4, 135.4, 134.2, 133.4, 130.2, 129.3, 121.6, 113.9, 80.0, 76.6, 75.8, 
73.3, 62.0, 55.4, 44.7, 35.5, 30.6, 25.9, 21.5, 18.2, 13.1, 11.3, 10.7, -5.4, -5.7. 
 
HRMS (ESI) calculated for C29H50O5NaSi ([M+Na]+): 529.3325, found 529.3326 
[]23D = + 19.5 (c =0.8 in CHCl3). 
 
 
 
 
6.6.3 TES-ether 243 
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To diol 240 (200 mg, 0.394 mmol) in CH2Cl2 (2 mL), was added 2,6-lutidine (136 L, 1.168 mmol), 
DMAP (4.8 mg) and TESCl (81 L, 0.478 mmol) at 78 °C, stirred for 2 h at this temp and additionally 1 
h at 0 °C. Quenched with sat. aq. NaHCO3 (20  mL), diluted with Et2O (20 mL) and warmed to room 
temperature, stirred for 5 min, organic layer separated, aqueous layer extracted with Et2O (2 × 10 
mL). Combined organic layers are dried over Na2SO4, filtered and concentrated in vacuo. Crude 
compound purified by silica gel column chromatography (pet ether-EtOAc, 12:1) to afford compound 
243 (190 mg, 80%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.25 (d, J = 8.6 Hz, HAr, 1H), 6.85 (d, J = 8.7 Hz, HAr,1H), 5.33 (ddt, J = 12.8, 
10.8, 6.4 Hz, H-6, 1H), 5.17-5.25 (m, H-2/3, 2H), 4.47-4.42 (m, H-16/16’/9, 3H), 4.23 (s, -OH, 1H), 4.03 
(d, J = 8.3 Hz, H-12, 1H), 3.80 (s, ArOCH3, 3H), 3.54-3.57 (m, H-15, 1H), 3.51-3.53 (m, H-11, 1H), 3.38- 
3.45 (m, H-15, 1H), 3.35-3.38 (m, H-4, 1H), 3.32 (dd, J = 10.3, 2.7 Hz, H-11, 1H), 2.05-2.19 (m, H-13, 
1H), 1.58-1.68 (m, H-10/1/8, 7H), 1.02 (d, J = 6.7 Hz, H-5, 3H), 0.95 (t, J = 7.9 Hz, SiCH2CH3,  9H), 0.93 
(d, J = 1.8 Hz, H-14, 3H), 0.86 (s, Si(CH3)3, 9H), 0.56 – 0. 96 (m, SiCH2, 6H), -0.03 (s, SiCH3, 3H), -0.02 (s, 
SiCH3, 3H). 
 
13C-NMR (100 MHz, CDCl3):  158.9, 134.9, 134.0, 133.3, 129.0, 122.1, 113.7, 81.4, 74.3, 72.6, 72.0, 
60.5, 55.4, 45.6, 35.4, 30.5, 25.9, 21.0, 18.1, 13.1, 11.3, 10.5, 6.9, 4.9, -5.4, -5.6. 
 
HRMS (ESI) calculated for C35H64O5NaSi2 ([M+Na]+): 643.4190, found 643.4187 
[]23D = + 15.0 (c =1.9 in CHCl3). 
 
 
 
 
 
6.6.4 PMP acetal 244 
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Molecular sieves 4Å (160 mg, powdered and dried) was added to a solution of compound 243 (56 mg, 
0.090 mmol) in CH2Cl2 (3.5 mL), stirred for 30 min at room temperature. Cooled to 5 °C, DDQ (30.6 
mg) was added in one portion, stirred for 45 min at this temp and quenched with sat. aq. NaHCO3 (50 
mL), diluted with Et2O (50 mL) and warmed to room temperature, aqueous layer separated, organic 
layer was washed with sat. aq. NaHCO3 until the organic layer was colorless. Dried over Na2SO4, 
filtered and concentrated in vacuo. Crude compound purified by silica gel column chromatography 
(pet ether: EtOAc, 20:1) to afford compound 244 (46 mg, 84%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3): 7.41 (d, J = 8.7 Hz, HAr, 1H), 6.89 (d, J = 8.8 Hz, HAr, 1H), 5.32-5.40 (m, H-3, 
1H), 5.31 (s, H-16, 1H), 5.18 (ddd, J = 10.6, 6.2, 1.6 Hz, H-2, 1H), 5.11 (d, J = 9.2 Hz, H-6, 1H), 4.50 (d, J 
= 4.4 Hz, H-9, 1H), 3.90-4.03 (m, H-12/15/11, 3H), 3.82 (s, ArOCH3, 1H), 3.68 (dd, J = 10.3, 1.9 Hz, H-
15’, 1H), 3.49 (dd, J = 10.1, 6.7 Hz, H-11’, 1H), 3.28-3.39 (m, H-4, 1H), 2.06 (ddt, J = 8.2, 6.4, 4.1 Hz, H-
10, 1H), 1.77 (dt, J = 8.6, 5.9 Hz, H-13, 1H), 1.65 (dd, J = 6.8, 1.7 Hz, H-1, 3H), 1.57 (d, J = 1.2 Hz, H-8, 
3H), 1.24 (d, J = 6.8 Hz, H-14, 3H), 0.92 (t, J = 7.9 Hz, SiCH2CH3, 9H), 0.91 (d, J = 1.6 Hz, H-5, 3H), 0.88 
(s, SI(CH3)3, 9H), 0.54 (dt, J = 7.9, 6.0 Hz, SiCH2, 6H), 0.04 (d, J = 1.5 Hz, SiCH3, 6H). 
 
13C-NMR (100 MHz, CDCl3):  159.8, 135.8, 133.0, 132.1, 131.5, 127.5, 121.8, 80.6, 74.5, 74.4, 59.7, 
55.4, 49.5, 31.2, 30.4, 26.1, 21.2, 18.3, 13.3, 12.8, 12.3, 7.0, 4.9, -5.4,-5.4. 
 
HRMS (ESI) calculated for C35H62O5NaSi2 ([M+Na]+): 641.4034, found 641.4030 
[]23D = + 23.29 (c =0.85 in CHCl3). 
 
 
 
6.6.5 Alcohol 245  
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DIBAL-H (1 mL, 1M in CH2Cl2) was added dropwise to a solution of benzylidene acetal 244 (160 mg, 
0.258) in CH2Cl2 (5.5mL) at 78 °C. The reaction mixture was stirred for 3 h at this temperature and 
quenched with EtOAc (1.2 mL), warmed to room temperature. Diluted with Rochelle’s salt (60 mL) 
and MTBE (60 mL) and the biphasic mixture was stirred for 1 h. Organic layer separated and the 
aqueous layer extracted with MTBE (2 × 15 mL). Combined organic layers are dried over Na2SO4, 
filtered and concentrated under vacuo. Crude compound purified by silica gel column 
chromatography (pet ether: EtOAc, 10:1) to afford alcohol 245 (120 mg, 75%) as a colorless oil.  
 
1H-NMR (400 MHz, CDCl3): 7.26 (d, J = 8.7 Hz, HAr, 1H), 6.87 (d, J = 8.7 Hz, HAr, 1H), 5.28-5.39 (m, H-2, 
1H), 5.16-5.23 (m, H-6, 1H), 5.12-5.16 (m, H-3, 1H), 4.56 (d, J = 11.2 Hz, H-13, 1H), 4.48 (d, J = 11.3 Hz, 
H-13’, 1H), 4.30 (d, J = 8.0 Hz, H-9, 1H), 3.81 (d, J = 1.2 Hz, ArOCH3, 3H), 3.71 (dd, J = 7.2, 2.0 Hz, H-12, 
1H), 3.58 (dt, J = 10.8, 3.7 Hz, H-11, 1H), 3.37-3.48 (m, H-11’/H-4, , 1H), 3.35 (d, J = 7.1 Hz, H-16, 1H), 
3.05 (bs,-OH, H), 2.17-2.31 (m, H-10/H-14, 2H), 1.64 (dd, J = 6.7, 1.7 Hz, H-1, 3H), 1.62 (d, J = 1.1 Hz, H-
8, 3H), 1.00 (d, J = 6.7 Hz, H-5, 3H), 0.98 (d, J = 6.9 Hz, H-15, 3H), 0.92 (t, J = 6.2 Hz, SiCH2CH3, 9H), 0.89 
(s, (SiCH3)3, 9H), 0.01 (s, SiCH3, 6H). 
 
13C-NMR (100 MHz, CDCl3):  159.0, 135.0, 134.0, 132.0, 131.7, 128.9, 121.8, 113.7, 80.6, 76.9, 73.7, 
66.9, 61.0, 55.4, 46.1, 39.5, 30.5, 26.1, 21.1, 18.3, 15.3, 13.2, 11.9, 7.0, 5.0, -5.2. 
 
HRMS (ESI) calculated for C35H64O5Si2Na ([M+Na]+): 643.4190, found 643.4191 
[]23D = + 21.2 (c =1.0 in CHCl3). 
 
 
 
 
6.6.6 Aldehyde 246 
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To the alcohol 245 (26 mg, 0.0418 mmol) in CH2Cl2 (1 mL) was added NaHCO3 (10.7 mg, 0.128 mmol) 
and DMP (27 mg, 0.0643 mmol) at rt. Reaction mixture was stirred for 1 h at room temperature. 
Diluted with Et2O (15 mL) and sat. aq. NaHCO3 (1.5 mL), washed with sat. aq. Na2S2O3 (3 × 5 mL). 
Organic layer dried over Na2SO4, filtered and concentrated in vacuo. Crude compound purified by 
silica gel column chromatography (pet ether: EtOAc, 10:1) to afford aldehyde 246 (24 mg, 98%) as a 
colorless oil.  
 
1H-NMR (400 MHz, C6D6): 9.74 (d, J = 0.9 Hz, H-16, 1H), 7.26 (d, J = 8.7 Hz, HAr, 2H), 6.81 (d, J = 8.7 
Hz, HAr, 2H), 5.22-5.48 (m, H-2/3/5,  3H), 4.58 (d, J = 5.5 Hz, H-9, 1H), 4.49 (d, J = 11.2 Hz, H-13, 1H), 
4.43 (d, J = 11.1 Hz, H-13’, 1H), 4.33 (t, J = 4.3 Hz, H-12, 1H), 3.86 (dd, J = 10.0, 6.8 Hz, H-11, 1H), 3.79 
(dd, J = 10.1, 6.1 Hz, H-11’, 1H), 3.35-3.48 (m, H-4, 1H), 3.29 (s, ArOCH3, 3H), 3.17-3.26 (m, H-14, 1H), 
2.31 (td, J = 10.6, 6.1 Hz, H-10, 1H), 1.64 (d, J = 1.2 Hz, H-8, 3H), 1.59 (dd, J = 6.4, 1.3 Hz, H-1, 3H), 
1.00-1.05 (m, H-5/SiCH2CH3, 12H), 1.00 (s, (SiCH3)3, 9H), 0.67 (dt, J = 8.4, 4.1 Hz, SiCH2, 6H), 0.11 (d, J = 
2.8 Hz, SiCH3, 6H). 
 
13C-NMR (100 MHz, C6D6):  203.3, 159.8, 135.5, 133.9, 131.7, 131.1, 122.1, 114.1, 75.8, 75.6, 72.6, 
60.5, 54.8, 50.2, 48.3, 30.8, 26.2, 21.4, 18.4, 13.2, 13.1, 10.0, 7.3, 5.3, -5.0, -5.1. 
 
HRMS (ESI) calculated for C35H62O5Si2Na ([M+Na]+): 641.4034, found 641.4031 
[]23D = + 16.0 (c =1.1 in CHCl3). 
 
 
 
 
6.7. Coupling of Fragments 
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6.7.1 Aldol product 247 
 
 
To the ketone 193 (0.143 g, 0.233 mmol) in THF (2 mL) at –78 °C was added LiHMDS (0.3 mL, 1M in 
THF, 0.298 mmol) dropwise over 5 min and the reaction mixture was stirred at –78 °C for 30 min. A 
solution of aldehyde 246 (0.130 g, 0.209 mmol) in pre-cooled THF (1.5 mL) to –78 °C was added 
dropwise over 5 min and the reaction mixture was stirred at –78 °C for 20 min. The cold mixture was 
quenched with pH7 buffer (2 mL) and warmed to room temperature, extracted with MTBE (50 mL), 
the aqueous layer was extracted with MTBE (2 × 10 mL) and the combined organic layers were dried 
over Na2SO4, filtered, and concentrated to afford 0.330 g of colorless oil. Column chromatography on 
25 g silica gel (gradient elution with 5–10% EtOAc-hexanes) provided 0.210 g (77%) of aldol adducts 
with 2.5:1 Felkin selectivity and ketone as colorless oil. Felkin aldol 247 was separated as colorless oil 
(84 mg, 30%) after preparative HPLC (elution with 7% EtOAc-heptanes, detection via UV absorption at 
220 nm). Both the starting materials Ketone (55 mg) and Aldehyde (40 mg) are recovered purely 
without epimerisation. 
 
1H-NMR (400 MHz, C6D6): 7.38 (d, J = 8.5 Hz, HAr, 1H), 6.85 (d, J = 8.5 Hz, HAr, 1H), 5.77 (dq, J = 10.6, 
5.8 Hz, H-2, 1H), 5.59 (d, J = 9.7 Hz, H-12, 1H), 5.27-5.45 (m, H-24/26/27, 3H), 5.18 (dd, J = 17.2, 1.3 
Hz, H-1, 1H), 5.00 (d, J = 10.4 Hz, H-1’, 1H), 4.59-4.78 (m, H-19/19’/22, 3H), 4.45-4.60 (m, H-
18/3/12/12’/5, 5H), 4.21 (dd, J = 6.1, 1.8 Hz, H-16, 1H), 4.17 (dd, J = 5.6, 4.5 Hz, H-6, 1H), 3.65-3.73 (m, 
H-21/21’, 2H), 3.56 (bs, -OH, 1H), 3.39-3.48 (m, H-25/ArOCH3, 4H), 3.28-3.37 (m, H-13/OCH3, 4H), 
3.02-3.11 (m, H-7, 1H), 2.95-3.02 (m, H-9, 1H), 2.88-2.95 (m, H-17, 1H), 2.44-2.59 (m, H-15/15’/20, 
3H), 1.72 (s, H-30, 3H), 1.66 (s, H-33, 3H), 1.60 (d, J = 5.4 Hz, H-28, 1H), 1.25-1.35 (m, H-31/35/34, 9H), 
1.18 (d, J = 6.8 Hz, H-32, 3H), 0.94-1.13 (m, H-29/SiCH2CH3, (SiCH3)3, 36H), 0.75 (q, J = 8.0 Hz, SiCH2, 
6H), 0.06-0.21 (m, SiCH3, 18H). 
 
13C-NMR (100 MHz, C6D6):  212.0, 210.3, 171.2, 159.5, 138.0, 135.2, 134.4, 132.0, 131.7, 131.5, 
129.4, 127.1, 121.6, 118.4, 113.8, 81.4, 80.2, 78.0, 76.9, 75.0, 73.3, 69.6, 65.3, 61.5, 59.9, 54.5, 49.1, 
46.5, 46.3, 46.2, 45.7, 41.1, 30.6, 26.0, 25.9, 25.9, 21.0, 18.4, 18.3, 18.2, 16.3, 12.9, 12.9, 12.8 , 12.3, 
11.3, 10.3, 7.1, 5.2, -4.4, -4.9, -5.0, -5.0, -5.3, -5.4. 
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HRMS (ESI) calculated for C67H122O12Si4Na ([M+Na]+): 1253.7911, found 1253.7910 
[]23D = + 55.9 (c =1.0 in CHCl3). 
 
6.7.2 SEM-ether 248 
 
 
To the Alcohol 247 (0.080 g, 0.0324 mmol) in 3 mL of THF at 0 °C was added DIPEA (0.225 mL, 1.296 
mmol) and SEMCl (0.116 mL, 0.6493 mmol) dropwise and the reaction mixture was stirred at 0 °C for 
30min.  Tetrabutylammonium iodide (0.013 mg, 0.0356 mmol) was added in one portion and heated 
at 50 °C for 3 days in a sealed tube in the absence of light. Reaction mixture was cooled to room 
temperature and diluted with MTBE (30 mL) washed with sat. aq. NaHCO3 solution (15 ml), aqueous 
layer was extracted with MTBE (2 × 10 mL) and the combined organic layers were dried over Na2SO4, 
filtered, and concentrated. Crude compound purified by column chromatography on silica gel 
(gradient elution with 3–10% EtOAc-pet ether) provided Compound 248 (78 mg, 90%) as colorless oil. 
 
1H-NMR (400 MHz, C6D6): 7.45 (d, J = 8.5 Hz, HAr, 1H), 6.89 (d, J = 8.5 Hz, HAr, 1H), 5.72-5.90 (m, H-2, 
1H), 5.68 (d, J = 9.7 Hz, H-12, 1H), 5.30-5.48 (m, H-24/26/27, 3H), 5.18 (dd, J = 17.2, 1.3 Hz, H-1, 1H), 
5.10 (d, J = 6.5 Hz, H-36, 1H), 5.01 (dd, J = 12.7, 3.6 Hz, H-36’/1’, 2H), 4.78 (d, J = 10.8 Hz, H-19/19’, 
1H), 4.41-4.65 (m, H-5/10/18/22/3/3’, 6H), 4.17 (d, J = 6.5 Hz, H-16, 1H), 4.13 (dd, J = 5.7, 4.4 Hz, H-6, 
1H), 3.92-4.02 (m, H-37, 1H), 3.70-3.78 (m, H-21/21’, 2H), 3.60-3.70 (m, H-37’, 1H), 3.39-3.53 (m, 
ArOCH3/13/25, 5H), 3.34 (s, OCH3, 1H), 3.05-3.16 (m, H-15, 1H), 2.94-3.04(m, H-7, 1H), 2.83-2.90(m, 
H-9, 1H), 2.76-2.82 (m, H-15’/17, 2H), 2.47 (q, J = 7.1 Hz, H-20, 1H), 1.83 (s, H-30, 3H), 1.70 (s, H-33, 
3H), 1.62 (d, J = 5.5 Hz, H-28, 3H), 1.38 (d, J = 7.0 Hz, H-31, 3H), 1.25-1.32 (m,H-35/34/32, 12H), 1.07-
1.14 (m, H-29/SiCH2CH3, 12H), 1.00-1.05 (m, H-38/(SiCH3)3, 29H), 0.76 (q, J = 7.9 Hz, H-SiCH2, 6H), 0.20 
(s, SiCH3, 3H), 0.16 (m, SiCH3, 12H), 0.12 (s, SiCH3, 3H), 0.08 (s, SiCH3, 9H), -0.02 (s, SiCH3, 3H). 
 
 13C-NMR (100 MHz, C6D6):  212.1, 208.5, 171.3, 159.6, 138.1, 135.6, 135.3, 132.3, 132.2, 131.9, 
129.4, 127.4, 121.8, 118.7, 114.1, 95.3, 92.0, 88.3, 81.8, 78.6, 78.0, 77.3, 75.9, 75.1, 74.2, 65.8, 65.6, 
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62.2, 60.2, 54.8, 49.2, 47.2, 46.8, 46.3, 44.4, 40.8, 30.9, 26.4, 26.3, 26.1, 21.4, 18.7, 18.7, 18.5, 18.5, 
18.3, 16.8, 13.4, 13.2, 12.7, 12.6, 11.8, 11.6, 7.5, 5.5, -1.1, -1.2, -4.0, -4.6, -4.7, -4.8, -4.9, -5.0. 
 
HRMS (ESI) calculated for C73H136O13Si5Na ([M+Na]+): 1383.8725, found 1383.8723 
[]23D = + 40.6 (c =1.0 in CHCl3). 
 
6.7.3 Allyl alcohol 249 
 
 
To the SEM product 248 (0.040 g, 0.0293 mmol) in methanol (2.3 mL) and THF (0.5 mL) was added 
PPTS (0.0133 mg, 0.0528 mmol) in one portion and stirred at room temperature for a period of 2 h, 
reaction mixture was quenched with sat. aq. NaHCO3 solution (10 ml) and extracted with MTBE (2 × 
10 mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated. Crude 
compound purified by column chromatography on silica gel (gradient elution with 5–10% EtOAc-pet 
ether) provided Compound 249 (25 mg, 70%) as colorless oil. Unreacted starting material 248 (5 mg) 
was recovered back.  
 
1H-NMR (400 MHz, C6D6): 7.45 (d, J = 8.5 Hz, HAr, 1H), 6.84 (d, J = 8.6 Hz, , HAr, 1H), 5.78 (dq, J = 10.5, 
5.9 Hz, H-2, 1H), 5.61 (d, J = 9.6 Hz, H-12, 1H), 5.52 (d, J = 8.6 Hz, H-24, 1H), 5.34-5.46 (m, H-26/27, 
2H), 5.18 (dd, J = 17.2, 1.4 Hz, H-1, 1H), 5.01 (d, J = 10.4 Hz, H-1’, 1H), 4.92-4.96 (m, H-36/19/19’, 1H), 
4.75 (d, J = 10.8 Hz, H-36’, 1H), 4.62 (d, J = 9.0 Hz, H-22, 1H), 4.43-4.60 (m, H-3/3’/5/10/16, 5H), 4.31 
(t, J = 4.3 Hz, H-18, 1H), 4.13 (dd, J = 5.8, 4.2 Hz, H-6, 1H), 3.78-3.91 (m, H-37, 1H), 3.62-3.78 (m, H-
21/21’/37’/OH, 4H), 3.53 (dd, J = 15.2, 8.1 Hz, H-25, 1H), 3.45 (s, ArOCH3, 3H), 3.36-3.42 (m, H-13, 1H), 
3.32 (s, OCH3, 3H), 2.90-3.11  (m,H-15/7/9, 3H), 2.87 (dd, J = 17.3, 4.7 Hz, H-16’, 1H), 2.41-2.52 (m, H-
17, 1H), 2.33 (dd, J = 8.8, 4.3 Hz, H-20, 1H), 1.93 (s, H-30, 3H), 1.67 (s, H-33, 3H), 1.62 (d, J = 5.0 Hz, H-
28, 3H), 1.24-1.36 (m, H-31/34/35, 9H), 1.20 (d, J = 6.8 Hz, H-32, 3H), 1.11 (d, J = 6.7 Hz, H-29, 3H), 
1.06-1.10 (m, H-38, 2H), 0.99-1.06 (m, SiC(CH3)3, 27H), 0.04-0.22 (m, SiCH3, 27H). 
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 13C-NMR (100 MHz, C6D6):  212.29 (s), 209.1, 171.4, 159.8, 138.2, 135.9, 135.0, 132.4, 132.2, 131.3, 
129.5, 128.3, 128.2, 127.9, 127.6, 127.4, 121.7, 118.8, 114.3, 95.4, 81.7, 80.2, 78.4, 77.1, 76.0, 75.2, 
74.1, 65.9, 65.6, 62.7, 60.3, 54.8, 49.2, 47.3, 46.9, 43.9, 42.3, 30.9, 26.4, 26.2, 26.1, 21.8, 18.7, 18.6, 
18.5, 18.5, 16.8, 13.1, 13.1, 13.1, 11.9, 11.5, 11.1, -1.2, -4.0, -4.6, -4.7, -4.7, -5.1, -5.1. 
 
HRMS (ESI) calculated for C67H122O13Si4Na ([M+Na]+): 1269.7860, found 1269.7864 
[]23D =  58.6 (c =1.0 in CHCl3). 
 
6.7.4 Macrolactone 251 
 
 
a) Allyester cleavage: 
 
To the allylester 249 (48 mg, 0.038 mmol) in CH2Cl2 (6 ml) was added Pd(PPh3)4 (8.7 mg,  0.0076 
mmol) followed by tributyltinhydride (41 l, 0.152 mmol) dropwise at room temperature. The 
solution turned into dark brown color in 5 min, reaction stirred for 1 h. The reaction mixture was 
diluted with MTBE (50 mL) and washed with a mixture of sat. aq. NH4Cl solution and NaHSO4 
solution (1M, 50 mL). The aqueous layer was back-extracted with MTBE (3 × 10 mL), and the 
combined organic layers were dried over MgSO4, filtered, and concentrated. Column 
chromatography on 5 g silica gel (gradient elution with 100% hexanes to 100% EtOAc) removed 
the excess tributylstannane and provided 0.050 g of semipure carboxylic acid that was used in the 
subsequent macrolactonization without further purification. 
 
b) Yamaguchi macrolactonisation: 
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To the crude carboxylic acid (0.050 g) obtained above in dry benzene (22 mL) was added TEA (81.6 
l, 0.584 mmol) and stirred for 30 min at room temperature. 2,4,6-Trichlorobenzoylchloride (28.8 
l, 0.177 mmol) was added dropwise and stirred for 1 h. DMAP (5.3 mg, 0.043 mmol) was added in 
one portion and the resulting yellow colored solution was stirred for 16 h at room temperature. 
The reaction mixture was diluted with MTBE (40 mL) and washed with sat. aq. NaHCO3 solution 
(30 mL). The aqueous layer was back-extracted with MTBE (3 × 10 mL), and the combined organic 
layers were dried over MgSO4, filtered, and concentrated. Column chromatography on 8 g silica gel 
(5% EtOAc-hexanes) gave the desired macrolactone 251 (23 mg, 51%) as yellow oil. 
 
NMR couldn’t be interpreted due to conformational instabilities. 
HRMS (ESI) calculated for C64H116O12Si4Na ([M+Na]+): 1211.7442, found 1211.7443 
[]23D = + 2.0 (c =1.1 in CHCl3). 
 
6.7.5 Alcohol 257 
 
 
To the macrolactone 251 (23 mg, 0.019 mmol) in CH2Cl2 (6 mL) was added pH7 buffer (0.6 mL). 
Cooled to 0 °C and DDQ (9.5 mg, 0.042 mmol) was added at once and the reaction was stirred for a 
period of 90 min. The reaction mixture was quenched into a solution of Et2O (50 mL) and aq. sat. 
NaHCO3 solution (20 mL), organic layer was separated and washed with aq. sat. NaHCO3 solution (3 × 
10 mL), and the organic layer was dried over MgSO4, filtered, and concentrated. Column 
chromatography on 8 g silica gel (5% EtOAc-pet ether) gave the desired compound 257 (16 mg, 80%) 
with little traces of p-methoxy benzaldehyde as yellow oil. 
1H-NMR (400 MHz, C6D6): 5.58 (d, J = 9.1 Hz, H-12, 1H), 5.29-5.49 (m, H-26/33/32, 3H), 5.24 (d, J = 
10.2 Hz, H-29, 1H), 4.80-4.89 (m, H-18/18’, 2H), 4.70-4.78 (m, H-17, 1H), 4.34-4.43 (m, H-2/9, 2H), 
4.26 (dd, J = 6.0, 3.2 Hz, H-3, 1H), 4.17 (d, J = 7.3 Hz, H-23, 1H), 3.67-3.87 (m, H-19/19’/25, 3H), 3.58-
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3.65 (m, H-25’, 1H), 3.51 (s, OCH3, 3H), 3.36-3.49 (m, H-13/7, 2H), 3.18-3.36 (m, H-21/30, 2H),  2.98 
(dd, J = 7.4, 3.0 Hz, H-4, 1H), 2.71-2.89  (m,H-16/16’, 2H), 2.61-2.72 (m, H-24, 1H), 2.33 (bs, -OH, 1H), 
1.73-1.81 (m, H-11/28, 6H), 1.47-1.63 (m, H-5/34, 6H), 1.30 (d, J = 6.8 Hz, H-8, 3H), 1.10-1.19 (m, H-
14/22/31, 9H), 1.03-1.09 (m, SiC(CH3)3/H-20, 11H), 0.98 (s, SiC(CH3)3, 9H), 0.88 (s, SiC(CH3)3, 9H), 0.24 
(s, SiCH3, 3H), 0.18 (s, SiCH3, 3H), 0.11 (m, Si(CH3)3/SiCH3, 12H), -0.10-0.04 (m, SiCH3, 9H). 
  
13C-NMR (100 MHz, C6D6):  214.1, 207.8, 169.9, 138.6, 136.2, 135.1, 129.6, 128.8, 122.1, 81.1, 78.3, 
76.7, 73.9, 65.9, 65.8, 61.3, 47.4, 42.1, 30.9, 30.5, 30.2, 26.2, 26.1, 25.9, 21.2, 18.6, 18.5, 18.4, 18.2, 
15.6, 15.0, 13.1, 12.1, 11.5, 11.2, -1.1, -4.2, -4.3, -4.7, -4.8, -5.5, -5.6. 
 
HRMS (ESI) calculated for C56H108O11Si4Na ([M+Na]+): 1091.6866, found 1091.6869 
[]23D = + 39.2 (c =1.5 in CHCl3). 
 
 6.7.6 Triketone 258 
 
 
To the alcohol 257 (14 mg, 0.013 mmol) in CH2Cl2 (4 mL) was added NaHCO3 (32.9 mg, 0.392 mmol) 
and Dess Martin Periodinane (55 mg, 0.131 mmol) at room temperature, the resulting cloudy solution 
was stirred for 1 h. The reaction mixture was diluted with aq. sat. NaHCO3 solution (5 mL), aq. sat. 
Na2S2O3 solution (10 mL), and Et2O (10 mL), and stirred at room temperature for 10 min. The biphasic 
mixture was diluted with Et2O (30 mL) and the organic layer was separated. The aqueous layer was 
extracted with Et2O (2 × 5 mL), combined organic layers are dried over MgSO4, filtered, and 
concentrated to afford awhite film. Column chromatography on 5 g silica gel (elution with 5% EtOAc-
hexanes) afforded triketone 258 (13 mg, quantitative) as a colorless oil. 
 
1H-NMR (400 MHz, C6D6): 5.58 (d, J = 1.86 Hz, H-26, 1H), 5.56 (d, J = 1.36 Hz, H-12, 1H), 5.32-5.43 
(m, H-33, 1H), 5.22-5.31 (m, H-29/32, 2H), 4.96 (dt, J = 7.3, 3.2 Hz, H-17, 1H), 4.92 (d, J = 6.8 Hz, H-18, 
1H), 4.85 (d, J = 6.8 Hz, H-18’, 1H), 4.39 (d, J = 9.7 Hz, H-9, 1H), 4.30 (d, J = 6.5 Hz, H-2, 1H), 4.01 (dd, J 
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= 6.4, 3.9 Hz, H-3, 1H), 3.88 (dt, J = 9.7, 8.8 Hz, H-19/21, 2H), 3.78 (dt, J = 16.7, 8.4 Hz, H-21’, 1H), 3.48-
3.60 (m, H.19’/20, 2H), 3.45 (s, -OCH3, 3H), 3.14-3.43 (m, H-7/13/16/21/30, 5H), 2.85 (d, J = 4.3 Hz, H-
16’, 1H), 2.73-2.81 (m, H-4, 1H), 1.83 (d, J = 1.1 Hz, H-28, 3H), 1.72 (d, J = 0.9 Hz, H-11, 3H), 1.56 (dd, J 
= 6.6, 1.5 Hz, H-34, 3H), 1.52 (d, J = 7.2 Hz, H-5, 3H), 1.31 (dd, J = 6.9, 3.6 Hz, H-8/22, 6H), 1.11 (dd, J = 
6.7, 3.1 Hz, H-14/31/20, 8H), 1.05 (s, SiC(CH3)3, 9H), 0.98 (s, SiC(CH3)3, 9H), 0.92 (s, SiC(CH3)3, 9H, 0.22 
(s, SiCH3, 3H), 0.15 (s, SiCH3, 3H), 0.10 (s, SiCH3, 3H), 0.08 (s, Si(CH3)3, 9H), 0.07 (s, SiCH3, 3H), 0.03 (s, 
SiCH3, 3H), 0.02 (s, SiCH3, 3H).
  
 
13C-NMR (100 MHz, C6D6):  214.7, 211.8, 208.1, 169.7, 138.9, 137.3, 134.9, 129.1, 125.9, 122.4, 94.1, 
83.3, 80.8, 78.8, 75.9, 73.2, 65.7, 62.1, 61.6, 56.7, 48.8, 47.9, 47.4, 42.8, 31.0, 30.5, 26.2, 26.1, 21.1, 
18.7, 18.5, 18.4, 14.8, 13.1, 11.7, 11.2, -1.1, -4.2, -4.3, -4.6, -4.8, -5.2, -5.3 
 
HRMS (ESI) calculated for C56H106O11Si4Na ([M+Na]+): 1089.6710, found 1089.6709 
[]23D = + 41.8 (c =1.3 in CHCl3). 
6.7.7 Alcohol 259 
 
 
 
To the sem alcohol 258 (13 mg, 0.012 mmol) in Et2O (5 mL) was added MgBr2 (44.8 mg, 0.244 mmol) 
and ethanethiol (0.39 mL, 1.217 mmol) at room temperature, the flask was closed tightly and the 
resulting solution was stirred at room temperature for 24 h. Reaction mixture was diluted with EtOAc 
(20 mL) and washed with sat. aq. NaHCO3 solution (10 mL), organic layer was separated and aqueous 
layer extracted EtOAc (3 × 5 mL), Combined organic layers were dried over MgSO4, filtered, and 
concentrated. Column chromatography on 8 g silica gel (5% EtOAc-hexanes) gave the desired 
compound 259 (9 mg, 80%). 
 
1H-NMR (400 MHz, C6D6): 5.49 (d, J = 9.2 Hz, H-26, 1H), 5.30-5.41 (m, H-23/30, 2H), 5.23-5.28 (m, H-
29, 1H), 5.18 (m, H-17, 1H), 5.17 (m, H-11, 1H), 4.33 (d, J = 3.1 Hz, H-2, 1H), 4.21 (d, J = 9.5 Hz, H-9, 
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1H), 4.17 (t, J = 2.9 Hz, H-3, 1H), 4.07 (t, J = 10.0 Hz, H-22, 1H), 3.83-3.93 (m, H-21, 1H), 3.61 (dd, J = 
9.7, 4.2 Hz, H-22’, 1H), 3.44 (s, -OCH3, 3H), 3.31-3.40 (m, H-27, 1H), 3.16-3.26 (m, H-18, 1H), 3.00-3.11 
(m, H-7/14/OH, 3H), 2.85 (dd, J = 18.3, 7.1 Hz, H-16, 1H), 2.75 (d, J = 5.8 Hz, H-16’, 1H), 2.66-2.72 (m, 
H-4, 1H), 1.72 (d, J = 0.7 Hz, H-25, 3H), 1.69 (d, J = 0.9 Hz, H-11, 3H), 1.51-1.56 (m, H-19/31, 6H), 1.39 
(d, J = 7.4 Hz, H-5, 3H), 1.24 (d, J = 6.8 Hz, H-8, 3H), 1.01-1.09 (m, SiC(CH3)3/H-28, 12H), 0.97 (s, 
SiC(CH3)3, 9H), 0.88-0.92 (m, SiC(CH3)3/H-14, 12H), 0.27 (s, SiCH3, 3H), 0.15 (s, SiCH3, 3H), 0.08 (s, 
SiCH3, 3H), 0.05 (s, SiCH3, 4H), 0.04 (s, SiCH3, 3H), -0.02 (s, SiCH3, 3H). 
 
 13C-NMR (100 MHz, C6D6):  213.0, 212.8, 209.3, 169.5, 138.6. 134.8, 128.4, 127.9, 122.0, 81.2, 79.6, 
78.8, 75.9, 66.3, 36.1, 59.6, 53.3, 50.9, 50.5, 48.6, 47.8, 42.7, 30.7, 25.9, 25.8, 25.7, 20.9, 18.5, 18.4, 
18.2, 15.6, 15.5, 12.9, 11.3, 10.9, 8.9, -4.4, -4.5, -5.1. 
 
HRMS (ESI) calculated for C56H92O10Si3Na ([M+Na]+): 959.5896, found 959.5889 
[]23D = + 17.2 (c =0.8 in CHCl3). 
 
6.7.8 Desepoxyisotedanolide 40 
 
 
To the TBS ether 259 (8 mg, 0.008 mmol) in CH3CN (1.5 mL) at 0 °C was added triethylamine (0.8 mL) 
and HF•Et3N (0.93 mL) dropwise. The resulting reaction mixture was stirred at room temperature 
over a period of 3 days. Cooled to 0 °C, reaction mixture was slowly quenched with sat. aq. NaHCO3 
solution until the effervescence subsides. Extracted with EtOAc (4 × 5 mL), combined organic layers 
were dried over MgSO4, filtered, and concentrated. Column chromatography on 3 g silica gel (3% 
MeOH-CH2Cl2) gave the desired compound 40 (3 mg, 60%). 
 
1H-NMR (500 MHz, C6D6): 5.48 (d, J = 8.2 Hz, H-26, 1H), 5.45 (d, J = 9.2 Hz, H-23, 1H), 5.30-5.36 (m, 
H-30, 1H), 5.25-5.28 (m, H-12, 1H), 5.17 (ddd, J = 10.8, 9.1, 1.7 Hz, H-29, 1H), 4.76 (tt, J = 6.8, 3.6 Hz, 
H-15, 1H), 3.90-3.97 (m, H-9, 1H), 3.86 (dd, J = 10.7, 1.1 Hz, H-2, 1H), 3.82 (dd, J = 6.6, 1.0 Hz, H-3, 1H), 
3.61-3.68 (m, H-21, 1H), 3.53-3.61 (m, H-22, 1H), 3.24-3.32 (m, -OCH3/H-27/13/22’, 6H), 3.20 (d, J = 
4.0 Hz, -OH, 1H), 2.91 (qd, J = 6.9, 2.9 Hz, H-18, 1H), 2.74-2.84 (m, H-16/16’/7/-OH, 4H), 2.68-2.74 (m, 
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H-4, 1H), 1.59 (d, J = 1.1 Hz, H-25, 3H), 1.54 (d, J = 1.2 Hz, H-H-11, 3H), 1.49 (dd, J = 6.8, 1.7 Hz, H-31, 
3H), 1.35 (d, J = 7.0 Hz, H-19, 3H), 1.16 (d, J = 6.8 Hz, H-8, 3H), 1.11 (d, J = 7.3 Hz, H-5, 3H), 0.99 (d, J = 
6.7 Hz, H-28, 3H), 0.91 (d, J = 7.0 Hz, H-14, 3H).  
 
13C-NMR (125 MHz, C6D6):  213.8, 213.5, 211.3, 171.3, 138.6, 136.8, 134.8, 131.5, 128.9, 122.5, 81.3, 
80.6, 79.8, 72.5, 68.0, 61.9, 60.4, 53.4, 51.2, 50.0, 48.8, 47.0, 43.6, 30.9, 21.1, 16.9, 15.2, 13.0, 12.6, 
11.2, 10.9, 10.5.  
 
HRMS (ESI) calculated for C32H50O10Na ([M+Na]+): 617.3302, found 617.3304 
[]23D =  25.7 (c =0.07 in CHCl3). 
 
Minor product 40a 
 
1H-NMR (500 MHz, C6D6): 5.51 (d, J = 8.1 Hz, H-23, 1H), 5.42 (d, J = 9.1 Hz, H-26, 1H), 5.28-5.37 (m, 
H-30, 1H), 5.21-5.29 (m, H-29, 1H), 5.15 (bs, -OH, 1H), 4.75-4.91 (m, H-2/9/12/17, 4H), 3.84–3.91 (m, 
H-3, 1H), 3.55 (dd, J = 10.9, 7.0 Hz, H-22, 1H), 3.26-3.42 (m, H-22’/27, 2H), 3.18 (s, -OCH3, 3H), 3.06-
3.23 (m, H-21, 1H), 3.04 (dd, J = 10.6, 6.5 Hz, H-13, 1H), 2.93-3.01 (m, H-16, 1H), 2.88 (ddd, J = 20.4, 
9.4, 4.9 Hz, H-16’, 1H), 242-2.52 (m, H-18, 1H), 2.32-2.39 (m, H-7, 1H), 2.18-2.28 (m, H-4/OH, 2H), 1.58 
(d, J = 1.1 Hz, H-25, 3H), 1.50 (dd, J = 6.6, 1.5 Hz, H-31, 3H), 1.48 (s, H-11, 3H), 1.27 (d, J = 6.6 Hz, H-5, 
3H), 1.15 (d, J = 6.9 Hz, H-19, 3H), 1.13 (d, J = 6.6 Hz, H-14, 3H), 1.00 (d, J = 6.8 Hz, H-28, 3H), 0.82 (d, J 
= 7.1 Hz, H-8, 3H). 
 
13C-NMR (125 MHz, C6D6):  211.3, 209.6, 168.6, 138.7, 136.7, 135.2, 128.8, 124.1, 122.2, 108.2, 89.5, 
80.4, 78.1, 74.2, 66.9, 62.9, 59.8, 53.7, 52.9, 47.6, 47.3, 46.7, 42.1, 30.9, 21.2, 14.9, 14.4, 14.2, 13.6, 
13.0, 12.2, 9.1. 
 
HRMS (ESI) calculated for C32H50O10Na ([M+Na]+): 617.3302, found 617.3304 
[]23D = 16.0 (c =0.03 in CHCl3). 
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6.8. 14-Membered Macrolactone: 
6.8.1 Diol 261 
 
 
To the TES ether 247 (10 mg, 0.008 mmol) in a mixture of MeOH (0.5 mL) and THF (0.1 mL) was added 
PPTS (3.6 mg, 0.014 mmol) in one protion and stirred at room temperature for a period of 2 h. 
Reaction mixture was quenched with sat. aq. NaHCO3 solution (5 ml) and extracted with MTBE (2 × 10 
mL) and the combined organic layers were dried over Na2SO4, filtered, and concentrated. Crude 
compound purified by column chromatography on silica gel (gradient elution with 15% EtOAc-pet 
ether) provided compound 261 (7 mg, 76%) as colorless oil. 
 
1H-NMR (400 MHz, C6D6): 7.37 (d, J = 8.7 Hz, HAr, 2H), 6.80 (d, J = 8.7 Hz, HAr, 2H), 5.77 (ddt, J = 16.3, 
10.4, 5.9 Hz, H-2, 1H), 5.53 (d, J = 9.8 Hz, H-15, 1H), 5.44 (d, J = 9.0 Hz, H-30, 1H), 5.30 – 5.41 (m, H-
33/34, 2H), 5.18 (dd, J = 17.2, 1.5 Hz, H-1, 1H), 5.00 (dd, J = 10.4, 1.4 Hz, H-1’, 1H), 4.77 (d, J = 10.7 Hz, 
H-24, 1H), 4.69 (d, J = 10.8 Hz, H-24’, 1H), 4.62 (d, J = 8.6 Hz, H-27, 1H), 4.51-4.57 (m, H-5/23, 1H), 
4.48-4.52 (m, H-3/OH, 1H), 4.46 (d, J = 6.7 Hz, H-12, 1H), 4.23 (dd, J = 5.6, 3.8 Hz, H-20, 1H), 4.17 (dd, J 
= 5.9, 4.1 Hz, H-6, 1H), 3.74 (bs, OH, 1H), 3.57 (d, J = 4.8 Hz, H-26, 2H), 3.47 (s, OCH3, 3H), 3.44-3.52 
(m, H-31, 1H), 3.30 (s, ArOCH3, 3H), 3.22-3.30 (m, H-16, 1H), 2.97-3.04  (m, H-7/10, 2H), 2.86 (dd, J = 
17.1, 9.0 Hz, H-19, 1H), 2.51 (dd, J = 17.1, 3.5 Hz, H-19’, 1H), 2.40 (dd, J = 9.1, 4.0 Hz, H-25, 1H), 2.21-
2.29 (m, H-21, 1H), 1.86 (d, J = 1.1 Hz, H-29, 3H), 1.65 (d, J = 0.6 Hz, H-11, 3H), 1.59 (d, J = 5.1 Hz, H-35, 
3H), 1.24 – 1.33 (m, H-8/11/22, 9H), 1.13 (d, J = 6.9 Hz, H-17, 1H), 1.08 (d, J = 6.8 Hz, H-32, 1H), 0.99 – 
1.05 (m, SiC(CH3)3, 18H), 0.20 (s, SiCH3, 3H), 0.16 (s, SiCH3, 3H), 0.13 (s, SiCH3, 3H), 0.12 (s, SiCH3, 6H), 
0.06 (s, SiCH3, 3H). 
 
13C-NMR (100 MHz, C6D6): 217.5, 211.0, 171.5, 159.9, 138.3, 135.8, 134.6, 132.7, 132.2, 131.0, 
129.9, 121.7, 118.8, 114.3, 81.9, 81.5, 78.9, 77.3, 75.3, 74.0, 68.7, 65.6, 60.3, 54.8, 49.3, 46.8, 46.1, 
45.6, 42.4, 30.8, 26.3, 26.2, 26.1, 16.5, 13.1, 12.7, 11.7, 11.5, 9.9, -4.2, -4.6, -4.7, -5.1, -5.2.  
HRMS (ESI) calculated for C61H108O12Si3Na ([M+Na]+): 1139.7046, found 1139.7045 
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[]23D = + 45.1 (c =0.7 in CHCl3). 
6.8.2 Macrolactone 260 
 
 
a) Allyester cleavage: 
 
To the diol 261 (7 mg, 0.006 mmol) in CH2Cl2 (2 ml) was added Pd(PPh3)2Cl2 (1 mg,  0.001 mmol) 
followed by tributyltinhydride (7 l, 0.025 mmol) dropwise at room temperature. The solution 
turned into dark brown color in 5 min, reaction stirred for 1 h. The reaction mixture was diluted 
with MTBE (20 mL) and washed with a mixture of sat. aq. NH4Cl solution and NaHSO4 solution 
(1M, 20 mL). The aqueous layer was back-extracted with MTBE (3 × 5 mL), and the combined 
organic layers were dried over MgSO4, filtered, and concentrated. Column chromatography on 5 g 
silica gel (gradient elution with 100% pet ether to 100% EtOAc) removed the excess 
tributylstannane and provided 0.015 g of semi-pure carboxylic acid, which is used in the 
subsequent macrolactonization without further purification. 
 
b) Shiiina macrolactonisation: 
 
The crude carboxylic acid (0.015 g) obtained above was dissolved in dry toluene (1 mL) and dry 
THF (0.5 mL) and added to a mixture of DMAP (6.5 mg, 0.063 mmol)  and 2-methyl-6-nitrobenzoic 
anhydride (6 mg, 0.018 mmol) in toluene (3 mL) and THF (4 mL) at room temperature. The 
resulting solution was stirred for 32 h at room temperature. The reaction mixture was diluted with 
MTBE (10 mL) and washed with sat. aq. NaHCO3 solution (10 mL). The aqueous layer was back-
extracted with MTBE (3 × 10 mL), and the combined organic layers were dried over MgSO4, 
filtered, and concentrated. Column chromatography on 8 g silica gel (15% EtOAc-hexanes) gave 
the macrolactone 260 (3 mg, 45%) as colorless oil. 
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1H-NMR (500 MHz, C6D6): 7.41 (d, J = 8.6 Hz, HAr, 2H), 6.78 (d, J = 8.6 Hz, HAr, 2H), 5.87 (dd, J = 8.0, 
6.7 Hz, H-17, 1H), 5.50 (dd, J = 19.0, 8.8 Hz, H-27, 1H), 5.34-5.44 (m, H-30/31, 2H), 5.05 (d, J = 9.9 Hz, 
H-12, 1H), 4.82 (d, J = 10.6 Hz, H-21, 1H), 4.58 (d, J = 10.7 Hz, H-21’, 1H), 4.49 (d, J = 9.4 Hz, H-24, 1H), 
4.38 (d, J = 9.3 Hz, H-2, 1H), 4.33 (dd, J = 9.2, 1.1 Hz, H-3, 1H), 4.26 (d, J = 10.0 Hz, H-9, 1H), 4.00 (dd, J 
= 5.4, 2.3 Hz, H-20, 1H), 3.61 (s, OCH3, 3H), 3.47-3.57 (m, H-23/28, 2H), 3.43 (dd, J = 10.3, 3.5 Hz, H-
23’, 1H), 3.28 (s, ArOCH3, 3H), 3.21-3.29 (m, H-13, 1H), 3.06-3.17 (m, H-7, 1H), 2.92 (dd, J = 19.2, 8.3 
Hz, H-16, 1H), 2.78 (dd, J = 19.1, 1.6 Hz, H-16’, 1H), 2.41 (q, J = 7.4 Hz, H-4, 1H), 2.28-2.36 (m, H-18, 
1H), 2.10 (dt, J = 9.3, 4.7 Hz, H-22, 1H), 1.83 (d, J = 0.7 Hz, H-26, 3H), 1.79 (d, J = 0.9 Hz, H-11, 3H), 1.61 
(d, J = 5.1 Hz, H-32, 3H), 1.36 (d, J = 7.5 Hz, H-5, 3H), 1.23 (d, J = 7.0 Hz, H-19, 3H), 1.21 (d, J = 6.6 Hz, 
H-8, 3H), 1.11 (d, J = 6.7 Hz, H-27, 1H), 1.09 (s, SiC(CH3)3, 9H), 1.06 (d, J = 6.6 Hz, H-14, 3H), 0.99 (s, 
SiC(CH3)3, 9H), 0.96 (s, SiC(CH3)3, 9H), 0.45 (s, SiCH3, 3H), 0.27 (s, SiCH3, 3H), 0.22 (s, SiCH3, 3H), 0.11 (s, 
SiCH3, 3H), 0.09 (s, SiCH3, 3H), 0.07 (s, SiCH3, 3H), -0.03 (s, SiCH3, 3H). 
 
13C-NMR (125 MHz, C6D6): 212.1, 205.4, 171.0, 160.1, 138.7, 135.8, 134.6, 133.0, 130.1, 130.0, 
121.9, 114.5, 80.7, 79.4, 78.6, 77.5, 74.8, 74.2, 71.9, 54.8, 50.6, 47.3, 47.2, 45.5, 42.0, 26.3, 26.2, 26.1, 
26.0, 18.7, 18.5, 18.4, 16.2, 15.4, 13.1, 11.7, 11.2, 9.8, -4.5, -4.6, -4.9, -5.2. 
 
HRMS (ESI) calculated for C58H102O11Si3Na ([M+Na]+): 1081.6628, found 1081.6628 
[]23D = + 45.4 (c =0.95 in CHCl3). 
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6.9. Simplified Tedanolide Analogs: 
 
6.9.1 Diol 264 
 
To the ketone 44 (78 mg, 0.15 mmol) in THF (8 mL) was added pyridine (8.1 mL) at 0 °C, HF-pyridine 
(5.26 mL) was added carefully dropwise to the reaction mixture, warmed to room temperature and 
stirred for 4 h. Reaction mixture was slowly added to sat. aq. NaHCO3, organic layer separated and the 
aqueous layer was extracted with EtOAc (3 x 15 mL), combined organic layers are dried over Na2SO4, 
filtered and concentrated in vacuo. Crude compound purified by silica gel column chromatography 
(pet ether: EtOAc, 3:1) to afford compound 53 (58 mg, 95%) as colorless liquid. 
 
1H-NMR (400 MHz, CDCl3):  7.19 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.37-5.31 (m, 1H), 5.30 (d, 
J = 7.6 Hz, 1H), 5.22-5.14 (m, 1H),  4.41 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 11.5 Hz, 1H), 4.26 (d, J = 8.5 Hz, 
1H), 3.79 (s, 3H), 3.65 (dt, J = 9.3, 7.9 Hz, 2H), 3.59 (dd, J = 11.6, 4.3 Hz, 1H), 3.49 (dd, J = 8.7, 4.5 Hz, 
1H), 3.42-3.32 (m, 1H), 3.19-3.09 (m, 2H), 2.55 (br s, 2H), 1.66 (d, J = 1.3 Hz, 3H), 1.62 (dd, J = 6.8, 1.7 
Hz, 3H), 1.01 (d, J = 3.3 Hz, 3H), 1.00 (d, J = 3.1 Hz, 3H).  
 
13C-NMR (100 MHz, CDCl3):  218.0, 159.6, 134.8, 133.9, 132.8, 129.6, 129.3, 122.3, 114.0, 76.8, 73.4, 
62.5, 57.9, 55.4, 47.7, 30.6, 21.4, 13.1, 12.9, 11.5. 
 
HRMS (ESI) calculated for C23H34O5Na ([M+Na]+): 413.5028, found 413.1573. 
[]23D =  11.0 (c = 1.5 in CHCl3). 
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6.9.2 Acetate 265 
 
 
To the diol 264 (57 mg, 0.14 mmol) in CH2Cl2 (7 mL) at 78 °C was added DIPEA (46 L, 0.26 mmol) 
and acetyl chloride (12.2 L, 0.17 mmol). Stirred for 1 h, again DIPEA (46 L, 0.26 mmol) and acetyl 
chloride (12.2 L, 0.17 mmol) were added and stirred for 5 h at 78 °C, and then at 50 °C for 16 h.  
Water (10 mL) and sat. aq. NaHCO3 (10 ml) was added, warmed to room temperature, organic layer 
separated, aqueous layer was extracted with CH2Cl2 (3 x 5 mL). Combined organic layers are dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. Crude compound purified by silica gel 
column chromatography on silica gel (pet ether: EtOAc, 3:1) to obtain compound 265 (45 mg, 80%) as 
colorless oil. 
 
1H-NMR (400 MHz, CDCl3):  7.23 (d, J = 8.7 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 5.36 (ddd, J = 10.7, 6.8, 
0.9 Hz, 1H), 5.30 (d, J = 9.0 Hz, 1H), 5.21 (ddq, J = 10.8, 9.2, 1.7 Hz, 1H), 4.46 (d, J = 11.8 Hz, 1H), 4.43 
(d, J = 11.7 Hz, 1H), 4.22 (d, J = 8.5 Hz, 1H), 4.03 (dd, J = 11.3, 5.4 Hz, 1H), 3.82 (s, 3H), 3.67 (d, J = 9.1, 
7.8 Hz, 1H), 3.42 (dd, J = 9.1, 5.5 Hz, 1H), 3.36-3.39 (m, 1H), 3.29-3.31 (m, 1H), 2.99-3.11 (m, 1H), 1.94 
(s, 3H), 1.70 (d, J = 1.3 Hz, 3H), 1.65 (dd, J = 6.8, 1.7 Hz, 3H), 1.08 (d, J = 7.0 Hz, 3H), 1.03 (d, J = 6.8 Hz, 
3H). 
 
13C-NMR (100 MHz, CDCl3): 214.3, 170.6, 159.4, 134.6, 134.1, 132.5, 129.9, 129.4, 122.5, 114.0, 
76.8, 73.1, 62.9, 55.4, 53.6, 47.1, 30.5, 21.3, 20.8, 13.2, 13.1, 11.5. 
 
HRMS (ESI) calculated for C25H36O6Na ([M+Na]+): 455.5395, found 455.3230. 
[]23D =  13.2 (c = 1.0 in CHCl3). 
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6.9.3 Epoxide 266 
 
 
To the allyl alcohol 265 (14 mg, 0.03 mmol) in CH2Cl2 (0.6 mL) was added NaHCO3 (9.5 mg) and m-
CPBA (5.6 mg, 0.03 mmol) at 78 °C, stirred for 1 h at this temp and warmed to 40 °C and stirred for 
16 h at this temperature. Sat. aq. NaHCO3 (2 mL) and CH2Cl2 (3 mL) were added and warmed to room 
temperature, organic layer was separated and the aqueous layer was extracted with CH2Cl2 (2 x 3 mL), 
combined organic layers are dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Crude 
compound purified by silica gel column chromatography (pet ether: EtOAc, 6:1) to afford compound 
266 (6.5 mg, 44%) as colorless liquid. 
 
1H-NMR (400 MHz, C6D6):  7.30 (d, J = 8.7 Hz, 2H), 6.91 (d, J = 8.7 Hz, 2H), 5.60 (m, 1H), 5.21-5.31 (m, 
1H), 4.48 (dd, J = 11.0, 4.9 Hz, 1H), 4.38 (s, 2H), 4.33 (dd, J = 10.9, 8.8 Hz, 1H), 3.77 (dd, J = 9.1,7.4 Hz, 
1H), 3.58 (dd, J = 8.8, 4.6 Hz, 1H), 3.45-3.51 (m, 1H), 3.40 (s, 3H), 3.23-3.13 (m, 1H), 2.62-2.66 (m, 1H), 
2.61 (s, 1H), 2.42-2.52 (m, 1H), 1.69 (s, 3H), 1.54 (dd, J = 6.9, 1.8 Hz, 3H), 1.41 (s, 3H), 1.28 (d, J = 6.9 
Hz, 3H), 1.19 (d, J = 6.6 Hz, 3H). 
 
13C-NMR (100 MHz, C6D6):  212.5, 169.9, 159.8, 130.8, 130.5, 129.5, 124.9, 114.1, 76.5, 73.1, 71.9, 
66.4, 62.9, 62.3, 54.7, 52.8, 48.4, 31.6, 20.3, 18.7, 13.3, 13.3, 13.2, 12.0. 
 
HRMS (ESI) calculated for C26H36O7Na ([M+Na]+): 471.5389, found 471.2265. 
 []23D =  4.5 (c = 0.35 in MeOH). 
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6.10. Kiyooka Aldol Methodology Analogs: 
 
6.10.1-Hydroxy acetal 291 
 
 
 
To a suspension of N-Ts-L-valine (67 mg, 0.25 mmol, 1.1 eq.) in CH2Cl2 (2.1 mL) was added BH3•THF 
complex (0.22 mL, 1M in THF, 1.0 eq.) dropwise at 0 °C. The resulting mixture was stirred for 30 min 
at 0 °C and 1 h at rt. Afterwards, the clear solution was cooled to 78 °C and benzaldehyde (23 mg, 
0.21 mmol, 1.0 eq.) in  CH2Cl2 (1.3 mL) was added followed by the subsequent addition of silyl ketene 
acetal 278 (80 mg, 0.29 mmol, 1.3 eq.) in  CH2Cl2 (1.3 mL). The mixture was stirred for 10 min at 78 
°C, quenched with phosphate buffer pH7 and the resulting biphasic mixture slowly warmed to rt. The 
two layers were separated, the organic phase was diluted with MTBE, washed with aq. sat. NaHCO3 
solution and brine and dried (Na2SO4). After removal of the solvents in vacuo the residue was purified 
by silica gel column chromatography (petroleum ether/EtOAc 10:1) to afford -hydroxy acetal 291 (68 
mg, 0.18 mmol, 83%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3):  7.40-7.46 (m, 2H), 7.25-7.35 (m, 3H), 4.68 (d, J = 7.6 Hz, 1H), 5.13 (d, J = 
3.0 Hz, 0.5H), 4.96 (d, J = 5.0 Hz, 0.5H), 4.02 (s, 1H), 3.90 (s, 1H), 3.53 (s, 1.5H), 3.40 (s, 1.5H), 1.18-
1.23 (m, 3H), 1.02-0.96 (m, 3H),  0.92-0.96 (m, 9H), 0.11-0.18 (m, 6H). 
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6.10.2 Aldehyde 285 
 
 
 
To a solution of -hydroxy acetal 291 (10 mg, 0.026 mmol, 1.0 eq.) in THF (0.8 mL) was added 
NaHMDS (36.5 L, 1M in THF, 1.0 eq.) at 78 °C. The resulting mixture was stirred for 5 min at 78 °C, 
warmed to 0 °C, stirred for 1 h and quenched with sat. aq. NH4Cl solution. The biphasic solution was 
diluted with MTB ether and the two layers were separated. The aqueous phase was washed with MTB 
ether and dried over Na2SO4. After removal of the solvents in vacuo the residue was purified by silica 
gel column chromatography (petroleum ether/EtOAc 10:1) to afford aldehyde 285 (6.0 mg, 0.017 
mmol, 66%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3):  9.76 (s, 1H), 7.29-7.33 (m, 5H),  4.82(s, 1H), 4.27 (d, J = 9.12 Hz, 1H), 
3.88 (dd, J = 8.0, 1.5 Hz, 1H), 1.35 (s, 3H), 1.15 (s, 3H), 0.86 (s, 9H), 0.00 (s, 3H), -0.24 (s, 3H). 
 
13C-NMR (100 MHz, CDCl3):  203.4, 128.3, 127.9, 119.6, 111.6, 89.5, 77.3, 67.8, 26.6, 25.8, 25.7, -4.5, 
-5.3.  
 
HRMS (ESI) calculated for C19H30O4SiNa ([M+Na]
+): 373.1811, found: 373.1448. 
[]23D = 41.2 (c = 0.5, CHCl3). 
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6.10.3 Ester 292 
 
To a solution of -hydroxy acetal 291 (10 mg, 0.026 mmol, 1.0 eq.) in CH2Cl2 (1.0 mL) was added TEA 
(29.6 L, 0.21 mmol, 8.0 eq.), DMAP (4.5 mg, 0.036 mmol, 1.4 eq.) and R-Moscher’s chloride (20 l, 
0.10 mmol, 4.0 eq,) at room temperature. The resulting mixture was stirred for 16 h. The reaction 
mixture was diluted with CH2Cl2 and washed with sat. aq. NaHCO3 solution and dried (Na2SO4). After 
removal of the solvents in vacuo the residue was purified by silica gel column chromatography 
(petroleum ether/EtOAc 10:1) to afford compound 292 (12 mg, 0.02 mmol, 77%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)   7.41-7.45 (m, 2H), 7.32-7.39 (m, 5H), 7.29-7.31 (m, 3H), 6.26 (s, 0.5H), 
6.12 (s, 0.5H), 4.66 (s, 0.5H), 4.62 (s, 0.5H), 4.06-4.15 (m, 1H), 3.91-4.01 (m, 1H), 3.48-3.52 (m, 3H), 
3.27 (s, 3H), 1.35 (s, 3H), 0.94 (s, 9H), 0.81 (s, 3H), 0.12 (s, 3H), 0.00 (s, 3H). 
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6.10.4 Aldehyde 293 
 
 
To a solution of compound 292 (5 mg, 0.008 mmol, 1.0 eq.) in THF (1.0 mL) was added TBAF (11.7 L, 
1M in THF, 1.4 eq.) at 0 °C. The resulting mixture was stirred for 45 min at 0 °C. The reaction mixture 
was washed with H2O (2 mL) and the aqueous layer was extracted with MTBE (2 × 3 mL). Combined 
organic layers are dried (Na2SO4). After removal of the solvents in vacuo the residue was purified by 
silica gel column chromatography (petroleum ether/EtOAc 4:1) to afford compound 293 (3.3 mg, 
0.007 mmol, 89%) as a colorless oil. 
 
1H-NMR (400 MHz, CDCl3)   9.57 (s, 1H), 7.37-7.44 (m, 10H), 6.12 (s, 1H), 4.21 (d, J = 9.6 Hz, 1H), 3.79 
(dd, J = 9.2 Hz, 0.8 Hz, 1H), 3.48 (d, J = 1.3 Hz, 1H), 1.38 (s, 3H), 1.06 (s, 3H). 
 
13C-NMR (100 MHz, CDCl3)   202.5, 165.5, 133.5, 131.8, 129.9, 129.7, 129.0, 128.5, 127.6, 112.9, 
88.1, 78.1, 68.2, 66.0, 55.7, 29.8, 26.7, 25.5. 
 
HRMS (ESI) calculated for C23H23F3O6Na ([M+Na]
+): 475.1344, found: 475.1197. 
[]23D = 11.51 (c = 0.33, CHCl3). 
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6.10.5-Hydroxy acetal 294 
 
 
To a suspension of N-Ts-L-valine (67 mg, 0.25 mmol, 1.1 eq.) in CH2Cl2 (2.1 mL) was added BH3•THF 
complex (0.22 mL, 1M in THF, 1.0 eq.) dropwise at 0 °C. The resulting mixture was stirred for 30 min 
at 0 °C and 1 h at rt. Afterwards, the clear solution was cooled to 78 °C and valeraldehyde (19.4 mg, 
0.22 mmol, 1.0 eq.) in  CH2Cl2 (1.3 mL) was added followed by the subsequent addition of silyl ketene 
acetal 278 (80 mg, 0.29 mmol, 1.3 eq.) in  CH2Cl2 (1.3 mL). The mixture was stirred for 1 h at 78 °C, 
quenched with phosphate buffer pH7 and the resulting biphasic mixture slowly warmed to rt. The 
two layers were separated, the organic phase was diluted with MTB ether, washed with sat. aq. 
NaHCO3 solution and brine and dried (Na2SO4). After removal of the solvents in vacuo the residue was 
purified by silica gel column chromatography (petroleum ether/EtOAc 10:1) to afford -hydroxy 
acetal 294 (36 mg, 0.10 mmol, 40%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)  4.75 (s, 1H), 3.97 (d, J = 10.1 Hz, 1H), 3.93 (d, J = 10.1 Hz, 1H), 3.47 (s, 3H), 
3.39 (d, J = 12.2 Hz, 1H), 1.43 (s, 6H), 1.25-1.39 (m, 8H), 0.91 (s, 9H), 0.16 (s, 6H), 0.13 (s, 3H). 
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6.10.6 Aldehyde 287 
 
 
To a solution of -hydroxy acetal 294 (10 mg, 0.027 mmol, 1.0 eq.) in THF (0.7 mL) was added 
NaHMDS (27.5 L, 1M in THF, 1.0 eq.) at 78 °C. The resulting mixture was stirred for 5 min at -78 °C, 
warmed to 0 °C, stirred for 1 h and quenched with sat. aq. NH4Cl solution. The biphasic solution was 
diluted with MTB ether and the two layers were separated. The aqueous phase was washed with 
MTBE and dried (Na2SO4). After removal of the solvents in vacuo the residue was purified by silica gel 
column chromatography (petroleum ether/EtOAc 10:1) to afford aldehyde 287 (8.0 mg, 0.024 mmol, 
87%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)  9.81 (s, 1H), 4.28 (d, J = 8.4 Hz, 1H), 3.91 (d, J = 10.9 Hz, 1H),  3.85 (dd, J = 
4.36, 2.1 Hz, 1H), 1.63-1.70 (m, 1H), 1.43-1.51 (m, 2H), 1.40 (d, J = 14.3 Hz, 6H), 1.25-1.36 (m, 5H), 
0.89 (s, 9H), 0.10 (s, 3H), 0.08 (s, 3H). 
 
13C-NMR (100 MHz, CDCl3): 201.9, 111.4, 89.3, 75.4, 68.4, 33.4, 28.0, 26.6, 26.5, 25.9, 23.0, 18.3, 
14.1, -3.9, -4.3. 
 
HRMS (EI) calculated for C17H34O4SiNa ([M+Na]
+): 353.2124, found: 353.1957.  
[]23D = 11.62 (c = 0.8, CHCl3). 
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6.10.7 Ester 295 
 
 
 
To a solution of -hydroxy acetal 294 (10 mg, 0.027 mmol, 1.0 eq.) in CH2Cl2 (1.1 mL) was added TEA 
(31.0 L, 0.22 mmol, 8.0 eq.), DMAP (4.7 mg, 0.038 mmol, 1.4 eq.) and R-Moscher’s chloride (21 l, 
0.11 mmol, 4.0 eq.) at room temperature. The resulting mixture was stirred for 16 h. The reaction 
mixture was diluted with CH2Cl2 and washed with sat. aq. NaHCO3 solution and dried (Na2SO4). After 
removal of the solvents in vacuo the residue was purified by silica gel column chromatography 
(petroleum ether/EtOAc 10:1) to afford compound 295 (10 mg, 0.017 mmol, 63%) as a colourless oil. 
 
1H-NMR (400 MHz, C6D6)  7.59-7.69 (m, 2H), 7.37-7.42 (m, 3H), 5.57 (dd, J = 9.1, 1.7 Hz, 1H), 4.68 (s, 
1H), 4.07 (d, J = 9.0 Hz, 1H), 3.81 (d, J = 9.0 Hz, 1H), 3.58 (s, 3H), 3.33 (s, 3H), 1.35 (s, 6H), 1.28-1.32 
(m, 9H), 0.91 (s, 9H), 0.1 (s, 6H). 
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6.10.8 Aldehyde 296 
 
 
To a solution of compound 295 (4 mg, 0.007 mmol, 1.0 eq.) in THF (0.8 mL) was added TBAF (9.7 L, 
1M in THF, 1.4 eq.) at 0 °C. The resulting mixture was stirred for 45 min at 0 °C. The reaction mixture 
was washed with H2O (2 mL) and the aqueous layer was extracted with MTBE (2 × 3 mL). Combined 
organic layers are dried (Na2SO4). After removal of the solvents in vacuo the residue was purified by 
silica gel column chromatography (petroleum ether/EtOAc 4:1) to afford compound 296 (2.8 mg, 
0.006 mmol, 94%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)   9.58 (s, 2H), 7.52-7.58 (m, 2H), 7.39-7.43 (m, 3H), 5.34 (dd, J = 9.6, 3.0 
Hz, 1H), 4.08 (d, J = 10.2 Hz, 1H), 3.82 (d, J = 10.2 Hz, 1H), 3.54 (s, 3H), 1.73-1.82 (m, 1H), 1.56-1.66 (m, 
1H), 1.37 (s, 6H), 1.24-1.33 (m, 4H), 0.83-0.90 (m, 3H). 
 
13C-NMR (100 MHz, CDCl3):  200.5, 166.1, 131.7, 129.9, 128.6, 127.5, 112.4, 87.5, 76.7, 67.7, 66.0, 
55.6, 29.8, 27.8, 26.4, 25.9, 22.4, 15.4, 13.9. 
 
HRMS (ESI) calculated for C21H27F3O6Na ([M+Na]
+): 455.1657, found: 455.1428. 
[]23D = 6.07 (c = 0.28, CHCl3).  
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6.10.9-Hydroxy acetal 297 
 
 
To a suspension of N-Ts-L-valine (67 mg, 0.25 mmol, 1.1 eq.) in CH2Cl2 (2.1 mL) was added BH3•THF 
complex (0.22 mL, 1M in THF, 1.0 eq.) dropwise at 0 °C. The resulting mixture was stirred for 30 min 
at 0 °C and 1 h at rt. Afterwards, the clear solution was cooled to 78 °C and trans-cinnamaldehyde 
(29.9 mg, 0.22 mmol, 1.0 eq.) in  CH2Cl2 (1.3 mL) was added followed by the subsequent addition of 
silyl ketene acetal 278 (80 mg, 0.29 mmol, 1.3 eq.) in  CH2Cl2 (1.3 mL). The mixture was stirred for 10 
min at 78 °C, quenched with phosphate buffer pH7 and the resulting biphasic mixture slowly 
warmed to rt. The two layers were separated, the organic phase was diluted with MTBE, washed with 
sat. aq. NaHCO3 solution and brine and dried (Na2SO4). After removal of the solvents in vacuo the 
residue was purified by silica gel column chromatography (petroleum ether/EtOAc 10:1) to afford -
hydroxy acetal 297 (75 mg, 0.18 mmol, 80%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)   7.40-7.45 (m, 2H), 7.20-7.35 (m, 3H),  6.66-6.77 (m, 1H), 6.38-6.49 (m, 
1H), 4.81-4.84 (m, 1H), 4.54-4.68 (m, 1H), 3.94-4.16 (m, 3H), 3.46-3.58 (m, 3H), 1.47 (d, J = 2.06 Hz, 
6H), 0.90-0.97 (m, 9H), 0.14-0.22 (m, 6H). 
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6.10.10 Aldehyde 286 
 
 
To a solution of -hydroxy acetal 297 (10 mg, 0.024 mmol, 1.0 eq.) in THF (0.8 mL) was added 
NaHMDS (36.5 L, 1M in THF, 1.0 eq.) at 78 °C. The resulting mixture was stirred for 5 min at 78 °C, 
warmed to 0 °C, stirred for 1 h and quenched with sat. aq. NH4Cl solution. The biphasic solution was 
diluted with MTBE and the two layers were separated. The aqueous phase was washed with MTBE 
and dried (Na2SO4). After removal of the solvents in vacuo the residue was purified by silica gel 
column chromatography (petroleum ether/EtOAc 10:1) to afford aldehyde 286 (6.0 mg, 0.016 mmol, 
65%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3) = 9.82 (s, 1 H), 7.40-7.24 (m, 5H), 6.57 (d, J = 16.5 Hz, 1 H), 6.25 (dd, J = 
8.7, 7.2 Hz, 1 H), 4.46 (dd, J = 7.6, 1.2 Hz, 1 H), 4.87 (d, J = 8.7 Hz, 1 H), 3.88 (dd, J = 8.8, 0.6 Hz, 1 H), 
1.43 (d, J = 8.4 Hz, 3 H), 0.89 (s, 9 H), 0.08 (s, 3 H), 0.04 (s, 3 H). 
 
13C-NMR (100 MHz, CDCl3):  203.5, 136.2, 133.3, 128.8, 128.7, 128.2, 126.9, 126.8, 119.7, 111.8, 
89.5, 76.1, 68.0, 29.8, 26.7, 26.3, 25.9, -3.7, -4.8.  
 
HRMS (ESI) calculated for C21H32O4SiNa ([M+Na]
+): 399.1968, found: 399.1631 
[]23D = 31.83 (c = 0.6, CHCl3). 
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6.10.11 Ester 298 
 
 
To a solution of -hydroxy acetal 297 (10 mg, 0.024 mmol, 1.0 eq.) in CH2Cl2 (1.0 mL) was added TEA 
(27.2 L, 0.19 mmol, 8.0 eq.), DMAP (4.2 mg, 0.034 mmol, 1.4 eq.) and R-Moscher’s chloride (18.5 l, 
0.10 mmol, 4.0 eq,) at room temperature. The resulting mixture was stirred for 16 h. The reaction 
mixture was diluted with CH2Cl2 and washed with sat. aq. NaHCO3 solution and dried (Na2SO4). After 
removal of the solvents in vacuo the residue was purified by silica gel column chromatography 
(petroleum ether/EtOAc 10:1) to afford compound 298 (11 mg, 0.017 mmol, 72%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)   7.50-7.59 (m, 2H), 7.23-7.42 (m, 8H), 6.72 (d, J = 16.3 Hz, 1H), 6.20-6.34 
(m, 1H), 5.92 (dd, J = 8.1, 0.8 Hz, 1H), 5.81 (dd, J = 8.4, 0.9 Hz, 1H), 4.71 (s, 0.5H), 4.61 (s, 0.5H), 4.07-
4.17 (m, 1H), 3.77-3.89 (m, 1H), 3.56 (s, 3H), 3.35 (s, 1.5H), 3.31 (s, 1.5H), 1.32-1.44 (m, 6H), 0.89-0.95 
(m, 9H), 0.07-0.14 (m, 6H). 
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6.10.12 Aldehyde 299 
 
 
To a solution of compound 298 (5 mg, 0.008 mmol, 1.0 eq.) in THF (1.0 mL) was added TBAF (11.7 L, 
1M in THF, 1.4 eq.) at 0 °C. The resulting mixture was stirred for 45 min at 0 °C. The reaction mixture 
was washed with H2O (2 mL) and the aqueous layer was extracted with MTBE (2 × 3 mL). Combined 
organic layers are dried (Na2SO4). After removal of the solvents in vacuo the residue was purified by 
silica gel column chromatography (petroleum ether/EtOAc 4:1) to afford compound 299 (3.3 mg, 
0.0068 mmol, 86%) as a colourless oil. 
 
1H-NMR (400 MHz, CDCl3)  9.55 (s, 1H), 7.28-7.55 (m, 10H), 6.82 (d, J = 15.8 Hz, 1H), 6.23 (dd, J = 8.2, 
7.2 Hz, 1H), 5.82 (dd, J = 8.4, 0.6 Hz, 1H), 4.19 (d, J = 9.3 Hz, 1H), 3.87 (dd, J = 9.2, 0.5 Hz, 1H), 3.51 (s, 
3H), 1.42 (d, J = 2.2 Hz, 6H). 
 
 13C-NMR (100 MHz, CDCl3):  201.9, 165.4, 138.5, 135.2, 131.8, 129.7, 129.0, 128.8, 128.5, 127.3, 
127.0, 119.5, 112.7, 87.7, 68.0, 55.9, 29.7, 26.4, 25.7. 
 
HRMS (ESI) calculated for C25H25F3O6Na ([M+Na]
+): 501.1501, found: 501.1398.  
[]23D = 11.51 (c = 0.3, CHCl3). 
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